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Dry powder inhalers (DPIs) are commonly used to deliver drugs to the lungs. The drug
particles used in these DPIs should possess a number of key properties. These include an
aerodynamic particle size < 5μm and particle crystallinity for long term formulation stability. The
conventionally
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micronization

technique

to

produce

inhalation

particles
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offers limited opportunities to control and optimize the particle characteristics. It is also known to
induce crystalline disorder in the particles leading to formulation instability. Hence, this research
project investigates and optimizes a solvent/anti-solvent crystallization process capable of directly
yielding inhalation particles using albuterol sulfate (AS) as a model drug. Further, the feasibility
of the process to produce combination particles of AS and ipratropium bromide monohydrate (IB)
in predictable proportions and in a size suitable for inhalation is also investigated.
The solvent / anti-solvent systems employed were water / ethyl acetate (EA) and water /
isopropanol (IPA). Investigation and optimization of the crystallization variables with the water /
EA system revealed that particle crystallinity was significantly influenced by an interaction
between the drug solution / anti-solvent ratio (Ra ratio), stirring speed and crystal maturation time.
Inducing a temperature difference between the drug solution and anti-solvent (Tdrug solution > Tantisolvent)

resulted in smaller particles being formed at a positive temperature difference of 65°C. IPA

was shown to be the optimum anti-solvent for producing AS particles (IPA-AS) in a size range
suitable for inhalation. In vitro aerosol performance of these IPA-AS particles was found to be
superior compared to the conventionally used micronized particles when aerosolized from the
Novolizer®.
The solvent / anti-solvent systems investigated and optimized for combination particles
were water / EA, water / IPA, and water / IPA:EA 1:10 (w/w). IPA was found to be the optimum
anti-solvent for producing combination particles of AS and IB with the smallest size. These
combination particles showed uniform co-deposition during in vitro aerosol performance testing
from the Novolizer®. Pilot molecular modeling studies in conjunction with the analysis of particle
interactions using HINT provided an improved understanding of the possible interactions between
AS and IB within a combination particle matrix.

CHAPTER I
INTRODUCTION

I.A

Significance and background
The purpose of this thesis was to investigate and optimize a solvent / anti-solvent

crystallization process as a single-step particle engineering technique to produce drug particles
with suitable characteristics for inhalation without the need for further size reduction. In order to
do so, albuterol sulfate (AS) was chosen as a model drug. Furthermore, it was the purpose to
extend this crystallization process to produce combination particles of albuterol sulfate and
ipratropium bromide monohydrate (IB) in predictable fixed ratios with a size suitable for
inhalation. In addition, in silico molecular modeling tools were used to study the interactions
between albuterol sulfate and ipratropium bromide (IB) in these combination particles. In this
chapter, a review of particle engineering for pulmonary drug delivery will discuss the desirable
characteristics of inhalation particles for dry powder formulations, the disadvantages of
micronization as a size reduction technique, alternative particle engineering techniques and the
solvent / anti-solvent crystallization as a potential particle engineering process. In addition, the
rationale for using combination therapy for the treatment and maintenance of asthma and the use
of molecular modeling tools to investigate the interactions between two drugs in a combination
particle matrix will also be discussed.
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I.A.1

Dry powder formulations for pulmonary drug delivery
Dry powder formulations are becoming increasingly popular for pulmonary drug

delivery. The drug particles constitute a principle component of these dry powder formulations.
These drug particles are usually present in a micronized form either alone or more commonly as
a binary mixture with large carrier particles. Lactose monohydrate is a typically used carrier in
these dry powder formulations. The formulation is delivered by means of devices known as dry
powder inhalers (DPIs). The efficiency of a dry powder formulation is usually characterized by
some critical features. One of these features is the emitted dose (ED) which indicates the amount
of drug that comes out from the device. This is important to characterize since it is only this mass
of drug that is available for deposition. Another important feature is the fine particle fraction
(FPF) which represents the fraction of drug < 5.0 µm in aerodynamic diameter. The FPF denotes
the dispersivity of the drug.
Pulmonary drug delivery from DPIs is a complex process and is influenced by the dry
powder formulation, the device characteristics, and patient factors such as inhalation flow rate
and breathing pattern. The dry powder formulation should possess certain desirable
characteristics. These include a high ED, and a high FPF. Ideally, these factors should be
independent of the inhalation flow rate. The drug particle characteristics such as the aerodynamic
diameter, interparticulate interactions, particle morphology, and solid state form and structure
significantly influence the efficiency of the dry powder inhalation system by influencing the
emitted dose and the fine particle fraction.
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I.A.1.1

Influence of drug particle characteristics on emitted dose
The emitted dose is significantly influenced by the size of the particles. For efficient lung

delivery, the drug particles should possess an aerodynamic diameter ranging from 2.5-6.0 µm
(Pritchard et al., 2001). Additionally, they should have a narrow particle size distribution (PSD)
(Shekunov et al., 2003; Shekunov et al., 2004). The aerodynamic diameter, dA, is defined as the
diameter of a sphere of unit density, which reaches the same velocity in the air stream as a nonspherical particle of arbitrary density (Chow et al., 2007). This diameter defines the mechanism
of particle deposition in the respiratory system. It has been shown that the aerodynamic diameter
(dA) generally depends on the airflow (particle Reynolds number, Re) as well as the particulate
properties (geometric size, shape and density) and can, therefore, be calculated numerically using
semi-empirical models. The well-known relationship depicted by Eq. I.1 below, though strictly
applicable only at the Stokes flow regime of Re < 0.1, can be used to estimate the aerodynamic
diameter (Chow et al., 2007):

dA (Stokes) ≈ dV √ρ/χρ0

Equation I.1

where dV is the volume-equivalent diameter, ρ0 is the unit density (of spherical calibration
spheres), ρ is the particle density and χ is the dynamic shape factor, defined as the ratio of the
drag force on a particle to the drag force on the particle volume-equivalent sphere at the same
velocity. Thus dA can be reduced by one or more of the following manipulations:
(a) Decreasing the volume-equivalent particle diameter (dV)
(b) Reducing the particle density (ρ)
(c) Increasing the particle dynamic shape factor (χ)
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Traditionally, reduction of dV has been carried out by micronization, usually by jetmilling. The small drug particles produced by micronization possess poor bulk flow properties
and are cohesive particularly when present as a drug only formulation (Crowder et al., 2006;
Rehman et al., 2004). The small size brings about particle cohesion by reducing the
interparticulate distances. This results in an increase in Van der Waals forces of interaction
thereby making the powders stick together as clumps and adversely affecting their flowability
(Terzano and Colombo, 1999). The emitted dose of a powder is a function of its flow properties
with better flowing powders exhibiting improved device emptying (Terzano and Colombo, 1999;
Chow et al., 2007; Iida et al., 2001). Further, these small inhalation particles produced by
micronization are also generally cohesive due to electrostatically charged surfaces produced
during the milling process, filling and device manipulation (Terzano and Colombo, 1999; Chow
et al, 2007, Louey et al., 2006; Danniher and Zhu, 2008; Iida et al., 2001). Electrostatically
charged surfaces are subject to Coulombic forces of interaction and it has been suggested in the
literature that such interactions are comparable in strength to the Van der Waals forces (Chan,
2006; Keil et al., 2006). The emitted dose is strongly and negatively influenced by the
electrostatic deposition in the inhalers and on the mouthpieces (Chan, 2006).
Due to the poor flow properties of micronized inhalation particles when present as drug
only formulations, a common practice is to blend the small drug particles with large carrier
particles. Addition of large (50-100 µm) carrier particles in the form of lactose results in an
increase in the interparticulate distances which therefore reduces the Van der Waal’s forces
making the particles less cohesive (Daniher and Zhu, 2008; Chow et al., 2007; Iida et al., 2001).
The drug particles adhere to the surfaces of the carrier lactose particles. This adherence further
reduces the cohesive forces between the drug-drug particles and promotes powder flow. The
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improvement in powder flow for dry powder formulations of fluticasone propionate in the
presence of lactose as a carrier has been studied by Louey et al. (2004). They employed measures
of flowability such as the Carr’s compressibility index calculated from tapped and bulk powder
density and the vibrating spatula method to generate powder mass flow vs. time profiles. They
showed an increase in powder flow with an increase in the lactose proportion in the dry powder
formulation. Therefore, it is believed that the increase in emitted fraction in drug / lactose blend
formulations is attributed to the role of lactose in promoting powder flow.
Apart from reducing the physical size of the particles by micronization, the aerodynamic
diameter can also be reduced by reducing the particle density and increasing the dynamic shape
factor. Decrease of both particle density and size is currently achieved by spray-drying (Platz et
al., 2003, Edwards et al., 2003) or more recently, by spray-freeze drying (Shekunov et al., 2006,
Shekunov et al., 2004, Truong-Lee et al., 2004, Shekunov et al., 2004). Theoretically, a smaller
dA can also be obtained with particles of non-spherical shapes, such as platelets, rods or fibers
(Shekunov et al., 2003, Shekunov et al., 2006, Chan et al., 1995, Crowder et al., 2002), because
the χ value for such particles can be as high as 10 (Shekunov et al., 2006). In terms of
aerodynamic performance, changing the ruggedness of particle surfaces, as quantified by the
surface fractal dimension (Shekunov et al., 2006, Chan et al., 2006), is analogous to a
simultaneous reduction of the particle density and increase of the dynamic shape factor. The
shape of the drug particles also influences their flow properties and hence the emitted dose.
Spherical particles tend to pack more closely together compared to acicular particles. The closer
packing leads to a decrease in the Van der Waals forces and makes these spherical particles more
cohesive and therefore adversely affects their flow properties.
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I.A.1.2

Influence of drug particle characteristics on fine particle fraction
FPF represents the mass fraction of the aerosol less than 5.0 µm and is considered to be

respirable. This denotes the ability of the particle agglomerates to disperse into discrete
individual particles during aerosolization. FPF is also influenced by the drug particle
characteristics. The size of the particles has a significant influence on particle dispersivity in both
drug only and drug / lactose formulations. Small micronized drug particles have a tendency to
form agglomerates with each other in drug only formulations. These agglomerates need to be
broken down into primary particles during aerosolization for a high FPF. Even though the
primary size of these micronized particles is small, high cohesion leads to a reduction in their
FPF. In drug / lactose blends, lactose particles possess active sites to which the small micronized
drug particles adhere (Chow et al., 2007). These micronized particles have surfaces with high
energy as a function of the micronization process and therefore adhere strongly to the lactose
particles. The strong adherence will lead to reduced dispersion and hence reduce the FPF for
these micronized drug particles. Particle morphology also influences the FPF. Acicular particles
tend to adhere less strongly to the lactose surface due to the reduced surface area of contact
available compared to spherical or plate-like particles (Louey et al., 2004).
Particle dispersibility is promoted by a large volume, low bulk density, and irregular
particle morphology, all of which prevent close packing between the particles and hence hinder
aggregation. Techniques such as spray drying utilize the concept of preparing porous particles
with large volume and low bulk density and hence better dispersibility. The low powder bulk
density has been observed for some non-spherical irregular particles produced by supercritical
fluid (SCF) precipitation (Shekunov et al., 2003) and this may partially explain their enhanced
performance.

6

I.A.1.3

Desirable attributes for a dry powder formulation
Based on the above attributes, a formulation intended for efficient pulmonary delivery

should possess the following optimal characteristics: narrow aerodynamic particle size range,
low surface energy and charge, non-spherical morphology, and low density or high porosity. The
physical stability and solid-state structure of particles need to be considered in conjunction with
their aerodynamic performance. It is preferred to use crystalline drug substances compared to
their amorphous counterparts since crystalline substances are more stable and hence less prone to
potential changes associated with solid-state transitions. Crystalline particles are typically nonspherical, have low-energy surfaces and are stable thermodynamically; however, they have a
relatively high particle density and tend to pack more tightly with a high tapped bulk density.
These properties, therefore, reduce the aerodynamic performance due to reduced dispersibility.

I.A.2

Rationale for using combination therapy for the treatment and maintenance
of asthma
Apart from β2 agonists, there are a number of other classes of compounds such as the

corticosteroids and anticholinergics that are also used for the treatment and maintenance of
asthma. All these compounds have different mechanisms of action. Both β2 agonists and
anticholinergics function as bronchodilators. However, they do so by different mechanisms.
While β2 agonists activate adenyl cyclase and stimulate the production of cyclic adenosine 3′,5′monophosphate (AMP) thereby reducing intracellular calcium concentrations; anticholinergics
competitively inhibit muscarinic cholinergic receptors and produce bronchodilation (Schreck et
al., 2006). There have been numerous studies to investigate the impact of adding an
anticholinergic such as ipratropium bromide to β2 agonist therapy. These studies have proven
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greater therapeutic benefit when the two classes of drugs are given together compared to
treatment with a single class alone (Bryant et al., 1985, Ward et al., 1985).
In order to take advantage of the greater therapeutic benefit offered by synergistic therapy
with β2 agonists and anticholinergics, formulations containing the two of them together have
been introduced. One such formulation is the Combivent® pMDI (Boehringer Ingelheim,
Ridgefield, CT) - a microcrystalline suspension of albuterol sulfate (AS) and ipratropium
bromide (IB) in a nominal ratio of 6:1 prepared in a blend of CFC propellants (Combivent
Package Insert). This product has however, now been withdrawn from the market due to the
inability of the manufacturers to manufacture it as a CFC-free formulation (Calderdale and
Huddersfield). There are numerous processing difficulties associated with formulating these
physical mixtures of micronized powders. Differences in the initial particle size distributions of
the two powders and a tendency for segregation of the mixture into its individual components are
well known (Nelson et al., 2003; Taki et al., 2006). These issues lead to variations in the
intended drug ratio.
In this regard, combination particles containing fixed proportions of the two components
may offer significant advantages. In order to investigate this potential, Jin et al. used a cooling
crystallization process to produce combination particles of albuterol sulfate and ipratropium
bromide in a nominal 6:1 (w/w) ratio (Jin et al., 2006). These particles, however, were too large
for inhalation and required micronization to reduce their particle size to the inhalation size range.
Formulation of these particles in a DPI (Dryhaler) and its in vitro aerosol performance testing
revealed co-deposition of AS and IB compared to the commercial Combivent® pMDI.
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I.B

Particle engineering for inhalation particles

I.B.1

Micronization
Micronization or milling is the most commonly used technique to produce particles for

use in marketed inhaler formulations. Such particles are initially produced by batch
crystallization, followed by filtering, drying and are then micronized. The particle size reduction
can be achieved by pressure, friction, attrition, impact, or shear. Vibration milling, ball milling
and, in particular, jet-milling (fluid energy) are well-established and well-validated techniques
used to manufacture dry powders for inhalation. In the jet-milling process, the starting material
undergoes many impact events before a significant quantity of the required particle size fraction
is achieved and separated from the larger particles by inertial impaction. This classification
ensures that the particle size required for respiratory delivery is eventually obtained. The
characteristic particle shape is either tabular or rounded leading to close packing between the
milled particles (Shekunov et al., 2004). Micronization is also notorious for inducing
electrostatic charge on the particle surface, which renders the milled material both cohesive and
adhesive (Crowder et al., 2006; Rehman et al., 2004). Generation of amorphous domains renders
the material unstable and prone to undergo recrystallization leading to crystal growth on the
milled particle surface and formation of solid bridges between the particles. The material is then
also prone to chemical decomposition and water sorption (Ward and Schultz, 1995; Pfeiffer et
al., 2003). All these physical and chemical changes are highly undesirable, and can adversely
affect the in vitro and in vivo performance of the respiratory formulations (Berard et al., 2002,
Rasenack et al., 2004). Therefore, although micronization is a simple and convenient technique
for size reduction, it is by nature a disruptive process and provides only limited opportunities to
manipulate and control the particle characteristics. Therefore, it is desirable to develop alternate
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particle engineering techniques capable of producing particles in a size range suitable for
inhalation without the need for further size reduction.

I.B.2

Alternate particle engineering techniques for producing inhalation particles

I.B.2.1

Sonocrystallization
Sonocrystallization is the application of power ultrasound to the crystallization process

and has shown potential for controlling the physical characteristics of the crystalline products.
Sonocrystallization is predominantly utilized to bring about controlled nucleation in a
crystallization process and to slow down crystal growth thereby resulting in small particles.
Ultrasound induces nucleation by acoustic cavitation by creating areas of high and low pressure
(Thompson et al., 1999). On implosion of the cavitations, areas of extremely high pressure and
temperature are created over a short time interval. This process may induce an increase in the
diffusion of the drug molecules and a concomitant decrease in the activation energy barrier for
the formation of a stable nucleus or nuclei for crystal growth (Thompson et al., 1999). Variations
in the amplitude and frequency of the ultrasonic energy may further control the rate of nucleation
and crystal growth. Using ultrasound to generate nuclei in a reproducible way provides a welldefined start point for the crystallization process, and allows the developer to focus on
controlling the crystal growth for the remainder of the residence time in the crystallizer. Using
sonocrystallization, Dennehy et al. reported the formation of significantly smaller crystals of a
drug substance relative to batch crystallization (Dennehy et al., 2003). Using an optimized
soncrystallization technique, Dhumal et al. reported the formation of AS particles with VMDs of
1.6 ± 0.1 µm (Dhumal et al., 2009). They also incorporated a spray drying step in their process
wherein the solvent / anti-solvent suspension containing the precipitated AS particles was spray
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dried. Using these particles, the authors reported an emitted fraction of 74.6 ± 1.4 % and a %
FPF of 44.2 ± 1.3 % expressed as a percentage of the nominal dose when tested from the
Rotahaler at a flow rate of 28.3 L/min. These aerosol performance characteristics were
significantly improved relative to micronized albuterol sulfate.
Kaerger et al. have utilized sonocrystallization in combination with solution atomization
to develop a technique known a solution atomization and crystallization by sonication (SAXS)
(Kaerger and Price, 2003). In this technique, the drug solution is atomized into solution droplets
and added to an anti-solvent with an immersed ultrasonic probe. The authors claim that control
of final particle size is achieved by modifying the initial atomized droplet size and sonication
conditions to induce nucleation. Using this technique, they reported the formation of spherical
particles in the inhalation size range. SAXS has also been used to produce combination particles
of different anti-asthmatic compounds. Using this technique, Shur et al. have produced
combination particles of fluticasone propionate and salmeterol with a VMD of 4.7 ± 0.01 µm
(Shur et al., 2006). The in vitro aerosol performance was tested by preparing a 1.6 % w/w blend
with lactose which was aerosolized using the Monohaler. Results indicated significantly smaller
emitted dose fractions for the combination particles compared to micronized powders. However,
the % FPF for the two drugs was higher when tested as combination particles (10.7 ± 0.3% for
fluticasone propionate; 11.6 ± 1.1% for salmeterol) compared to a physical mixture of
micronized drugs (7.9 ± 0.5% for fluticasone propionate; 6.7 ± 0.5% for salmeterol).
Pitchayajittipong et al. have also reported the formation of combination particles of budesonide
and formoterol with a VMD of 4.17 ± 0.04 µm using the SAXS technique (Pitchayajittipong et
al., 2009). Using a 1.6% w/w drug / lactose blend in the Cyclohaler, a higher % FPF for the
combination particles (21.78 ± 1.4 % for Budesonide; 14.19 ± 0.92 % for formoterol) compared
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to a physical mixture of micronized drugs (14.75 ± 0.63 % for Budesonide; 6.19 ± 1.87 % for
Formoterol) was reported. However, there results showed a large difference in the % FPFs of the
two drugs formulated in the combination particles indicating non-uniform deposition upon
aerosolization. The authors attributed this difference to mechanical disruption of particles upon
blending with lactose. They also report that upon formulating these particles in pMDIs, fine
particle delivery of both drugs was similar. Although sonocrystallization appears to be a simple
process for producing inhalation particles comprised of a single drug, its utility in producing
fixed ratio combination particles that aerosolize to produce uniform co-deposition does not
appear to be well established.

I.B.2.2

Spray drying
Spray drying (SD) is a popular particle engineering technique owing to its relative

simplicity, availability of large scale equipment, and ease of operation. A typical SD process
consists of four steps (Master et al., 1991):
(a) Atomization of feed solution into a spray
(b) Spray-air contact involving flow and mixing
(c) Drying of sprayed droplets at elevated temperatures
(d) Separation of dried product from the air.
For each of these operating steps, a wide variety of process designs are available, depending on
specific applications. To modify or optimize the particulate product characteristics, advantages
can be taken of the operating parameters of the SD process such as atomization pressure, feed
properties, feed rate, airflow and drying temperature (inlet or outlet) (Master et al., 1991). For
particle size control, the plain-jet air-blast atomizer offers the advantage of generating smaller
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initial droplet size over ultrasonic atomizer, thus yielding particles within the respirable size
range (Dunbar et al., 1998). Control of particle shape/morphology can be gained by varying the
feed solvent (Gilani et al., 2005) or adjusting the outlet drying temperature (Maa et al., 1997).
Both feed concentration and atomization rate can be concomitantly manipulated to generate
particles with different degrees of surface corrugation (Chew et al., 2005). Common excipients
such as lactose and polysorbate 20 (Tween 20) can also be added to the feed solution to yield
particles with rougher surfaces (Maa et al., 1997).
Using the spray drying process, combination particles of albuterol sulfate and ipratropium
bromide have been produced (Corrigan et al., 2006). These particles were spherical and ranged
in size from 0.2-4.8 µm. However, these particles were amorphous in nature. Production of
amorphous products is a common disadvantage associated with the spray drying process.
Although there are advantages of increased dissolution and bioavailability associated with
amorphous substances, they are relatively unstable compared to their crystalline counterparts.
This instability might lead to recrystallization, crystal bridging and a subsequent increase in
particle size thereby nullifying the earlier particle engineering efforts to generate small inhalation
sized particles.

I.B.2.3

Supercritical fluid technologies
Supercritical fluid (SF) technology is considered to be an innovative and promising way

to produce inhalation particles. A supercritical fluid is any substance at a temperature and
pressure above its critical point. Of all the gases available for use as SFs, carbon dioxide is the
most widely used because of its low critical temperature (31.1°C), which makes it particularly
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suitable for heat sensitive materials. Broadly speaking, supercritical fluid crystallization
technologies can be divided into two categories (Tong et al., 2006):
Firstly, precipitation from supercritical solutions, for example, the rapid expansion of
supercritical solution (RESS). The drug is first dissolved in the SF to form a solution, which is
then allowed to undergo expansion through an orifice to create extremely high supersaturation.
This induces homogeneous nucleation and subsequent particle formation in the precipitation unit.
This method relies on the fact that drug solubility can be reduced drastically by decreasing the
SF density through the rapid expansion of the fluid. Primary factors influencing the particle
properties include the drug solubility in SF, the dimensions of orifice, expansion time scale, and
the operating pressure/temperature in the precipitator.
Secondly, precipitation using SFs as non-solvents or anti-solvents, for example, gas anti solvent (GAS), supercritical anti-solvent (SAS), precipitation with compressed anti-solvents
(PCA), aerosol spray extraction system (ASES), and solution enhanced dispersion by
supercritical fluids (SEDS) (Tong and Chow, 2006). These methods utilize a similar concept to
the use of anti-solvents in traditional solvent-based crystallization processes. The relatively low
solubilities of drugs in carbon dioxide are used in this process. Initially, the drug is dissolved in a
conventional organic solvent to form a solution. The drug is virtually insoluble in dense carbon
dioxide while the solvent is completely miscible with dense carbon dioxide at the crystallization
temperature and pressure (Subramaniyam et al., 1997). The solute is crystallized from solution in
one of the three ways discussed below.
In the first method, the volume of the solution containing the drug is expanded several
fold by mixing with dense carbon dioxide in a vessel. Since the expanded carbon dioxide solvent
has a lower solvent strength than the pure solvent, the mixture becomes supersaturated, forcing
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the solute to precipitate or crystallize as microparticles. This process is termed gas anti-solvent
(GAS) recrystallization (Gallagher et al., 1989). Sodium cromoglycate has been synthesized
using this technique (Jaarmo et al., 1997).
The second method involves spraying the drug solution through a nozzle as fine droplets
into compressed carbon dioxide. This process is commonly known as the 'precipitation with
compressed anti-solvent' (PCA) technique and employs a supercritical fluid as the anti-solvent
(Dixon et al., 1993). Examples of PCA processed materials are indomethacin (Bodmeir et al.,
1995), methylprednisolone acetate and hydrocortisone acetate (Schmitt et al., 1995). When a
supercritical fluid is used as anti-solvent, the spray process is termed as 'supercritical antisolvent' (SAS) process or 'aerosol spray extraction system' (ASES) (Subramaniyam et al., 1997).
The third method, known as ‘solution enhanced dispersion by supercritical fluids’
(SEDS), utilizes a coaxial nozzle design with a mixing chamber. In this arrangement the drug in
the organic solvent interacts and mixes with the SF anti-solvent in the mixing chamber of the
nozzle prior to dispersion via a restricted orifice into a particle-formation vessel (York et al.,
1999). High mass transfer rates are achieved with a high ratio of SF to solvent, and high velocity
of the SF facilitates break up of solution feed (York et al., 1999). Using this technique, albuterol
sulfate particles with a mass median diameter of 7.5 µm have been reported by Najafabadi et al.
(Najafabadi et al., 2005).

I.B.2.4

Controlled precipitation techniques
Controlled precipitation utilizes the crystallization process to produce inhalation sized

particles in a number of ways. One of the techniques is referred to as in situ micronization and
employs crystal growth inhibitors in the crystallization medium. These crystal growth inhibitors
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limit the growth of crystals by adsorbing onto the surface of the formed particles and blocking
the passage of other drug molecules thereby limiting deposition of further drug molecules on the
preformed particles and hence controlling size (Rasenack et al., 2002). Commonly used crystal
growth inhibitors are polymeric in nature such as hydroxy propyl methyl cellulose (HPMC), and
methyl cellulose. Beclomethasone dipropionate, budesonide, triamcinolone acetate and
indomethacin crystals in the inhalation size range of 1-5 µm have been produced using this
technique (Rasenack et al., 2002). However, this method is very specific for the drug and
polymer for which it is developed and cannot be generalized for other drugs without carrying out
a new development process. Furthermore, the crystal growth inhibitors are adsorbed to the
surface of the formed particles. None of the polymers used thus far has proven lung safety
records and hence such particles with appreciable levels of polymers on their surface cannot be
used for lung delivery.
Another technique is the high gravity controlled anti-solvent precipitation. This technique
utilizes solvent / anti-solvent precipitation in a high gravity controlled precipitator (HGCP). The
HGCP is basically a rotating packed bed in which two liquid streams can be fed via distributors
and mixed into the centre of a packed bed, which is subjected to high gravity due to centrifugal
force. This causes the mixture to flow through the packing before leaving the reactor (Chiou et
al., 2007). Due to high centrifugal force, the liquid stream is subjected to high stress and breaks
into ribbons affording intense mixing between the drug solution and the anti-solvent which leads
to very high levels of supersaturation and produces particles with a small particle size. Albuterol
sulfate crystals with a VMD ranging from 2.2-4.8 µm were produced using this process (Chiou et
al., 2006).
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I.C.

Solvent / anti-solvent crystallization
There are a number of particle engineering techniques for the formation of particles for

respiratory drug delivery. However, most of these techniques are either complex with special
equipment needs, and/or difficult to scale up. Solvent / anti-solvent crystallization as a particle
engineering technique offers attractive benefits. The principle of solvent / anti-solvent
crystallization is rapid precipitation by generation of high supersaturation levels leading to the
formation of small crystals. However, because of its rapid nature, it is difficult to control the
particle characteristics of products formed from this technique. This has led to the use of
additional growth control methods such as the use of growth inhibitors or ultrasound. It would be
advantageous to develop a simple solvent / anti-solvent crystallization process that controls
particle size through hydrodynamic factor optimization alone. In order to do so, it is important to
understand the mechanism of solvent / anti-solvent crystallization and the influence of critical
processing variables on particle characteristics for controlling the final product.

I.C.1

Theory of solvent / anti-solvent crystallization
Crystallization is defined as a phase change that results in the formation of a crystalline

solid (Myerson, 1999). The most common type of crystallization is crystallization from solution,
in which a drug is dissolved in a solvent and crystallization is induced by changing the state of
the system in some way that reduces the solubility of the drug. In solvent / anti-solvent
crystallization, this reduction in solubility is achieved by an anti-solvent. The kinetic process of
crystallization involves two main steps: nucleation and crystal growth and the properties of the
formed particles are determined by them.
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I.C.1.1

Driving force for crystallization
Figure I.1 shows the schematic solubility/super solubility diagram.

Figure I.1 Schematic solubility diagram

Crystallization can take place over the concentration range limited by the equilibrium
composition of the system at specified conditions. Thermodynamic equilibrium refers to the
solutions saturated with respect to the solute (i.e., the concentration of the solution represents the
solubility value for that solid phase); the rates of dissolution and crystallization are equal under
these conditions. A solution with solute concentration below the saturation limit (shown by solid
line) is termed under-saturated and existing crystals will dissolve. In order for crystallization to
occur, the system must be brought into a non-equilibrium state where the concentration of the
solute exceeds its equilibrium concentration (i.e., the solution is supersaturated). The driving
force for crystallization is therefore the degree of supersaturation, expressed as the difference in
concentration between the supersaturated and saturated solutions. The most common methods to
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create supersaturation in a solution include temperature change, solvent evaporation, chemical
reaction, pH change, and alteration in solvent composition. The metastable limit (dashed line)
defines the compositions at which spontaneous crystallization occurs and the region bounded by
the solubility curve and the metastable limit is termed metastable zone. The metastable zone
width (MSZW) depends on purity of the system, thermal history of solution and density of
foreign particles present in the solution and is of practical importance since it defines the
working area for designed crystallizations (Beckmann, 2000).

I.C.1.2

Nucleation
Nucleation involves the aggregation of dissolved molecules in the supersaturated solution

into organized clusters (embryos) thus developing a surface that separates them from the
environment. This nucleation process can be split into two main categories (Zettlemoyer, 1969;
Mullin, 2001): (1) primary nucleation, when no crystals are initially present in the solution, and
(2) secondary nucleation, when crystals of the solute are already present or are deliberately
added to the solution as seeds. Primary nucleation is further classified into homogeneous
nucleation, which occurs spontaneously in bulk solutions, and heterogeneous nucleation, which
is induced by foreign particles. Homogeneous nucleation rarely occurs in large volumes (greater
than 100 μl), as most solutions contain random impurities which may induce nucleation
(Perepezko, 1994; Gunton, 1999). Although heterogeneous and/or secondary nucleations are
commonly encountered in practice, homogeneous nucleation forms the basis for classical
nucleation theory. Metastable zone widths (MSZW) with respect to nucleation type are
schematically shown in Figure I.2.

19

Figure I.2 Schematic diagram showing metastable zone width with respect to nucleation
type
It is observed that the MSZW is narrowest for secondary nucleation and increases
successively for primary heterogeneous and primary homogeneous nucleation. This is because
the energy barrier to induce nucleation is smallest for secondary nucleation since seeds are
already present to act as embryos. For primary homogeneous nucleation, this energy barrier is
highest since nucleation has to occur by spontaneous fluctuations in solvent density and
composition (Mullin, 2001; Mersmann, 2001).

I.C.1.2a

Classical nucleation theory

Classical nucleation theory (Volmer, 1939; Gibbs, 1948; Nielsen, 1964) was originally
derived for the condensation of vapor into liquid and has been extended to crystallization from
solutions. According to this theory, the free energy change (ΔGtotal) for a cluster undergoing a
phase transition is given by
20

ΔGtotal = ΔGsurface + ΔGvolume
where ΔGvolume is a volume free energy term that is proportional to the cube of the radius and
favors aggregation of molecules. ΔGsurface is a surface free energy term that is proportional to the
square of the radius of the cluster and favors the dissolution of molecular clusters. Thus for a
small radius, r, where the positive surface energy predominates, the nucleus is unstable and tends
to dissolve. Eventually, the cluster attains the critical size (r = rc) at which the surface term and
volume term exactly balance. At this point the total free energy of the cluster attains a maximum,
which corresponds to the activation free energy of nucleation (ΔG*) as shown in Figure I.3.

Figure I.3 Schematic plot of Gibbs free energy change (Mullin, 2001) (Reproduced with
permission from Elsevier)
Supersaturation is required to overcome the free energy barrier to nucleation. After this stage, the
cluster becomes viable and is termed a nucleus, which eventually grows into a crystal. For a
polymorphic system, the polymorph that nucleates first is thought to come from the cluster that
exhibits the fastest growth rate as a result of its lowest free energy barrier to nucleation.
However, the nature of the polymorph that eventually crystallizes is determined by the
combination of the relative nucleation rates and the relative crystal growth rates of the
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polymorphs (Bernstein et al., 1999). Recent theoretical and experimental evidence however
suggests that the classical nucleation theory may not be qualitatively correct (Oxtoby, 1998;
Davey et al., 2002; Vekilov, 2004; Parveen et al., 2005). The latest studies suggest that
nucleation of solutes from solution is a two-step process (Wolde and Frenkel, 1997; Galkin and
Vekilov, 2000; Vekilov, 2004; Chattopadhyay et al., 2005): the creation of a droplet of a dense
liquid, metastable with respect to the crystalline state, followed by ordering within this droplet to
form a three-dimensional lattice structure.

I.C.1.3

Crystal growth
Once formed, nuclei begin to grow larger through the addition of solute molecules to the

crystal lattice, and this stage of the crystallization process is known as crystal growth. Crystal
growth is a multi-step process (Rodríguez-Hornedo and Murphy, 1999, Davey and Garside,
2000), which includes (1) transport of a growth unit (a single molecule, atom, ion, or cluster)
from or through the bulk solution to an impingement site, which is not necessarily the final
growth site (i.e. site of incorporation into the crystal); (2) adsorption of the growth unit at the
impingement site, (3) diffusion of the growth units from the impingement site to a growth site,
and (4) incorporation into the crystal lattice. Desolvation of the growth unit may take place
anywhere in steps 2–4 or the solvent may be adsorbed with the growth unit. The relative
importance of each step depends on the surface structure of the crystals and the properties of the
solution (Meenan et al., 2002). Based on their ability to capture arriving growth units, three types
of crystal surfaces (and thus growth sites created by these surfaces) can be differentiated
(Hartman and Perdock, 1955): kink, step and flat faces, which provide three, two and one surface
bond(s), respectively (Figure I.4)
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Figure I.4 A three dimensional crystal surface showing three types of growth sites (Mullin,
2001) (Reproduced with permission from Elsevier)
Assuming the linear relationship between a face growth rate and the total binding energy of a
growth unit to the surface, the final shape of a crystal is defined by the slowest growing flat
faces. Crystal growth theories are therefore concerned with the mechanisms by which these faces
grow.

I.C.1.3a

Crystal growth theories

The possible pathways by which a growth unit passes from solution to become integrated into
the crystal lattice are known as growth mechanisms. Two mechanisms are considered to be important
for the actual process of growth on crystal faces – two-dimensional (2-D) nucleation and screw
dislocation (Davey and Garside, 2000). Two-dimensional nucleation, also called the Birth and Spread
(B+S) model, occurs when nuclei at the crystal surfaces act as sources of steps that allow for the
further incorporation of growth units (Volmer, 1922). This mechanism has gained popularity, since it
is simple yet based on firm thermodynamic and kinetic principles. However, it mainly accounts for
the crystal growth observed at high supersaturations (Rodríguez-Hornedo et al., 2006). An
alternative mechanism suggested by Burton, Cabera and Frank (BCF) underlines the assumption that
growth occurs by flow of steps across the surface (Burton et al., 1951). Screw dislocation, a common
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crystal defect formed when one region of the crystal is pushed up through one (or more) unit cells

relative to another region, can be an infinitive source of these steps, onto which oncoming growth
units can be incorporated. Since screw dislocations exist on crystal faces at low supersaturation
levels, the model suggest that the growth can take place under realistic conditions.

I.C.1.4

Crystal morphology
At equilibrium, the external shape of a crystal, also termed habit, form or morphology, is

determined by its internal structural symmetry. In practice, crystal morphology is usually
described in terms of length, width and thickness. Within the pharmaceutical industry the
classifications of crystal shapes adopted by either British Standard (BS 2955:1993) or the US
Pharmacopoeia (monograph 776) (Table I.1) are commonly used for routine microscopical
examination of solid materials.
Table I.1 Crystal Morphologies for pharmaceutical solids

Equant
Flakes
Plates
Laths
Needles
Columnar

Crystals with similar length, width, and
thickness
Thin, flat crystals of similar width and length
Flat, tabular crystals with similar width and
length but thicker than flakes
Elongated, thin, and blade-like crystals
Acicular, thin, and highly elongated crystals
having similar width and breadth
Elongated, prismatic crystals with greater width
and thickness than needles

Flake

Lath (Blade)
Plate (Tabular)

Equant

Columnar
(Prismatic)
Needle (Acicular)

Experimentally obtained crystals however exhibit a growth habit since the crystal growth is a
non-equilibrium process. The equilibrium form can be achieved through an aging process, which
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involves solvent mediated dissolution and regrowth of the crystal faces equilibrated in a
saturated solution over time (Stranski and Honigmann, 1950; Saska and Myerson, 1987).

I.C.1.5

Role of different crystallization variables on particle characteristics
In order to efficiently use the solvent / anti-solvent crystallization process to yield

particles with desirable and reproducible characteristics, it is important to understand the effect
of different crystallization variables. Literature has predominantly focused on the effect of
crystallization variables on particle size. There are reports by O’Grady et al about the effect of
anti-solvent addition location, addition rate and stirring speed on particle size of benzoic acid
crystals wherein the authors have reported a parabolic relationship of particle size with stirring
speed in conjunction with the addition location (O’Grady et al., 2001). When the anti-solvent is
added close to the impeller, an increase in agitation intensity results in a narrower MSZW,
possibly due to the increased probability of contact between solute molecules. When the antisolvent is added close to the wall, an increase in agitation results in a wider MSZW and a
significant improvement in the batch-to-batch repeatability (O’Grady et al., 2001). These results
can be explained in terms of mixing conditions at each of the addition locations. Close to the
impeller, mixing conditions allow for the rapid incorporation of the anti-solvent and a
homogenous mixture of solution and anti-solvent. However, close to the wall, mixing conditions
are less suitable and areas of supersaturation build up leading to narrower MSZWs and a
reduction in the batch-to-batch repeatability. In this situation, when the agitation is increased, the
local areas of supersaturation can be dissipated, to some degree, and the MSZW is wider and the
batch-to-batch repeatability improves. Abdel-Al et al. (2004) have studied the effect of different
supersaturation ratios on crystallization of calcium sulfate dehydrate. They have reported the
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formation of large crystals at lower supersaturation ratios. Genoveva et al. (2007) have reported
the effect of agitation speed on the particle size of Zr(HPO4)2.H2O. They have described an
increase in crystal size as a function of increasing agitation.
Monitoring of the crystallization process is necessary to understand the effects of
different crystallization variables. The techniques employed have ranged from the traditional
methods such as particle harvesting and characterization by powder X-ray diffraction, particle
sizing methods, differential scanning calorimetry, isothermal microcalorimetry, and dynamic
vapor sorption gravimetry. Newer real time in-situ monitoring techniques are now being used as
part of the QbD initiative including focused beam reflectance measurement (FBRM) (Markande
et al., 2007), attenuated total reflectance-fourier transform infra red (ATR-FTIR) (Yu et al.,
2006; Barrett et al., 2005), Raman spectroscopy (Falcon et al., 2004), and ultrasound
spectroscopy (Hipp et al., 2000). These online or in situ monitoring techniques have enabled
high-throughput screening of the effects of crystallization variables and hence faster optimization
of the crystallization process. Yu et al have used ATR-FTIR for the monitoring and control of
solvent / anti-solvent crystallization of paracetamol from a water-acetone mixture (Yu et al.,
2006). Using this technique, they have monitored the nucleation kinetics and have utilized
feedback control for the addition of anti-solvent and have hence maintained constant
supersaturation throughout the crystallization process thereby leading to a narrow particle size
distribution. Penttila and co-workers have used fluorescence spectroscopy to monitor the solvent
/ anti-solvent crystallization of L-lysine monohydrochloride (Penttila and Berglund, 1996).
Emission spectra have been recorded and intensity changes in the emission spectrum have been
used to monitor the effect of anti-solvent addition rate on particle size distribution. The most
commonly used in situ monitoring tool is the FBRM. This technique uses laser light to measure
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the particle size distribution in situ. The particle size distribution is obtained as a chord length
distribution which is obtained as a product of the time of backscattering of the laser beam from
one edge of an individual particle to another and the scan speed. This in situ analysis of the
particle size is very useful because it provides information on when to terminate the
crystallization process. This technique can also detect the appearance of nuclei in the
crystallization medium and can hence be used to determine the metastable zone width; and
important crystallization parameter (Sheikhzadeh et al., 2008).

I.D.

Molecular modeling

I.D.1

Molecular modeling as a tool to study interactions
The molecular modeling methods function on the principle of molecular mechanics, often

referred to as the Force Field method. Molecular mechanics is the application of classical
mechanics to molecules. Classical mechanics is used to describe the motion of macroscopic
objects. In molecular mechanics, atoms are treated as spheres whose mass depends on the
element. Chemical bonds are treated as springs whose stiffness depends on which elements are
bound together and whether the bond is single, double or triple. Other types of springs are used
to model changes in bond angles, and dihedral angles. Each of these springs will have spring
constants associated with them. Experimental and theoretical methods are used to determine
these parameters. Additional equations from classical physics, such as Coulomb’s law are used
to handle any electrostatic interactions present within a molecule. The sum of all energy terms
that apply to a particular molecule are added together to give the “steric” or potential energy of
the molecule. All the equations and associated parameters used to calculate each energy term are
collectively called the force field.
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In real molecules, there are forces present other than those between bonded atoms. There
may be charges present that can repel or attract. Repulsions between non-bonded atoms that are
close together in space might also occur. These forces may act to change bond angles or cause
twisting around single bonds. To describe the energy of the system, all of the different types of
applicable interactions need to be taken into account. The sum of the energy of all of these
various components is the basis of a force field. A force field allows for calculation of all the
forces on the system which in turn gives the energy of the system. There is an intimate
connection between structure and energy and hence, molecular mechanics calculations always
involve both. In order to find the structure or predict geometry, it is necessary to examine the
energy to find where energy minima and hence the stable geometries exist.

I.D.2

SYBYL software
Sybyl is a software that employs the molecular mechanics principles to perform

molecular modeling studies. It is a general molecular modeling program written by Tripos.
SYBYL is a comprehensive computational tool kit for molecular design and analysis, with a
special focus on the creation of new chemical entities. Sybyl provides essential construction and
analysis tools for both organic and inorganic molecular structures. It employs molecular
mechanics or the force field method to calculate the molecular geometry, energies and various
other properties of the compound of interest (Tripos Bookshelf Force Field Manual 2006). A
force field is used to calculate the interaction forces for both bonding (covalent) and non-bonding
(Van der Waals and electrostatic) interactions for all the atoms in the molecule. The molecule
can rotate, vibrate and translate in response to the inter- and intra-molecular forces acting upon it
to attain its most favored conformation in space (Schlick 2000). Electrostatic point charges on
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the atoms in a molecule drawn in Sybyl can be calculated using various empirical methods, one
of them being the Gasteiger-Huckel method. In this method, the calculation of charges on the
molecule is based on the relationship between the orbital electronegativity and the atomic charge
given by equation I.1 (Tripos Bookshelf Force Field Manual 2006):

XA = aA + bA.Q + cA.Q2

Equation I.1

Where XA = orbital electronegativity and is represented as a function of the total charge (Q) on
an atom (A), and aA, bA and cA are the coefficients of the quadratic equation based on the
ionization potential and electron affinity of the atom.
The energy associated with a molecular model of a compound is a function of its atomic
coordinates. Energy minimization needs to be carried out in Sybyl after a molecular model is
constructed. In the process of energy minimization, the atomic coordinates of the constructed
molecular model are iteratively changed until a minimum energy value relative to the energy
associated with the initial set of atomic coordinates is obtained. The resulting atomic coordinates
corresponding to the local energy minimum correspond to the favored structural conformation of
the molecule in space (Tripos Bookshelf Force Field Manual 2006).
The properties of the molecules can be studied in vacuum. However, since in real
practice, most of the interactions happen in a solvent system, the software offers three options to
take into account the solvent effects in the study of molecular interactions. These include:
1. A distance dependent dielectric screening term in the force field to simulate the solvent
screening effects on electrostatic charge
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2. Implicit solvation of the molecule by adding a new term/terms to the force field to
account for solvent effects
3. Explicit inclusion of solvent molecules in the calculation of the intermolecular forces
(Tripos Bookshelf Force Field Manual 2006).
Sybyl has several inbuilt programs that allow the study of interactions between compounds. Two
of these programs are discussed in the subsequent sections.

I.D.3

GOLD program
GOLD is a program for calculating the docking modes of small molecules in protein

binding sites. It applies a genetic algorithm for generating ligand-docked poses and the results
are scored by an empirical function based on interaction possibilities derived from atom-atom
contact probabilities in the Cambridge Structural Database (CSD).

I.D.4

HINT! program for interaction classification and quantitative scoring
HINT! or the Hydropathic Interaction is a program that uses the experimental data from

solvent partitioning experiments between water and 1-octanol (LogPo/w) for interaction
classification and quantitative scoring. HINT was created to specifically include all non-covalent
interactions. Hydrophobic and polar interactions, which are collectively referred to as
hydropathy, between molecules in biologically important systems are empirically quantified. In
this scheme, hydropathic attractions between species include hydrogen-bonding, acid–base
interactions, Coulombic attractions as well as hydrophobic interactions. All of these are related
to solvent partitioning phenomena because the dissolution of a ligand in a mixed solvent system
(such as water/1-octanol) involves the same fundamental processes and atom–atom interactions
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as biomolecular interactions within or between proteins and ligands. HINT scores each atomatom interaction, within or between the molecules with the following equation (Kellogg et al.,
2000):

bij = aiSi ajSj TijRij + rij

Equation I.2

where bij is the interaction score between atoms i and j, a is the hydrophobic atom constant, S is
the solvent accessible area, Tij is a logic function which returns a value of 1 or -1 depending on
the character of the interacting polar atoms (a<0 for polar atoms), there are three possibilities:
acid-acid, base-base and acid-base of which only the acid-base interactions are scored
positively/favorably. Rij is the exponential e-r (r is the distance between the atoms i and j) and rij
is an implementation of the Lennard-Jones potential function. The total HINT interaction score is
given by the sum of the individual interaction scores (ΣΣbij). The HINT convention is that
favorable interactions are scored with bij > 0 and unfavorable interactions are scored with bij < 0.
The logic function Tij returns a value of 1 or –1 depending on the character of the interacting
polar atoms (i.e. a < 0): there are three possibilities: acid–acid, acid–base, or base–base; only
acid–base is scored favorably. Tij also flags hydrogen bonds which are in the HINT model a
special case of acid–base interactions.

I.E

Overview
This dissertation is organized to address the investigation and optimization of a solvent /

anti-solvent crystallization process to produce particles for inhalation. Chapter II states the
individual hypotheses and the specific aims that will be addressed in the succeeding chapters.
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Each of the chapters consists of a brief introduction, a materials and methods section, followed
by a results and discussion section. Chapter III describes the investigation and optimization of
the solvent / anti-solvent crystallization process to produce particles suitable for inhalation using
albuterol sulfate as the model drug. Chapter IV discusses the further optimization of this
crystallization method to produce combination particles of albuterol sulfate and ipratropium
bromide monohydrate. Characterization of these combination particles by different analytical
techniques to understand the nature of interactions between albuterol sulfate and ipratropium
bromide is also described. In silico molecular modeling tools to carry out a computational
analysis of the possible interactions between albuterol sulfate and ipratropium bromide within a
combination particle matrix constitutes the final section of this chapter. The in vitro aerosol
performance of the engineered albuterol sulfate particles and combination particles of albuterol
sulfate and ipratropium bromide produced from the optimized solvent / anti-solvent
crystallization process is investigated as dry powder formulations in Chapter V. Comparison
with conventionally used micronized powders in commercial formulations is also discussed.
Finally, Chapter VI summarizes the results from each chapter as they relate to the original
hypotheses.
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CHAPTER II
HYPOTHESES AND RESEARCH PLAN

II.A.

Hypothesis 1
An understanding of the degree of influence of crystallization variables such as the

solvent/anti-solvent ratio, agitation speed, temperature, and crystal maturation time upon particle
characteristics allows optimization and control of the final product and its aerosol performance.
More specifically, it was hypothesized that micro-crystals of AS with suitable characteristics for
dry powder inhalation could be produced by proper selection and optimization of the
crystallization variables.
In order to test this hypothesis, a solvent / anti-solvent crystallization process was
investigated with respect to the effect of crystallization variables on two particle characteristics;
particle crystallinity and particle size. Solid-state characterization techniques were used to
characterize the final products.

II.B.

Hypothesis 2
The solvent / anti-solvent crystallization process can be further optimized to produce

combination particles of albuterol sulfate (AS) and ipratropium bromide monohydrate (IB) in
predictable ratios with suitable characteristics for inhalation.
In order to test this hypothesis, the crystallization conditions were studied and eventually
and optimized to produce combination particles of AS and IB in predictable ratios of 1:1, 2:1,
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6:1, and 10:1 (w/w). The performance of different anti-solvents in the form of ethyl acetate,
isopropanol and mixtures of the two were reviewed at selected initial drug concentrations, drug
solution / anti-solvent ratio, stirring speed, and crystallization conditions. Particles
characterization was carried out to understand the nature of the interactions between AS and IB
to distinguish them from physical mixtures of AS and IB.

II.C.

Hypothesis 3
Molecular modeling tools can be used to identify and understand the likely interactions

between AS and IB within a combination particle matrix.
Molecular modeling software Sybyl 8.0 was used to study interactions between randomly
orientated AS and IB molecules and the HINT program was employed to classify and score
favorable and unfavorable interactions between the molecules. Furthermore, a unit cell of AS
was constructed and GOLD program was used to perform docking experiments wherein the
effects of introducing a single molecule of IB were studied within the AS unit cell. HINT was
again employed to classify and score the favorable and unfavorable interactions between AS and
IB in this cell arrangement.

II.D.

Hypothesis 4
It is hypothesized that the albuterol sulfate particles and combination particles of

albuterol sulfate and ipratropium bromide monohydrate can be engineered with superior aerosol
performance properties as compared to the conventionally used micronized albuterol sulfate and
physical mixtures of separately micronized AS and IB.
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In order to test this hypothesis, the engineered particles of albuterol sulfate and
combination particles of AS and IB were be formulated as dry powder inhaler formulations.
Their in vitro aerosol performance testing was assessed using different dry powder inhalers. The
in vitro aerosol performance of the engineered AS particles was compared to a reference
commercial dry powder formulation of albuterol sulfate (Novolizer®) containing micronized
albuterol sulfate mixed with carrier lactose while the in vitro aerosol performance of the
combination particles was compared to the commercial formulation containing individually
micronized AS and IB as a physical mixture (Combivent® pMDI).

35

CHAPTER III
INVESTIGATION AND OPTIMIZATION OF A SOLVENT / ANTI-SOLVENT
CRYSTALLIZATION PROCESS USING ALBUTEROL SULFATE AS A MODEL
DRUG

III.A.

INTRODUCTION
In this chapter the effects of solvent / anti-solvent crystallization conditions on particle

characteristics; predominantly particle size and crystallinity were investigated using albuterol
sulfate (AS) as a model drug. Since an understanding and control of the critical processing
variables is integral to producing particles with desirable characteristics, the influence of
crystallization variables upon precipitated particle characteristics was determined to allow
optimization and control of the final product. Specifically, it was hypothesized that microcrystals of AS with suitable characteristics for inhalation (i.e.; complete crystallinity and size
range between 1-5 µm) can be produced by proper selection and optimization of the
crystallization variables.

III.B.

CHEMICALS

Albuterol Sulfate ((RS)-1- (4-hydroxy-3-hydroxymethylphenyl)-2-(tert-butylamino) ethanol
sulfate): Spectrum Chemical Mfg. Corp., New Brunswick, NJ
HPLC grade ethyl acetate: Fischer Scientific, Pittsburgh, PA
HPLC grade isopropyl alcohol: Fischer Scientific, Pittsburgh, PA
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HPLC grade methanol: Fischer Scientific, Pittsburgh, PA
Ammonium Formate: Fischer Scientific, Pittsburgh, PA
Lactose Monohydrate: DMV Fonterra Excipients, Princeton, NJ

III.C.

METHODS

III.C.1

Crystallization of albuterol sulfate

III.C.1.1

Preparation of a saturated aqueous solution of albuterol sulfate

An aqueous solution of AS (concentration: 0.22g/g) was prepared by weighing 0.14g of
albuterol sulfate into a glass beaker and adding 0.5g water to achieve the required concentration.
The beaker was covered with parafilm and heated to 40°C. Following dissolution of albuterol
sulfate, the saturated solution was allowed to cool to room temperature (25-27°C) (Nocent et al.,
2001).

III.C.1.2

Crystallization by the anti-solvent method

The experimental setup is shown in Figure III.1. In each experiment, an appropriate
amount of ethyl acetate (based on the drug solution / anti-solvent ratio (Ra ratio) being tested)
was added to a 1000mL cylindrical flat-bottomed vessel (Height = 15.2 cm, ID = 10.1 cm). The
aqueous solution of albuterol sulfate was added to ethyl acetate over a 30 second period at a
fixed infusion rate of 1 mL/min by means of a syringe pump (Harvard Apparatus, Holliston,
MA) using a 500μL Hamilton gastight syringe. The drug solution was transferred to the
crystallization vessel via a 12 cm PEEK tubing (ID = 0.007 inches, Upchurch Scientific, Oak
Harbor, WA) which was held in a fixed position 5 cm above the anti-solvent. Mixing between
the drug solution and anti-solvent was achieved by a stirrer (Caframo stirrer type RZR 50,
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Wiarton, ON, Canada) with a single bladed paddle with dimensions of 5.1 × 2.5 × 1.5 cm.
Stirring was initiated with the addition of the drug solution and was carried out for a fixed 30
minute period at a range of stirring speeds. Experiments were carried out at room temperature
(25-27°C) resulting in no temperature difference between the AS solution and ethyl acetate
unless otherwise stated. Following the 30 minute stirring period, the AS particles were either
harvested immediately (crystal maturation time = 0) or allowed to remain in the solvent/antisolvent mixture for upto 1440 minutes (24 hours) resulting in different crystal maturation times
ranging from 0-24 hours. Particles were recovered from the anti-solvent by vacuum filtration
using a 0.45μm nylon membrane filter (45mm diameter; Fischer Scientific, Pittsburgh, PA)
housed in a glass filter unit. The filter paper containing the wet cake was washed with and the
particles resuspended in 4mL of the saturated filtrate solution. This concentrated suspension was
sonicated at 40KHz for 45minutes in a Branson ultrasonic bath to allow complete evaporation of
the filtrate solution and to maintain particle separation during solvent removal. The particles
were then dried for 24 hours at room temperature. Samples were then stored in sealed containers
in a dessicator containing dried silica as the dessicant at room temperature.

III.C.1.3

Experimental design for screening the effects of crystallization conditions

A multi-factorial experiment was designed using JMP software (JMP, version 7.0, SAS
Institute Inc., Cary, NC). Albuterol sulfate was crystallized from its aqueous solution using the
general crystallization method described in section III.C.1.2. The factors investigated are shown
in Table III.1 for the three Ra ratios of 1:200, 1:500, and 1:1000 (w/w). For each of the three Ra
ratios, the effects of stirring speed at four levels of 100, 200, 500, and 800 r.p.m. and crystal
maturation times ranging from 0-1440 minutes were examined. Two response variables were
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investigated. These were the geometric median diameter (D0.5) of the particles as measured by
laser diffraction and crystallinity as assessed by differential scanning calorimetry. Preliminary
studies revealed little effect of crystal maturation time on the final particle size. Therefore, the
particle size measurements were carried out only at two extremes of the crystallization period
i.e.; after 0 and 24 hours. AS samples for particle size measurement were prepared by vacuum
filtration, sonication and subsequent drying at room temperature described in section III.C.1.8.
To examine the effect of crystal maturation time, the particle crystallinity was measured at
different time points during the 24 hour period. These time points were 0, 60, 120, 180, and 1440
minutes. Particles were characterized for their % crystallinity by DSC immediately after
sampling from the crystallization vessel described in section III.C.1.6.1. Particle crystallinity was
also examined by observation under plane-polarized light using an optical microscope. An
additional assessment was performed using X-ray powder diffraction on particles collected after
a 24 hour crystal maturation time as described in section III.C.1.6.3. The water content of the
particles was measured by coulometric Karl Fischer titration and complementary weight loss
analysis was carried out by thermogravimetric analysis on samples collected at the different
crystal maturation time points. These measurements were carried out on particles sampled
directly from the crystallization vessel. Drug yields were quantified using gravimetric analysis
using Equation III.1. AS content in each sample was estimated using HPLC following
dissolution of a known weight of particles, as described in section III.C.1.9.

Drug Yield in
Particles =

Mass of AS particles after filtration,
sonication, and drying
Mass of AS in the starting drug solution
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× 100

Equation III.1

1.5 cm

2.5 cm
5.1 cm

AS Soln.

Cooled to 260C

Supersaturated
AS Soln.
(280mg/mL)

Hamilton
Syringe
Plastic
Tubing

Hot Plate
(400C)
Syringe Pump
(1ml/min)
Volume of addition =
0.5mL
Time of addition = 30s

Stirrer (variable stirring
speeds)
Mixing time = 30 minutes

AS Solution droplets

Ethyl
Acetate

Variable Ra ratio

Variable temperature

Variable crystallization time

Particles harvested

Figure III.1 Experimental setup for albuterol sulfate crystallization (insets show the
crystallization setup and the paddle dimensions)
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III.C.1.4

Strategies investigated to reduce albuterol sulfate particle size

III.C.1.4.1

Effect of temperature difference between the drug solution and anti-solvent

Using the crystallization conditions that yielded the smallest particles under isothermal
conditions, the effect of a temperature difference between the drug solution and anti-solvent on
particle size was investigated (Tsolution > Tanti-solvent). In order to create this difference, the
temperature of the anti-solvent was reduced by cooling the crystallization vessel in either ice
(5°C) or dry ice (-40°C) for the 30 minute duration of mixing. The temperature of the drug
solution was maintained at 25-27°C. This resulted in temperature differences of 20°C and 65°C
for ice and dry ice respectively. The crystallization conditions employed were a drug solution
concentration of 0.22g/g, Ra ratio of 1:200 (w/w), an infusion rate of 1mL/min, a stirring speed
of 200 r.p.m., a stirring time of 30 minutes, and a total crystal maturation time of 1440 minutes.

Table III.1 Factorial experimental design for Ra ratio’s of 1:200, 1:500, and 1:1000 (w/w)
Stirring speed (r.p.m.) Crystal maturation time (minutes)
0
60
100
120
180
1440
0
60
200
120
180
1440
0
60
500
120
180
1440
0
60
800
120
180
1440
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A 30 minute stirring period and cooling duration was chosen since particle formation was
observed to take place throughout this time period. Since crystallization temperature theoretically
influences particle size predominantly by affecting the nucleation and growth phases of the
crystallization process, this 30 minute period was deemed to be most critical. At the end of
mixing, the crystallization vessel was kept at room temperature for 1440 minutes before
harvesting the particles by vacuum filtration. These particles were then re-suspended in 4mL of
the saturated filtrate and sonicated to dryness at 40 KHz for 45 minutes. The particles were then
dried at room temperature for 24 hours before storing them in sealed containers in a dessicator
containing dried silica as the dessicant at room temperature until further analysis.

III.C.1.4.2

Effect of isopropyl alcohol as the anti-solvent on albuterol sulfate particle
size

Using the crystallization conditions that yielded the smallest particles with ethyl acetate,
the effect on AS particle size of an alternate anti-solvent, isopropyl alcohol, was investigated
(Dhumal et al., 2009). The conditions employed used identical equipment with a drug solution
concentration of 0.22g/g, Ra ratio of 1:200 (w/w), an infusion rate of 1mL/min, a stirring speed
of 200 r.p.m., a stirring time of 30 minutes, and a total crystal maturation time of 1440 minutes.
The temperature of both the drug solution and anti-solvent was 25-27°C, thereby resulting in no
temperature difference. Once again, the particles were harvested by vacuum filtration, followed
by re-suspension in 4mL of the saturated filtrate solution, sonication to dryness at 40 KHz for 45
minutes and subsequent drying at room temperature for 24 hours.

III.C.1.5

Assessment of water / solvent loss

III.C.1.5.1

Karl Fischer titration

42

The % water content in the AS particles at different crystal maturation times of 0, 60,
120, 180, and 1440 minutes was measured using a Moisture Meter, Model VA-05 (Mitsubishi,
White Plaine, NY). In order to measure the in-process water content during crystal maturation,
AS particles in concentrated suspension were sampled directly from the base of the
crystallization vessel and subjected to water content determination without filtration. A
background water content titration was performed to account for any residual water held in the
titration vessel. Determinations were performed as follows: Albuterol sulfate particles were
sampled from the crystallization vessel and quickly transferred to an aluminum pan. Due to the
rapid initial solvent loss, an initial weight of the sample was not determined. The aluminum pan
was placed in the thermal solid-state accessory of the Moisture Meter with the oven preheated to
140ºC. Dry compressed air (100mL/min) was passed over the sample pan and the released water
vapor transferred into the titration vessel for quantification. Following titration, the sample was
weighed and this final dry weight together with the Karl Fischer determined mass of water was
used to calculate the % water content in the AS particle samples as shown in Equation III.2.

KF determined mass of water

×

% Water Content =

100

Equation III.2

(Final dry weight of sample
+ KF determined mass of
water)

The Karl Fischer method was validated using lactose monohydrate powder with known
water content. The % water content of lactose monohydrate was determined using the method
described in section III.C.1.5.1. The measured % water content was found to be 4.8 ± 0.4% after
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three replicate measurements. This value was consistent with the reported certificate of analysis
value of 4.0-6.0% and a calculated % of 4.8% representing the water of crystallization present as
a monohydrate. In the solid-state, this water was known to be released at temperatures around
140°C and therefore, was suitable for validating the Karl Fischer method (Listiohadi et al.,
2008).

III.C.1.5.2

Thermogravimetric Analysis (TGA)

The AS samples were also analyzed at different crystal maturation times of 0, 60, 120,
180, and 1440 minutes by TGA (Pyris1 TGA equipped with a data station Pyris Software for
Windows, version 3.81, Perkin Elmer, Covina, CA). The method involved sampling the AS
particles and quickly transferring them into an aluminum pan. The samples were heated under a
stream of flowing dry nitrogen (Fischer Scientific, Pittsburgh, PA) at 30-35mL/min. The heating
temperature program employed was: a 10 minute hold at 25°C followed by heating to 140°C at
10°C/min, holding at 140°C for 5 minutes followed by heating to 250°C at 10°C/min as shown
in Figure III.2. It should be noted that unlike KF titration which is a specific method for the
determination of water, the TGA method determines non specific weight loss that could include
both water and anti-solvent. The weight loss was measured as the reduction in mass from the
start of the temperature program until 140°C beyond which no weight loss was observed until the
onset of melting. The final dry weight of the sample before melting together with the TGA
determined weight change was used to calculate the % solvent content in the samples as shown
in Equation III.3. The TGA determined non-specific solvent content was compared with the KF
determined water content.
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% Solvent Content

Total weight loss between 25140°C

×

100

Equation III.3

Final dry weight of sample
+ TGA determined mass of
water

Figure III.2 TGA temperature program

III.C.1.6

Assessment of crystallinity

III.C.1.6.1

Differential Scanning Calorimetry (DSC)

DSC analysis was carried out using a DSC 7 (Perkin Elmer, Covina, CA) equipped with a
data station Thermal Analysis Controller 7/DX, Pyris Software for Windows, version 3.81. AS
particles were sampled from the crystallization vessel at different time points of 0, 60, 120, 180,
and 1440 minutes. These samples were transferred into aluminum pans. The pans were
immediately sealed non-hermetically and the weight of the sample was recorded. The samples
were then heated under a flowing stream of dry nitrogen (Fischer Scientific, Pittsburgh, PA) as
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the purge gas at a flow rate of 30-35mL/min. The temperature program used was: a 10 minute
hold at 25°C followed by heating to 250°C at 10°C/min. Figure III.3 shows the temperature
program.

Figure III.3 DSC temperature program
The enthalpy of fusion was measured by integrating the endothermic peak associated with
melting and normalizing for solvent-corrected dry sample weight. The % crystallinity of the
particles was then calculated by equation III.4 (Huang et al, 2000; Bassett et al, 1988; Toda et al,
1995):

% Crystallinity =

Enthalpy of fusion for the
sample
(Enthalpy of fusion for the
reference standard)
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×

100

Equation III.4

The enthalpy of fusion for reference crystalline AS (Spectrum Chem. Mfg. Corp., New
Brunswick, NJ) was taken as a mean value from three replicate measurements. When using DSC
to measure crystallinity in literature, some allowances have also been made for the sample
recrystallizing upon heating by separately integrating the recrystallization exotherm and
subtracting this value from the enthalpy of fusion (Huang et al., 2000). However, in our case, no
recrystallization exotherm was observed. Therefore, the above mentioned formula was used for
all DSC estimations of % crystallinity.

III.C.1.6.2

Optical microscopy

AS particles were sampled from the crystallization vessel at different crystal maturation
times of 0, 60, 120, 180, and 1440 minutes and directly observed under a polarizing optical
microscope (Optiphot, Nikon, Tokyo, Japan). Presence of birefringence under crossed polars was
noted as an indicator of crystallinity.

III.C.1.6.3

Powder X-ray diffraction

AS samples were subjected to analysis by powder X-Ray diffraction (Panalytical XRPD,
Panalytical Inc, Westborough, MA) by scanning from 5°2θ - 35°2θ over a period of 2 hours at 45
KV and 40mA. The presence of sharp, characteristic diffraction peaks and no halo was taken as
an indicator of crystallinity. The diffractograms were compared to reference crystalline AS
(Spectrum Chem. Mfg. Corp., New Brunswick, NJ) scanned under the same program.

III.C.1.7

Scanning electron microscopy
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Particle morphology was observed using a scanning electron microscope (EVO 50 XVP
scanning electron microscope (SEM) equipped with digital image acquisition). The samples were
prepared for analysis by sputter coating for 2 minutes using a EMS 550x sputter coater. Imaging
was performed at 15kV.

III.C.1.8

Particle size determination by laser diffraction

The particle size distribution of the AS samples was measured by laser diffraction using
the Mastersizer 2000 equipped with the Scirocco dry dispersion accessory (Malvern,
Westborough, MA). The air flow and feed rate were adjusted to control the powder dispersion.
The optimized particle size measurement conditions sufficient to achieve deagglomeration of
primary particles without attrition were an air pressure of 2 bar and a feed rate of 50%.
Obscuration was deemed acceptable when readings occurred in the range of 2-6% over a
measurement cycle time of 10 seconds. Triplicate measurements were made for each sample.
Crystallization batch-to-batch reproducibility was assessed using three replicate crystallization
experiments in each case.

III.C.1.9

High performance liquid chromatography (HPLC)

Samples were assayed for %AS content by HPLC by a validated method. The method
employed a Waters 2690 separations module, a 2996 PDA detector, a Restek Allure PFP column
(15×3.2mm), a mobile phase of 75% methanol and 25% ammonium formate buffer (20mM, pH
3.4) at a flow rate of 0.75mL/min and an injection volume of 100 µL. Precision of the method
was estimated by assaying the 0.1 µg/mL standard 9 times and calculating the % RSD. The
accuracy was determined by using the HPLC method to analyze the 0.1 µg/mL standard 9 times
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and then calculated as a percentage of the analyte recovered by the assay. The limit of detection
and quantitation were calculated from equation III.5 and III.6.

3.3 × SD of calibration curve intercept

Limit of Detection =

Equation III.5

Mean slope of the calibration curve

Limit of Quantitation =

10 × SD of calibration curve intercept

Equation III.6

Mean slope of the calibration curve

Table III.2 shows the system suitability parameters for this method.
Table III.2 System suitability parameters for the HPLC method
System Suitability Parameter
Linearity range
Precision
Accuracy
Limit of detection
Limit of quantitation

Value
0.1-100 µg/mL
1.02%
99.6%
0.03 µg/mL
0.1 µg/mL

To measure the % AS content, accurately weighed particles were dissolved in water to
prepare a solution of adequate concentration in a target range of 20-25 µg/mL. UV detection was
performed at 276nm. The stoichiometric AS content was calculated using equation III.7.

AS mass determined by HPLC

×

% AS content =
Sample weight
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100

Equation III.7

III.D.

RESULTS AND DISCUSSION

III.D.1

Characterization of albuterol sulfate reference standard
Figure III.4 shows a representative thermogram for albuterol sulfate reference standard

(Spectrum Chem. Mfg. Crp., New Brunswick, NJ) which was the starting material for all
crystallization experiments. A single thermal event was observed which corresponded to the
melting of AS. Melting is an endothermic process and is shown as the sharp peak in the
thermogram. The mean enthalpy of fusion for AS was 200 ± 1.8 J/g with a mean melting point of
204 ± 0.6°C calculated from three replicate measurements. These values agreed with the heat of
fusion of approximately 198.0 J/g and a melting point of approximately 200°C reported in
literature (Begat et al, 2002, Ticehurst et al, 1994) under similar heating profiles.

Figure III.4 Representative DSC thermogram for reference standard albuterol sulfate
measured at a heating rate of 10°C/min
The % water content as measured by KF titration was 0.4 ± 0.2 %. This agreed with the
Certificate of Analysis for AS (% water content = 0.4-0.6%). Thermogravimetric analysis
yielded a similar value of 0.5 ± 0.3 % for weight loss. Figure III.5 shows the X-Ray powder
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diffraction pattern for reference albuterol sulfate. The characteristic peak positions are tabulated
in Table III.3. This diffraction pattern agreed with the reported diffraction pattern for albuterol
sulfate in literature (Ward et al, 1995) as shown in Figure III.6.

Intensity

23.03

4500
4000
3500
3000
2500
2000
1500
1000
500
0

10.45

21.21
20.39

15.27

0

5
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20

24.43

25

30

35

40

2 Theta

Figure III.5 Representative X-ray powder diffractogram for reference standard albuterol
sulfate
Table III.3 Characteristic AS peaks
2θ
10.45
11.47
12.93
15.27
17.75
18.43
19.35
20.39
21.21
23.03
24.43
25.67
26.39
28.63
29.51

Intensity
2097
494
248
508
885
1177
228
576
1325
4058
694
280
642
652
434
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Figure III.6 X-ray powder diffractogram for albuterol sulfate reported by Ward et al.
(1995) (Reproduced with permission from Springer)

The particle size distribution of reference albuterol sulfate is shown in Figure III.7. The
average VMD measured from three replicate measurements was 9.8 ± 0.2 µm. Figure III.8 shows
a representative microscopic image of reference AS. The particles appeared to be a mixture of

% Cumulative Volume less than stated size

plate-like and columnar in shape.

100
80
60
40
20
0
0.1

10

1000

Geometric Diameter (microns)

Figure III.7 Cumulative % undersize volume distribution of reference albuterol sulfate
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Figure III.8 Representative SEM image for reference albuterol sulfate

III.D.2

Characterization of AS particles produced by solvent / anti-solvent
crystallization

III.D.2.1

Characterization after a crystal maturation time = 0

III.D.2.1.1

Estimated % crystallinity

In the solvent / anti-solvent crystallization process, particle formation was observed to
occur immediately after addition of the drug solution to the anti-solvent. These results were not
surprising given the nature of solvent / anti-solvent crystallization which is a rapid precipitation
process. This particle formation appeared to be complete at the end of the mixing period of 30
minutes which was designated as crystal maturation time = 0. Completion of particle formation
was confirmed by calculation of drug yields which were between 97-99 % for all crystallization
conditions. At this time, these particles were sampled from the crystallization vessel and the %
crystallinity was estimated using DSC by the method described in section III.C.1.6.1. As a
technique, DSC is usually believed to be sufficiently sensitive to detect amorphous contents
above 5% (Ward et al., 1995; Pfeiffer et al., 2003; Gorny et al., 2007). Table III.4 shows the
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heats of fusion and estimated % crystallinity (expressed as mean ± SD from three replicate
crystallization experiments) for AS samples obtained after a crystal maturation time = 0 from the
three Ra ratios at the four different stirring speeds employed. The heats of fusion for all particles
were significantly smaller compared to reference albuterol sulfate (∆Hf = 200 ± 1.8 J/g)
indicating incomplete crystallinity. For Ra ratio 1:200 (w/w), similar values for estimated %
crystallinity were obtained at all stirring speeds (p-value > 0.05, Tukey’s HSD), indicating no
significant influence of stirring speed on estimated % crystallinity. Similarly, for Ra ratios 1:500
and 1:1000 (w/w), there was no influence of stirring speed on % crystallinity at crystal
maturation time = 0 with similar values being obtained under all stirring speeds investigated (pvalue > 0.05, Tukey’s HSD). Moreover, the estimated % crystallinity values were comparable
for all Ra ratios as well. For example, Ra ratios 1:200, 1:500, and 1:1000 (w/w) yielded similar
estimated % crystallinity values of 66.3 ± 1.5%, 55.4 ± 2.9%, and 49.4 ± 20.2% for particles
produced at 100 r.p.m. at crystal maturation time = 0. In a similar manner, comparable values for
estimated % crystallinity were obtained at the other 3 stirring speeds for all Ra ratios. Therefore,
these results indicated a significant finding that after stirring for 30 minutes (crystal maturation
time = 0), complete crystallization had not taken place regardless of the crystallization
conditions.
These results showing incomplete crystallization after 30 minutes stirring were contrary
to those reported by Nocent et al. (2001). In their study, the formation of crystalline AS particles
was reported after 30 minutes mixing. However, it was unclear whether their particles were
crystalline at the time of sampling or whether crystallization took place during the harvesting and
drying steps. The authors failed to describe the handling of their particles following harvesting or
the method for crystallinity assessment. Our studies have demonstrated that subsequent drying of
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particles can induce solid-state crystallization. Partially crystalline AS particles obtained at each
of the Ra ratios and stirring speeds after crystal maturation time = 0 were harvested by the
method described in section III.C.1.2 and subjected to drying under ambient relative humidity
(40% R.H.) and temperature (25°C) conditions for 24 hours. Table III.5 shows the heats of
fusion and estimated % crystallinity values for these particles. These particles were found to be
completely crystalline. The crystalline nature of these particles was confirmed by powder X-ray
diffraction. Representative X-ray powder diffractograms for AS particles produced from Ra ratio
1:200, 1:500, and 1:1000 (w/w) after crystal maturation time = 0 at 500 r.p.m. after filtration and
drying are shown in Figures III.9, III.10, and III.11. For all of these diffractograms, characteristic
peaks were observed at 2θ values of 10.45, 15.27, 20.39, 21.21, 23.03, and 24.43 which were
similar to those of reference AS. These results along with the absence of any halo indicated the
virtually complete crystalline nature of these particles. This change in crystallinity of these
samples confirms that complete crystallization had not taken place in solution after stirring for 30
minutes. In addition, it suggests that the particles characterized by Nocent et al. (2001) required
that they were harvested and dried in order to obtain 100% crystallinity under conditions that
were not specified by the authors.
It was mentioned in section III.A that particle crystallinity and size were the two major
response variables of interest. Therefore, the AS particles produced after a crystal maturation
time = 0 were characterized for their particle size distribution using laser diffraction as described
in section III.C.1.8. Since the measurement of particle size necessitated drying, all of these
particles were harvested by the method described in section III.C.1.2 and dried. Hence, these
particles were completely crystalline.
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III.D.2.1.2

Particle size distribution

Particle size was measured by laser diffraction using harvested AS particles that were
subjected to filtration, sonication and drying as described in section III.C.1.8. The sonication step
was included to bring about particle deagglomeration and dispersion of particle aggregates into
primary particles. However, it was also possible that the sonication step itself may bring about a
change in particle size. There are predominantly two main mechanisms by which this may be
happening. The particles are being sonicated after re-suspending them in the concentrated filtrate
solution. This filtrate solution evaporates during sonication which would lead to some degree of
secondary precipitation of AS on the pre-formed particles. The amount of albuterol sulfate
present in the saturated filtrate solution was therefore calculated based on its equilibrium
solubility in the final crystallizing medium according to equation III.8:
Amount of AS in the
filtrate solution =

Equilibrium solubility
Volume of the filtrate
of AS in the crystallization ×
used for
medium
sonication

Equation III.8

Based on the above equation, the amount of albuterol sulfate present in the saturated
filtrate solution was calculated as 0.4 mg, 0.6 mg, and 1.0 mg for Ra ratios 1:200, 1:500, and
1:1000 respectively. These small amounts comprised of less than 1% of the total amount of AS.
Therefore, it is highly improbable that they had a significant impact on the particle size
distribution due to drug addition to the primary particles. Another mechanism by which
sonication may bring about a change in particle size is by breaking down the primary particles.
In order to rule this out, reference standard albuterol sulfate was suspended in 4.0mL of the
saturated filtrate solution and sonicated to dryness at 40 KHz for 45 minutes. As shown in Figure
III.12, the particle size distribution did not change after sonication. The VMD was statistically
comparable pre and post sonication (9.8 ± 0.2 µm vs. 9.6 ± 0.3 µm). Statistical analysis by one-
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way ANOVA yielded a non-significant p-value (>0.05) thereby suggesting that sonication does
not bring about an actual breakdown of primary particles. Figures III.13 and III.14 show the
cumulative % undersize volume distributions and frequency distributions for the AS particles
obtained after crystal maturation time = 0 from Ra ratio 1:200 (w/w) under the four different
stirring speeds investigated. Similar particle size distributions for Ra ratios 1:500 and 1:1000 are
shown in Figures III.15, III.16, III.17, and III.18. Table III.6 shows the average VMDs and span
indices for these AS particles produced after a crystal maturation time = 0 from three Ra ratios
under the four different stirring speeds. Span index is a measure of the spread of the distribution
and is measured as the ratio of the difference of the 90th and 10th percentile diameter and the
VMD. The particle size distributions for AS particles obtained from all Ra ratios under the four
stirring speeds were bimodal (Figure III.14, III.16, III.17).

Table III.4 Mean ± SD heats of fusion and estimated % crystallinity of AS particles
precipitated using EA after crystal maturation time = 0
Ra ratio
(w/w)
1:200

1:500

1:1000

Stirring speed
(r.p.m.)
100
200
500
800
100
200
500
800
100
200
500
800

Heat of fusion (Mean ± SD)
J/g
132.6 ± 2.9
128.0 ± 7.3
123.9 ± 11.9
145.8 ± 20.2
110.7 ± 5.9
137.9 ± 19.0
128.1 ± 21.7
130.6 ± 47.3
98.8 ± 40.3
109.2 ± 8.9
103.3 ± 5.8
99.3 ± 11.4
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Estimated % crystallinity
(Mean ± SD)
66.3 ± 1.5
64.0 ± 3.6
62.0 ± 5.9
72.9 ± 10.1
55.4 ± 2.9
69.0 ± 9.5
64.0 ± 10.8
65.3 ± 23.7
49.4 ± 20.2
54.6 ± 4.4
51.7 ± 2.9
49.7 ± 5.7

Table III.5 Mean ± SD heats of fusion and estimated % crystallinity values of AS particles
precipitated using EA harvested after a crystal maturation time 0, filtered, and dried under
ambient conditions for 24 hours
Ra ratio
(w/w)
1:200

1:500

1:1000

Stirring speed
(r.p.m.)
100
200
500
800
100
200
500
800
100
200
500
800

Heat of fusion (Mean ± SD)
J/g
199.1 ± 1.2
197.8 ± 3.9
197.6 ± 1.6
201.6 ± 1.9
200.3 ± 1.0
200.0 ± 2.8
199.8 ± 0.5
196.7 ± 1.4
199.5 ± 2.1
196.3 ± 1.7
198.3 ± 2.5
199.3 ± 2.0
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Estimated % crystallinity
(Mean ± SD)
99.0 ± 0.6
98.2 ± 1.9
98.2 ± 0.8
100.8 ± 0.9
100.1 ± 0.5
100.0 ± 1.5
99.8 ± 0.2
97.8 ± 0.7
99.2 ± 1.2
97.7 ± 0.8
99.2 ± 1.2
99.2 ± 0.9
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Figure III.9 X-ray powder diffractogram for AS particles precipitated using EA produced
from Ra ratio 1:200 (w/w) at 500 r.p.m. after crystal maturation time 0, filtration and
drying
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Figure III.10 X-ray powder diffractogram for AS particles precipitated using EA produced
from Ra ratio 1:500 (w/w) at 500 r.p.m. after crystal maturation time 0, filtration and
drying
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Figure III.11 X-ray powder diffractogram for AS particles precipitated using EA produced
from Ra ratio 1:1000 (w/w) at 500 r.p.m. after crystal maturation time 0, filtration and
drying
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Figure III.12 Particle size distribution of reference standard albuterol sulfate pre and post
sonication
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Figure III.13 Cumulative % undersize volume distribution for AS particles precipitated
using EA produced from Ra ratio 1:200 (w/w) after crystal maturation time = 0 under four
different stirring speeds
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Figure III.14 Frequency volume distribution for AS particles precipitated using EA
produced from Ra ratio 1:200 (w/w) after crystal maturation time = 0 under four different
stirring speeds
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Figure III.15 Cumulative % undersize volume distribution for AS particles precipitated
using EA produced from Ra ratio 1:500 (w/w) after crystal maturation time = 0 under four
different stirring speeds
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Figure III.16 Frequency volume distribution for AS particles precipitated using EA
produced from Ra ratio 1:500 (w/w) after crystal maturation time = 0 under four different
stirring speeds
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Figure III.17 Cumulative % undersize volume distribution for AS particles precipitated
using EA produced from Ra ratio 1:1000 (w/w) after crystal maturation time = 0 under
four different stirring speeds
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Figure III.18 Frequency volume distribution for AS particles precipitated using EA
produced from Ra ratio 1:1000 (w/w) after crystal maturation time = 0 under four different
stirring speeds

Table III.6 Mean ± SD volume median diameters and span indices of AS particles
precipitated using EA produced after crystal maturation time = 0 under different
crystallization conditions
Ra ratio
(w/w)
1:200

1:500

1:1000

Stirring speed
(r.p.m.)
100
200
500
800
100
200
500
800
100
200
500
800

VMD ± SD
(µm)
18.9 ± 7.9
17.9 ± 7.4
19.9 ± 8.0
18.7 ± 6.7
25.6 ± 5.4
28.6 ± 3.3
26.6 ± 10.9
95.6 ± 28.9
26.7 ± 6.0
32.9 ± 12.6
90.7 ± 8.2
93.4 ± 4.2
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Span index
7.7
8.9
7.8
8.5
5.9
6.2
6.1
2.2
6.3
5.9
2.5
2.2

If VMD is assumed to be a representative median sign that indicates the feasibility of
using a powdered drug for inhalation purposes, Ra ratio 1:200 (w/w) resulted in the formation of
AS particles with comparable average VMDs of 18.9 ± 7.9, 17.9 ± 7.4, 19.9 ± 8.0, and 18.7 ± 6.7
µm under the four stirring speeds of 100, 200, 500, and 800 r.p.m. respectively indicating that
stirring speed had no influence on particle size (Table III.6). Overall particle size distributions
were very broad as indicated by the large span values of 7.7, 8.9, 7.8, and 8.5 for particles
produced at 100, 200, 500, and 800 r.p.m. respectively. For Ra ratio 1:500, particles with
statistically indistinguishable VMDs of 25.6 ± 5.4, 28.6 ± 3.3, and 26.6 ± 10.9 µm were
produced at 100, 200, and 500 r.p.m. respectively (p-value > 0.05, Tukey’s HSD). However,
significantly larger particles with a VMD of 95.6 ± 28.9 µm were produced at 800 r.p.m (p-value
< 0.05, Tukey’s HSD). Therefore, for Ra ratio 1:500 (w/w), there was a counter-intuitive
influence of stirring speed where the highest stirring speed of 800 r.p.m. producing significantly
larger particles compared to the lower stirring speeds of 100, 200, and 500 r.p.m. For Ra ratio
1:1000, particles produced at 100, and 200 r.p.m. had similar VMDs of 26.7 ± 6.0, and 32.9 ±
12.6 µm which were significantly smaller than the particles produced at 500 (VMD = 90.7 ± 8.2
µm) and 800 (93.4 ± 4.2 µm) r.p.m. Hence, for Ra ratio 1:1000 (w/w) also, stirring speed had a
significant influence with larger particles being produced at higher stirring speeds of 500 and 800
r.p.m. Furthermore, Ra ratio 1:200 (w/w) resulted in the formation of smallest particles compared
to the other Ra ratios at all stirring speeds investigated. For example, at a stirring speed of 100
r.p.m., particles produced from Ra ratio 1:200 (w/w) had a VMD of 18.9 ± 7.9 µm which was
significantly smaller than the VMDs of 25.6 ± 5.4 µm and 26.7 ± 6.0 µm produced from Ra
ratios 1:500 (w/w) and 1:1000 (w/w) respectively.

64

Some of these results can be at least partly explained on the basis of the supersaturation
ratios that prevailed at the different Ra ratios. The supersaturation values for a solvent / antisolvent crystallization in terms of an index described as the supersaturation ratio in equation III.9
by Murnane et al., (2008) have been expressed (Murnane et al., 2008).

(Cs X Ws)
Supersaturation Ratio = Ln

Equation III.9

(Ecs X Wcs)

In the above equation, Cs is the concentration of the drug solution, Ws is the weight of
the drug solution, Ecs is the equilibrium solubility of the drug in the final solvent / anti-solvent
mixture, and Wcs is the weight of the final crystallizing medium. Applying this equation, the
“supersaturation ratios” were calculated for the three solvent / anti-solvent ratios as 5.2, 4.5, and
3.4 for Ra ratios 1:200, 1:500, and 1:1000 respectively. Thus, Ra ratios 1:200 had higher
supersaturation levels compared to Ra ratios of 1:500 (w/w) and 1:1000 (w/w).
The largest supersaturation ratio (5.2) for the 1:200 Ra ratio should result in an increased
driving force for crystallization and a theoretical decrease in the metastable zone width (MSZW)
which is the allowable supersaturation level for a crystallization process. Spontaneous nucleation
cannot take place in this metastable zone and narrower the MSZW, the faster should be the
nucleation process, with nucleation predominating over crystal growth, resulting in the formation
of smaller particles. Hence, for Ra ratio 1:200 (w/w), the largest supersaturation ratio was
expected to lead to a narrower MSZW and increased formation of fines with nucleation
predominating over crystal growth. For this ratio, however, increasing the agitation speed failed
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to produce a significant change in the VMD with comparable average VMDs of 18.9 ± 7.9, 17.9
± 7.4, 19.9 ± 8.0, and 18.7 ± 6.7 µm under the four stirring speeds of 100, 200, 500, and 800
r.p.m. respectively (p-value > 0.05; Tukey’s HSD). This appeared to indicate that the
supersaturation effect predominated over the mixing and turbulence effects on crystal growth.
Notably, addition of a highly saturated drug solution to the anti-solvent leads to very high
supersaturation at the point of addition and this is not taken into account in these calculations of
supersaturation ratios. However, stirring the mixture is believed to lead to fairly rapid and
uniform mixing resulting in the dissipation of this localized supersaturation and a more uniform,
albeit lower supersaturation ratio being attained in the final crystallization mixture. However, if
the supersaturation is very high as is the case with Ra ratio 1:200, even the higher stirring speeds
appeared to be insufficient to bring about uniform mixing faster than the local zones of high
supersaturation and high nucleation rates could result in overall small particle sizes. Generation
of such high supersaturation levels also leads to crash precipitation, and hence a broader particle
size distribution which is indicated by the large span values for the 1:200 (w/w) particles. This
explanation was strengthened by the results obtained with the other two Ra ratios. Ra ratio 1:500
failed to show any significant effect of stirring speed on particle size at stirring speeds of 100,
200, and 500 r.p.m. until at 800 r.p.m., there was a significant increase in particle size. The same
effect was seen at a lower stirring speed for Ra ratio 1:1000 (w/w) (Table III.6). The trend was
clear therefore; high nucleation rates at high supersaturation values appeared to dominate at Ra
ratio 1:200 (w/w). As supersaturation was progressively reduced however, mixing (producing
lower supersaturation values rapidly at high rates of stirring) allowed crystal growth to dominate
in cases where VMD was observed to increase significantly (Ra ratio 1:500, 1:1000).

66

In practice, the application of crystal theory in all technologic situations that are aimed at
controlling the interplay of hydrodynamics (mixing) as well as solvent-solute and solute-solute
interactions with molecular-structure dependent kinetics is bound to require experimental review.
In differently designed systems, an increase of particle size with increased agitation has been
explained by Mullin (2001) with particle size showing a parabolic dependence on stirring speed.
Particle size passed through a minimum as the stirring speed was increased due apparently to
particle collisions that resulted in attrition. However, beyond a certain stirring speed, the particle
size increased once again due to the particle collisions that led to aggregate formation. Such a
parabolic relationship of particle size with stirring speed was also been reported by O’Grady et
al. (2001), Abdel-Al et al. (2004), and Genoveva et al. (2007). In studies carried out by O’Grady
et al., the effect of stirring speed was investigated in conjunction with anti-solvent addition
location, and addition rate (O’Grady et al., 2001). When the anti-solvent was added closer to the
impeller, an increase in agitation intensity was claimed to result in a narrower MSZW, possibly
due to the increased probability of contact between solute molecules. When the anti-solvent was
added closer to the vessel wall, there was a significant improvement in their batch-to-batch
repeatability. Those results showed the importance of mixing conditions at each of the addition
locations in solvent / anti-solvent crystallizers. The overall effects however, must be influenced
by the relative and drug-dependent rates at which nuclei are formed, disintegrate and crystals
grow in different solvent environments.
The interplay between the supersaturation levels and stirring speeds was also reflected in
particle morphology. Ra ratios 1:200 and 1:500 (w/w) under all stirring speeds yielded particles
that were irregular in morphology as shown in Figures III.19 and III.20. Particle morphology is
known to be influenced by the supersaturation levels prevailing in the crystallization vessel at
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different sites (Mersmann, 2001). Ideally, under efficient mixing conditions, similar
supersaturation is expected throughout the crystallization vessel at a given time. However,
inefficient mixing, particularly in the presence of high supersaturation levels can lead to zones of
locally high and low supersaturation that may cause one plane of the crystal to grow faster that
another. Non-homogeneous solute concentrations can thus result in the observable irregular
morphology.
For the Ra ratio 1:1000 (w/w) stirring speed had a significant influence on particle size
where larger particles with VMDs of 90.7 ± 8.2, and 93.4 ± 4.2 µm were produced at 500 and
800 r.p.m. compared to the 26.7 ± 6.0, and 32.9 ± 12.6 µm particles produced at 100, and 200
r.p.m. This effect may once again be explained by increased agitation bringing about greater
mixing, reduced zones of locally high supersaturation, and hence, an increased metastable zone
width. The effect of stirring speed is most predominant in this Ra ratio due to its smallest
supersaturation ratio (3.2). These factors would lead to an increased formation of larger particles.
The interplay between mixing and supersaturation was reflected in particle morphology. Particles
produced at the lower stirring speeds of 100 and 200 r.p.m. were irregular in shape (Figure
III.21) and appeared similar to the particles produced from Ra ratio 1:200 and 1:500 (w/w) under
the same stirring speeds. This was due to inefficient mixing at lower stirring speeds. Conversely,
at higher stirring speeds of 500 and 800 r.p.m., spherical particles were produced (Figure III.22)
due to efficient mixing, homogeneous supersaturation and hence equivalent growth on all crystal
faces.
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Figure III.19 Scanning Electron Micrograph of AS particles precipitated using EA
produced at 500 r.p.m. from a solvent / anti-solvent ratio of 1:200 (w/w) at crystal
maturation time = 0 after filtration and drying

Figure III.20 Scanning Electron Micrograph of AS particles precipitated using EA
produced at 500 r.p.m. from a solvent / anti-solvent ratio of 1:500 (w/w) at crystal
maturation time = 0 after filtration and drying
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Figure III.21 Scanning Electron Micrograph of AS particles precipitated using EA
produced at 100 r.p.m. from a solvent / anti-solvent ratio of 1:1000 (w/w) at crystal
maturation time = 0 after filtration and drying

Figure III.22 Scanning Electron Micrograph of AS particles precipitated using EA
produced at 500 r.p.m. from a solvent / anti-solvent ratio of 1:1000 (w/w) at crystal
maturation time = 0 after filtration and drying
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In summary, in the experimental crystallizer described in this thesis, after a crystal
maturation time = 0, partially crystalline particles of AS were produced under all crystallization
conditions. These particles completed their crystallization during filtration and drying. Particle
size distributions of the particles revealed an effect of different crystallization conditions such as
Ra ratio and stirring speed on particle size. These effects were explained on the basis of the
interplay between the effects of the supersaturation ratio and the speed at which mixing was
accomplished. Ra ratio 1:200 (w/w), where supersaturation was highest resulted in the smallest
particles under all four stirring speeds relative to Ra ratios of 1:500 and 1:1000 (w/w). However,
these particles were approximately 20 µm in diameter with broad PSDs and remained unsuitable
for inhalation. It must be remembered that these particles produced after a crystal maturation
time = 0 were only partially crystalline and underwent complete crystallization upon harvesting
and drying. Because it has been demonstrated in literature that harvesting partially crystalline
particles can induce solid-state crystallization (Ward et al., 1995; Pfeiffer et al., 2003) leading to
the formation of crystalline bridges between adjacent particles such an event is considered
undesirable particularly for aerosol formulations where size and the ability to disperse the
individual particles is a primary concern.
In an attempt to bring about complete solution crystallization, the particles produced after
a crystal maturation time = 0 were allowed to remain in the solvent / anti-solvent mixture for
longer crystallization periods upto 24 hours since crystallization is a time dependent process. The
subsequent sections address the characteristics of those particles.

III.D.2.2

Characterization of AS particles after different crystal maturation times
between 0 – 24 hours

III.D.2.2.1

Estimated % crystallinity
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Tables III.7, and III.8, show the heats of fusion and calculated % crystallinity values for
AS particles produced from Ra ratios 1:200, and 1:500 (w/w) at different time points under the
four different stirring speeds investigated. For Ra ratio 1:200 (w/w), increased heats of fusion and
hence increased estimated % crystallinity values were observed for all stirring speeds as a
function of increasing crystal maturation time. Figure III.23 reveals a similar trend of increasing
crystallinity as a function of increasing crystal maturation time for each of the stirring speeds for
the 1:200 (w/w) Ra ratio.

Table III.7 Mean ± SD heats of fusion and estimated % crystallinity values for AS particles
precipitated from EA produced from Ra ratio 1:200 (w/w) at different crystal maturation
times
Stirring speed
(r.p.m.)

100

200

500

800

Crystal
maturation
time (minutes)
0
60
120
1440
0
60
120
1440
0
60
1440
0
60
120
180
1440

Heat of fusion
(Mean ± SD) J/g
132.6 ± 2.9
157.2 ± 10.1
160.1 ± 2.4
202.1 ± 2.1
128.0 ± 7.3
135.3 ± 3.8
160.5 ± 3.6
194.3 ± 6.9
123.9 ± 11.9
152.2 ± 5.7
198.4 ± 1.5
147.8 ± 20.2
162.7 ± 2.6
173.5 ± 4.4
184.0 ± 13.6
201.6 ± 2.6
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Estimated %
crystallinity (Mean
± SD)
66.3 ± 1.5
78.6 ± 5.0
80.1 ± 1.2
101.0 ± 1.1
64.0 ± 3.6
67.7 ± 1.9
80.3 ± 0.8
97.2 ± 3.5
62.0 ± 5.9
76.3 ± 2.9
99.2 ± 0.8
72.9 ± 10.1
81.4 ± 1.4
86.8 ± 2.2
92.0 ± 6.8
100.8 ± 1.3
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Figure III.23 Estimated % crystallinity of AS particles precipitated from EA as a function
of crystal maturation time for Ra ratio 1:200 (w/w)
Table III.8 Mean ± SD heats of fusion and estimated % crystallinity values for AS particles
precipitated from EA produced from Ra ratio 1:500 (w/w) at different crystal maturation
times
Stirring speed
(r.p.m.)

100

200

500

800

Crystal
maturation
time (minutes)
0
60
180
1440
0
60
120
180
1440
0
60
120
180
1440
0
60
120
180
1440

Heat of fusion
(Mean ± SD) J/g
110.7 ± 5.9
114.1 ± 8.1
168.8 ± 6.1
199.5 ± 0.7
137.9 ± 19.0
145.1 ± 11.8
154.1 ± 3.0
174.1 ± 3.3
199.5 ± 12.5
128.1 ± 21.7
141.6 ± 7.1
149.7 ± 4.5
182.4 ± 2.0
199.6 ± 0.6
130.6 ± 47.3
145.9 ± 10.7
173.1 ± 6.2
190.3 ± 1.6
196.0 ± 6.7
73

Estimated %
crystallinity (Mean ±
SD)
55.4 ± 2.9
57.0 ± 4.1
84.4 ± 3.1
99.7 ± 0.4
69.0 ± 9.5
72.6 ± 5.9
77.0 ± 1.5
87.0 ± 1.7
99.8 ± 6.5
64.0 ± 10.8
70.8 ± 3.5
74.8 ± 2.3
91.2 ± 1.0
99.8 ± 0.3
65.3 ± 23.7
73.0 ± 5.4
86.6 ± 3.1
95.2 ± 0.8
98.0 ± 3.4
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Figure III.24 Estimated % crystallinity of AS particles precipitated from EA as a function
of crystal maturation time for Ra ratio 1:500 (w/w)
For all four stirring speeds, complete crystallinity was observed at the end of 1440
minutes of crystallization for the Ra ratio 1:200 (w/w) particles. Similar results were obtained for
the Ra ratio 1:500 (w/w) where AS particles produced under all four stirring speeds underwent an
increase in % crystallinity as a function of crystal maturation time (Table III.8, Figure III.24).
These particles were also completely crystalline at the end of 1440 minutes of crystallization.
In both cases however, particles produced at the higher stirring speed of 800 r.p.m.
showed a faster rate of crystal maturation than the others. There was no obvious explanation for
this observation. Representative DSC thermograms for AS particles produced from Ra ratio
1:200 and 1:500 (w/w) at 200 r.p.m. after 1440 minutes are shown in Figures III.25 and III.26.
Similar heats of fusion compared to reference AS and sharp melting peaks were indicative of
approximately 100% crystallinity. These particles were also assessed for their % crystallinity
after filtration and drying under ambient conditions for 24 hours. The values for these particles
are shown in Table III.9.
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Figure III.25 Representative DSC thermogram of AS particles precipitated from EA
produced from Ra 1:200 at 200 r.p.m. after 1440 minutes

Figure III.26 Representative DSC thermogram for AS particles precipitated from EA
produced from Ra 1:500 at 200 r.p.m. after 1440 minutes
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Table III.9 Mean ± SD heats of fusion and estimated % crystallinity values for AS particles
precipitated from EA obtained from Ra ratios 1:200 and 1:500 (w/w) after crystal
maturation time 1440 minutes under different stirring speeds after filtration and drying
(Shown in parentheses are the measured estimated % crystallinities prior to filtration and
drying)
Ra Ratio
(w/w)
1:200

1:500

Stirring speed
(r.p.m.)
100
200
500
800
100
200
500
800

Heat of fusion
(Mean ± SD) J/g
200.1 ± 1.1
195.8 ± 3.2
199.4 ± 1.4
200.6 ± 1.3
199.5 ± 1.3
200.5 ± 2.5
198.4 ± 1.2
196.0 ± 3.7

Estimated % crystallinity
(Mean ± SD)
100.0 ± 0.9 (101.0 ± 1.1)
98.2 ± 2.5 (97.2 ± 3.5)
99.6 ± 1.0 (99.2 ± 0.8)
100.2 ± 0.7 (100.8 ± 1.3)
99.7 ± 0.6 (99.7 ± 0.4)
100.1 ± 1.2 (99.8 ± 6.5)
99.8 ± 0.6 (99.8 ± 0.3)
98.0 ± 1.8 (98.0 ± 3.4)

No difference in the heats of fusion was observed compared to the values measured at the
end of 1440 minutes of crystallization indicating that crystallization was complete at 1440
minutes. Figures III.27 and III.28 show the representative thermograms for AS particles
produced from Ra ratios 1:200 and 1:500 (w/w) at 200 r.p.m. after 1440 minutes of
crystallization, filtration and drying. These thermograms are similar to those for reference AS
and to particles produced under similar conditions before filtration and drying (Figures III.25,
III.26) indicating that after 1440 minutes 100% crystalline AS particles were produced in the
solution state. The filtered and dried particles were also subjected to powder X-ray diffraction.
The diffractograms are shown in Figures III.29 and III.30 for AS particles produced at 200 r.p.m.
from Ra ratios 1:200 and 1:500 (w/w) respectively. For both of these particles characteristic
peaks were observed at 2θ values of 10.45, 15.27, 17.75, 21.21, 23.03, and 24.43 which were
comparable to the characteristic peaks for reference AS once again indicating that these particles
were crystalline and of the same polymorphic form as the standard and other AS crystals. Since,
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the powder X-ray diffraction analysis sample preparation necessitated particle drying; this
analysis could not be carried out on particles immediately sampled from the crystallization
vessel.
The heats of fusion and estimated % crystallinity values for AS particles produced from
Ra ratio 1:1000 (w/w) at different crystal maturation time points are shown in Table III.10. This
Ra ratio revealed a difference in the crystallization behavior as a function of crystal maturation
time depending upon the stirring speed employed as shown in Table III.10 and Figure III.31.

Figure III.27 Representative DSC thermogram for AS particles precipitated from EA
produced from Ra ratio 1:200 at 200 r.p.m. after 1440 minutes of crystallization, filtration,
and drying

Figure III.28 Representative DSC thermogram for AS particles precipitated from EA
produced from Ra ratio 1:500 at 200 r.p.m. after 1440 minutes of crystallization, filtration,
and drying
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Figure III.29 Powder X-ray diffractogram for AS particles precipitated from EA produced
from Ra ratio 1:200 (w/w) after a crystal maturation time of 1440 minutes, filtration, and
drying
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Figure III.30 Powder X-ray diffractogram for AS particles precipitated from EA produced
from Ra ratio 1:500 (w/w) after a crystal maturation time of 1440 minutes, filtration, and
drying

78

Particles produced from Ra ratio 1:1000 (w/w) using the lower stirring speeds (i.e.; 100
and 200 r.p.m.) underwent an increase in % crystallinity as a function of crystal maturation time
and attained 100% crystallinity at the end of 1440 minutes. Thermal analysis of these particles
after filtration, and drying revealed no difference in the heats of fusion and estimated %
crystallinity values relative to those obtained before filtration (100 r.p.m.: ∆Hf = 198.6 ± 2.4 J/g,
estimated % crystallinity = 98.8 ± 0.7%; 200 r.p.m.: ∆Hf = 199.2 ± 2.8 J/g, estimated %
crystallinity = 99.3 ± 0.8%) thereby indicating that the particles produced after a crystal
maturation time of 1440 minutes at 100 and 200 r.p.m. were 100% crystalline and did not
undergo any changes in their solid form and structure upon harvesting and drying. These 100 and
200 r.p.m. particles were therefore observed to behave similarly to particles produced at each of
the stirring speeds with the Ra ratios 1:200 and 1:500 (w/w) illustrating the fact that crystal
maturation could occur within and without the bulk of the mother liquor. In contrast, despite
having similar initial % crystallinity at crystal maturation time = 0, compared to the 100 and 200
r.p.m. particles (49.4 ± 20.2 and 54.6 ± 4.4% respectively), the particles produced at 500 and 800
r.p.m. (51.7 ± 2.9 and 49.7 ± 5.7 % respectively) showed markedly different crystallization
behavior as a function of crystal maturation time. Table III.10 shows that at both stirring speeds
(i.e.; 500 and 800 r.p.m.), estimated % crystallinity decreased over prolonged crystal maturation
times where the final % crystallinity at 1440 minutes for 500 and 800 r.p.m. particles was 38.0 ±
3.9 and 36.4 ± 6.5% respectively. Given that the only change in these experiments was stirring
speed, it is tempting to speculate that the nature of these crystals initially seeded at 500 and 800
r.p.m. had a crystal structure that was polymorphically different to that seen in the other
particles. This was something that could not be confirmed by crystallography because of the
need to dry the product before study. However, when these particles were harvested by filtration
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and dried under ambient conditions for 24 hours, complete crystallization was then found to
occur. This was indicated by their heats of fusion (199.8 ± 2.7 J/g for particles produced at 500
r.p.m., 200.2 ± 1.8 J/g for particles produced at 800 r.p.m.) which resulted in estimated %
crystallinity values of 99.9 ± 1.3% for particles produced at 500 r.p.m., 100.0 ± 0.8% for
particles produced at 800 r.p.m. respectively.

Table III.10 Mean ± SD heats of fusion and estimated % crystallinity values for AS
particles precipitated from EA produced from Ra ratio 1:1000 (w/w) at different crystal
maturation times
Stirring speed
(r.p.m.)

100

200

500

800

Crystal
maturation
time (minutes)
0
60
180
1440
0
60
1440
0
60
180
1440
0
60
120
1440

Heat of fusion
(Mean ± SD) J/g
98.8 ± 40.3
118.9 ± 8.6
158.4 ± 3.4
198.3 ± 11.1
109.2 ± 8.9
114.5 ± 11.3
189.3 ± 15.4
103.3 ± 5.8
79.3 ± 27.1
66.9 ± 26.0
76.0 ± 7.9
99.3 ± 11.4
76.5 ± 34.0
61.7 ± 18.5
72.7 ± 13.0

80

Estimated %
crystallinity (Mean
± SD)
49.4 ± 20.2
59.4 ± 4.3
79.2 ± 1.8
99.2 ± 5.6
54.6 ± 4.4
57.3 ± 5.7
94.7 ± 7.7
51.7 ± 2.9
39.6 ± 13.5
33.5 ± 13.0
38.0 ± 3.9
49.7 ± 5.7
38.2 ± 17.0
30.9 ± 9.2
36.4 ± 6.5
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Figure III.31 Estimated % crystallinity of AS particles precipitated from EA as a function
of crystal maturation time for Ra ratio 1:1000 (w/w)
A representative powder X-ray diffractogram for the particles produced at 500 r.p.m.
from Ra ratio 1:1000 (w/w) after 1440 minutes of crystallization, filtration, sonication and drying
under ambient conditions is shown in Figure III.32. This diffractogram showed characteristic
peaks at the same positions as reference AS and no halo indicating the crystalline nature of these
particles.
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Figure III.32 Powder X-ray diffractogram for AS particles precipitated from EA produced
from Ra ratio 1:1000 (w/w) at 500 r.p.m. after crystal maturation time 1440 minutes,
filtration, sonication, and drying
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The results for estimated % crystallinity therefore showed an influence of the
crystallization conditions, notably the speed of mixing, on the crystallization kinetics of AS
particles. In order to understand the effects that different crystallization variables had on the
estimated % crystallinity of AS particles, the data for estimated % crystallinity was statistically
analyzed without any transformation using JMP 7.0 as the statistical software. The model fitting
platform was used to analyze the data for each response variable wherein the variables were split
into:
1) Main Factors: Ra ratio, stirring speed, crystal maturation time
2) Interactions: Ra ratio × stirring speed × crystal maturation time
3) Response variable: Estimated % crystallinity
The results for statistical analysis of the estimated % crystallinity are shown in Table III.11.

Table III.11 Statistical analysis of the effect of crystallization variables on AS particle
crystallinity
Source
Model
Ra Ratio
Stirring Speed
Crystal maturation time
Ra Ratio × Stirring Speed × Crystal maturation
time
R2
2

Adj R

Degrees of freedom
52
2
6
4

F-value
20.4
60.9
41.5
58.9

p-value
<0.0001
<0.0001
<0.0001
<0.0001

40

4.8

<0.0001

0.89
0.85

The model was found to be significant and capable of accounting for 85% of the
variability in the estimated % crystallinity. The three main factors showed a significant
interaction. Therefore, it is not possible to comment on the influence of any one crystallization
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variable on the estimated % crystallinity although it can be said that the estimated % crystallinity
of the AS particles was influenced by Ra ratio, stirring speed, and crystal maturation time where
all these parameters significantly interacted with each other.
In summary, it was demonstrated that a crystal maturation time = 0 was insufficient to
bring about complete solution crystallization regardless of the crystallization conditions
employed. These particles were found to undergo complete crystallization in the solid-state.
Prolonging the crystallization for longer time periods was an effective means of bringing about
complete solution crystallization for particles produced under all crystallization conditions
except those produced from Ra ratio 1:1000 (w/w) at 500 and 800 r.p.m. These particles also
underwent complete crystallization in the solid state. A complex interplay between the different
crystallization variables was also revealed wherein Ra ratio, stirring speed and crystal maturation
time revealed a significant interaction in their influence on estimated % crystallinity. In order
understand these effects, the mechanism of crystallization was investigated.

III.D.2.2.2

Mechanism of crystallization

Crystallization is a dynamic process. The basic driving force for a crystallization process
is supersaturation as discussed in section I.A.3.1.1. Supersaturation levels are influenced by the
crystallization conditions. Therefore, the role of supersaturation was investigated as a means of
explaining the observed effects of different crystallization variables on estimated % crystallinity.

III.D.2.2.2a

Role of supersaturation

The two most significant observations for the solvent / anti-solvent crystallization of AS
were:
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1) Incomplete crystallization after a crystal maturation time = 0
2) Increase in estimated % crystallinity with increasing crystal maturation time for all
crystallization conditions except Ra ratio 1:1000 (w/w) at 500 and 800 r.p.m.
This partial crystallinity of AS particles after a crystal maturation time 0 was not
surprising because of the nature of crystallization which is a kinetic process described in terms of
two distinct steps, nucleation and crystal growth driven by the supersaturation levels. The
properties of the crystals obtained are the result of the kinetic relationship between these two
processes. The role of supersaturation in influencing particle size was discussed in section
III.D.2.1.2. In solvent / anti-solvent crystallization, this supersaturation is attained very rapidly
owing to the drowning out effect of the anti-solvent which reduces the solubility of the solute
and causes it to precipitate out (Beckmann, 2000). This precipitation process is a combination of
two steps; nucleation and crystal growth. Nucleation is the first decisive step in crystallization.
Nucleation of solutes from solution is a two-step process (Wolde and Frenkel, 1997; Galkin and
Vekilov, 2000; Vekilov, 2004; Chattopadhyay et al., 2005): the creation of a droplet of a dense
liquid, metastable with respect to the crystalline state, followed by ordering within this droplet to
form a three-dimensional lattice structure. The second step involved in crystallization is crystal
growth. Crystal growth is a multi-step process (Rodríguez-Hornedo and Murphy, 1999, Davey
and Garside, 2000), which includes (1) transport of a growth unit (a single molecule, atom, ion,
or cluster) from or through the bulk solution to an impingement site, which is not necessarily the
final growth site (i.e. site of incorporation into the crystal); (2) adsorption of the growth unit at
the impingement site, (3) diffusion of the growth units from the impingement site to a growth
site, and (4) incorporation into the crystal lattice. This final step of incorporation of molecules
into the crystal lattice is a determinant of crystallinity. The crystallinity is determined by the
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formation of a perfect crystalline lattice which is a time dependent process (Mullin, 2001).
Therefore, even though particle formation may occur rapidly in solvent / anti-solvent
crystallization, the re-organization of the molecular units into the crystal lattice takes time and is
drug-dependent. This time dependent nature of the crystallization process may be responsible for
the incomplete crystallinity after a crystal maturation time = 0 observed for all conditions.
The differences in the crystallization behavior as a function of time that were observed
for particles produced under different crystallization conditions may be explained by the
supersaturation levels. Supersaturation drives the nucleation process which is the first decisive
step in crystallization and involves clustering of solute molecules to form embryos that grow into
nuclei. According to the classical nucleation theory (Volmer, 1939; Gibbs, 1948; Nielsen, 1964),
an activation energy barrier needs to be overcome for nucleation to proceed. A certain degree of
supersaturation is required to overcome the free energy barrier to nucleation. Higher the
supersaturation, lower is the free energy barrier to nucleation and hence, faster is the nucleation
process. After this stage, the cluster becomes viable and is termed a nucleus, which eventually
grows into a crystal. Hence, it is easier to form nuclei at higher supersaturation levels leading to
an increased driving force for crystallization. This leads to faster nucleation and therefore, faster
subsequent crystallization.
The supersaturation levels for the three Ra ratios were calculated in section III.D.2.1.2 as:
Ra ratio 1:200 (w/w): 5.2
Ra ratio 1:500 (w/w): 4.5
Ra ratio 1:1000 (w/w): 3.4
The higher levels of supersaturation for Ra ratios 1:200 and 1:500 (w/w) would lead to a
higher driving force for crystallization, faster nucleation, and hence faster subsequent
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crystallization. This mechanism might account for the observation that particles produced from
Ra ratio 1:200 and 1:500 (w/w) underwent complete solution crystallization over a 24 hour
period. For Ra ratio 1:1000, a difference in crystallization behavior was observed as a function of
the crystallization conditions wherein particles produced at 100 and 200 r.p.m. underwent
complete solution crystallization over a 24 hour period while particles produced under 500 and
800 r.p.m. did not do so. These differences cannot be explained solely by the role of
supersaturation since the supersaturation ratio would be the same for Ra ratio 1:1000 (w/w)
irrespective of stirring speed. Therefore, in order to explain these differences in crystallization
behavior, the role of water in solution crystallization was investigated.

III.D.2.2.2b

Role of water

It is known that in the solid state, the amount of water present in a crystallizing particle
plays an important role in determining the rate of crystallization. Crowley and Zografi (2002)
have discussed the role of absorbed water in bringing about crystallization of amorphous
drug/poly(vinylpyrrolidine) dispersions and have stated that water uptake by the amorphous
dispersion can bring about recrystallization. Similar work by Marsac et al. (2008) on Nifedipine
and Felodipine solid dispersions has also revealed a significant role of water in recrystallization
of the amorphous solid dispersions. Wu and Yu (2006) have explored the role of sorbed moisture
in bringing about surface crystallization of indomethacin. The work carried out by Schmitt et al.
(1998) on the nucleation and crystallization kinetics of amorphous lactose has shown that
moisture uptake by amorphous lactose is capable of bringing about an amorphous to crystalline
transition. The moisture induced surface crystallization of spray dried amorphous lactose has
also been studied by Mahlin et al. (2003) with similar results as Schmitt et al. (1998). Ballesteros
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et al. (2002) have utilized microcalorimetric measurements to investigate the interactions of
water vapor with amorphous pharmaceutical solids. This interaction has also been explored using
Fourier transform Raman spectroscopy by Taylor at al. (2000). Ward et al. (1995) have
investigated the role of moisture in bringing about solid-state recrystallization of partially
amorphous albuterol sulfate. They reported that exposure to relative humidities greater than 50%
was required for complete recrystallization. However, these studies investigated the solid-state
crystallization of AS. In this section, the role of water in the solution crystallization i.e.;
crystallization in particles suspended in solution is described. The % water content in the AS
particles was measured by coulometric KF titration at different time points during the 0-1440
minutes crystallization period. In addition, solvent weight loss was similarly investigated using
TGA.

III.D.2.2.2b.1 % water content after crystal maturation time = 0
Table III.12 shows the results of % water content determined using Karl Fischer
titration and % weight loss determined using TGA in AS particles produced under different
crystallization conditions at crystal maturation time = 0. The estimated % crystallinity values at
crystal maturation time = 0 for each of these conditions are also shown in the table. The values
for solvent loss obtained by the TGA agreed with the specific % water content determined by
Karl Fischer titration (significant positive correlation with R = 0.96, p-value < 0.0001) indicating
that the TGA method could also be used to assess % water content of the initially formed ‘semicrystalline’ particles. For Ra ratio 1:200 (w/w), at crystal maturation time = 0, there was no
difference in % water content for particles produced at 100, and 200 r.p.m. An increase in
%water content was observed at stirring speeds of 500 and 800 r.p.m. that may explain the more
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rapid arrival of complete crystallization at longer maturation times (Figure III.23, and III.24).
However, despite a change in the % water content for the Ra ratio 1:200 (w/w) particles as a
function of stirring speed, there was no significant change in estimated % crystallinity as shown
in Table III.12 at a maturation time = 0. Particles produced from Ra ratio 1:500 (w/w) showed
similar % water contents under all four stirring speeds (p-value > 0.05, Tukey’s HSD). This
similarity in initial water contents at crystal maturation time = 0 was also reflected in similarity
in estimated % crystallinity values for these particles (Table III.12). Therefore, for Ra ratios
1:200 and 1:500 (w/w), there did not appear to be a significant influence of stirring speed on %
water content implying that the the stirring speeds employed were not been sufficiently high to
bring about efficient mixing between the drug solution and anti-solvent leading to zones of
locally high supersaturation causing solute-solute interactions to dominate during particle
precipitation.
Table III.12 Mean ± SD % water contents (determined by Karl Fischer titration) and %
weight loss (determined by TGA) for AS particles precipitated from EA produced after
crystal maturation time 0 under different crystallization conditions
Ra ratio
(w/w)

1:200

1:500

1:1000

Stirring speed
(r.p.m.)

% Weight loss
(Mean ± SD)

% Water
(Mean ± SD)

100
200
500
800
100
200
500
800
100
200
500
800

24.6 ± 7.5
23.5 ± 4.8
33.9 ± 1.4
43.2 ± 1.4
37.7 ± 8.4
33.1 ± 4.4
27.9 ± 6.4
32.1 ± 6.6
25.3 ± 4.8
27.2 ± 4.3
10.5 ± 1.2
12.2 ± 3.5

23.4 ± 6.5
24.4 ± 8.3
33.5 ± 1.7
44.2 ± 1.4
30.0 ± 1.8
32.0 ± 6.8
29.9 ± 7.5
29.8 ± 6.0
26.9 ± 7.5
25.9 ± 8.1
9.1 ± 1.9
11.7 ± 3.3
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Estimated %
crystallinity
(Mean ± SD)
66.3 ± 1.5
64.0 ± 3.6
62.0 ± 5.9
72.9 ± 10.1
55.4 ± 2.9
69.0 ± 9.5
64.0 ± 10.8
65.3 ± 23.7
49.4 ± 20.2
54.6 ± 4.4
51.7 ± 2.9
49.7 ± 5.7

In contrast to the results for 1:200 and 1:500 (w/w) Ra ratios, the % water content in
particles produced from Ra ratio 1:1000 (w/w) was observed to decrease at higher stirring speeds.
The particles produced under lower stirring speeds of 100, and 200 r.p.m. had significantly
higher % water contents at crystal maturation time = 0 than the particles produced at the higher
stirring speeds of 500, and 800 r.p.m.
While differences in % water content were not related to estimated % crystallinity values
because similar values for % crystallinity were obtained for particles produced under all
crystallization conditions as shown in Table III.12 the fact that the only significant deviation in
water content was only observed for particles produced at crystal maturation time = 0 for the Ra
ratio 1:1000 (w/w) when mixed at 500 and 800 r.p.m. was impossible to ignore. It appeared
therefore, that these particles with % water contents around 10% began at a crystal maturation
time = 0, with a comparable % crystallinity to all the others (Table III.12). Unlike all the other
AS particles, however, these particles showed evidence of reduced water content. This change in
content appeared to coincide with either a lack of subsequent recrystallization or a net fall in
crystallinity over time when left in contact with the mother liquor (Figure III.31).

III.D.2.2.b.2 % water content at crystal maturation times between 0 – 24 hours
Table III.13 shows the % water contents for AS particles produced from Ra ratio 1:200
(w/w) under different stirring speeds at different crystal maturation times. The TGA estimated %
weight loss and estimated % crystallinity values from DSC measurements are also shown. Once
again, the % weight loss estimated from the TGA agreed with the % water content measured by
Karl Fischer titration indicating the suitability of the TGA method to estimate % water content
also.
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Table III.13 Mean ± SD % water contents, % weight loss, and estimated % crystallinity for
AS particles precipitated from EA produced from Ra ratio 1:200 (w/w) under different
stirring speeds as a function of crystal maturation time
Stirring speed
(r.p.m.)
100

200

500

800

Crystal
maturation
time (minutes)
0
60
120
1440
0
60
120
1440
0
60
1440
0
60
120
180
1440

% Weight loss
(Mean ± SD)

% Water
(Mean ± SD)

24.6 ± 7.5
15.7 ± 2.4
6.8 ± 0.9
0.9 ± 1.2
23.5 ± 4.8
17.2 ± 4.3
9.8 ± 2.4
5.2 ± 0.9
33.9 ± 1.4
25.6 ± 4.3
2.0 ± 1.0
43.2 ± 1.4
35.4 ± 2.8
11.7 ± 1.9
9.9 ± 2.6
3.9 ± 1.8

23.4 ± 6.5
16.5 ± 1.1
6.8 ± 0.4
0.9 ± 1.1
24.4 ± 8.3
16.1 ± 0.3
12.6 ± 0.8
5.4 ± 0.4
33.5 ± 1.7
27.6 ± 2.6
2.0 ± 0.9
44.2 ± 1.4
38.6 ± 1.2
12.9 ± 1.7
10.7 ± 1.3
4.4 ± 1.4

Estimated %
crystallinity
(Mean ± SD)
66.3 ± 1.5
78.6 ± 5.0
80.1 ± 1.2
101.0 ± 1.1
64.0 ± 3.6
67.7 ± 1.9
80.3 ± 0.8
97.2 ± 3.5
62.0 ± 5.9
76.3 ± 2.9
99.2 ± 0.8
72.9 ± 10.1
81.4 ± 1.4
86.8 ± 2.2
92.0 ± 6.8
100.8 ± 1.3

Figure III.33 shows the estimated % crystallinity values and % water contents for Ra ratio
1:200 (w/w) particles at different stirring speeds as a function of crystal maturation time. It was
observed that the % water content in the particles decreased as the crystal maturation time
increased and this decrease in % water content was accompanied by an increase in the estimated
% crystallinity of the AS particles produced from Ra ratio 1:200 (w/w) under all four stirring
speeds. At the end of 1440 minutes, the % water content in these particles was approximately 15% and crystallization appeared to be complete with estimated % crystallinity values of 97101%. A correlation analysis between % water content and estimated % crystallinity for Ra ratio
1:200 (w/w) for all four stirring speeds resulted in a strong, negative correlation (R = -0.71, pvalue < 0.0001) as shown in Figure III.34. Table III.14 shows the % water contents for AS
particles produced from Ra ratio 1:500 (w/w) under different stirring speeds at different crystal
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maturation times. The TGA estimated % weight loss and estimated % crystallinity values from
DSC measurements are also shown. Figure III.35 shows the estimated % crystallinity values and
% water contents for Ra ratio 1:500 (w/w) particles at different stirring speeds as a function of
crystal maturation time.
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Figure III.33 Estimated % crystallinity and % water content for AS particles precipitated
from EA produced from Ra ratio 1:200 (w/w) under different stirring speeds at different
crystal maturation times
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Figure III.34 Correlation analysis between estimated % crystallinity and % water content
for AS particles precipitated from EA produced from Ra ratio 1:200 under all stirring
speeds
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Table III.14 Mean ± SD % water contents (determined by Karl Fischer titration) and %
weight loss (determined by TGA) for AS particles precipitated from EA produced from Ra
ratio 1:500 (w/w) under different stirring speeds as a function of crystal maturation time
Stirring speed
(r.p.m.)

100

200

500

800

Crystal
maturation
time (minutes)
0
60
180
1440
0
60
120
180
1440
0
60
120
180
1440
0
60
120
180
1440

% Weight loss
(Mean ± SD)

% Water
(Mean ± SD)

37.7 ± 8.4
29.2 ± 2.6
15.4 ± 3.5
3.8 ± 0.9
33.1 ± 4.4
28.7 ± 3.2
15.7 ± 2.4
13.4 ± 1.8
3.4 ± 1.2
27.9 ± 6.4
25.6 ± 2.6
11.4 ± 1.9
10.3 ± 2.8
5.7 ± 1.0
32.1 ± 6.6
25.4 ± 3.6
12.8 ± 1.5
5.4 ± 1.2
3.0 ± 0.5

30.0 ± 1.8
28.4 ± 1.9
14.6 ± 0.8
3.2 ± 0.6
32.0 ± 6.8
28.0 ± 2.9
16.5 ± 1.0
13.2 ± 1.8
3.6 ± 1.7
29.9 ± 7.5
26.9 ± 5.4
10.7 ± 1.9
12.5 ± 1.2
5.5 ± 0.9
29.8 ± 6.0
26.0 ± 3.4
12.5 ± 0.7
5.0 ± 0.8
2.7 ± 0.6
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Estimated %
crystallinity
(Mean ± SD)
55.4 ± 2.9
57.0 ± 4.1
84.4 ± 3.1
99.7 ± 0.4
69.0 ± 9.5
72.6 ± 5.9
77.0 ± 1.5
87.0 ± 1.7
99.8 ± 6.5
64.0 ± 10.8
70.8 ± 3.5
74.8 ± 2.3
91.2 ± 1.0
99.8 ± 0.3
65.3 ± 23.7
73.0 ± 5.4
86.6 ± 3.1
95.2 ± 0.8
98.0 ± 3.4
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Figure III.35 Estimated % crystallinity and % water content for AS particles precipitated
from EA produced from Ra ratio 1:500 (w/w) under different stirring speeds at different
crystal maturation times
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It was observed that the % water content in the particles decreased as the crystal
maturation time increased and this decrease in % water content was accompanied by an increase
in the estimated % crystallinity of the AS particles produced from Ra ratio 1:500 (w/w) under all
four stirring speeds. At the end of 1440 minutes of crystallization, the % water content in these
particles was approximately 3-5% and crystallization appeared to be complete with estimated %
crystallinity values of 98-100%. A correlation analysis between % water content and estimated
% crystallinity for Ra ratio 1:500 (w/w) for all four stirring speeds resulted in a strong and
negative correlation (R = -0.85, p-value < 0.0001) as shown in Figure III.36.
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Figure III.36 Correlation analysis between estimated % crystallinity and % water content
for AS particles precipitated from EA produced from Ra ratio 1:500 under all stirring
speeds
These results for Ra ratio 1:500 (w/w) were therefore similar to Ra ratio 1:200 (w/w)
where a similar correlation between estimated % crystallinity and % water content was observed
as a function of crystal maturation time for all four stirring speeds. In contrast, particles produced
from Ra ratio 1:1000 (w/w) behaved differently in terms of crystallization behavior and
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accompanying water loss. These differences were observed to be related to the stirring speeds.
Table III.15 shows the % water contents for AS particles produced from Ra ratio 1:1000 (w/w)
under different stirring speeds at different crystal maturation times. The TGA estimated %
weight loss and estimated % crystallinity values from DSC measurements are also shown.

Table III.15 Mean ± SD % water contents (determined by Karl Fischer titration) and %
weight loss (determined by TGA) for AS particles precipitated from EA produced from Ra
ratio 1:1000 (w/w) under different stirring speeds as a function of crystal maturation time
Stirring
speed
(r.p.m.)
100

200

500

800

Crystal
maturation
time (minutes)
0
60
180
1440
0
60
1440
0
60
180
1440
0
60
120
1440

% Weight loss
(Mean ± SD)

% Water
(Mean ± SD)

25.3 ± 4.8
21.2 ± 1.3
15.4 ± 2.4
3.6 ± 2.5
27.2 ± 4.3
16.5 ± 1.8
3.3 ± 3.4
10.5 ± 1.2
7.2 ± 1.8
5.1 ± 1.6
4.4 ± 0.8
12.2 ± 3.5
10.2 ± 2.4
8.2 ± 1.9
4.0 ± 1.0

26.9 ± 7.5
20.9 ± 0.4
16.9 ± 0.9
3.4 ± 2.3
25.9 ± 8.1
15.5 ± 1.2
1.9 ± 2.4
9.1 ± 1.9
6.7 ± 3.1
5.0 ± 3.3
3.7 ± 1.7
11.7 ± 3.3
9.6 ± 3.6
7.8 ± 3.5
3.7 ± 0.7

Estimated %
crystallinity
(Mean ± SD)
49.4 ± 20.2
59.4 ± 4.3
79.2 ± 1.8
99.2 ± 5.6
54.6 ± 4.4
57.3 ± 5.7
94.7 ± 7.7
51.7 ± 2.9
39.6 ± 13.5
33.5 ± 13.0
38.0 ± 3.9
49.7 ± 5.7
38.2 ± 17.0
30.9 ± 9.2
36.4 ± 6.5

Figure III.37 shows the estimated % crystallinity values and % water contents for Ra ratio 1:1000
(w/w) particles at different stirring speeds as a function of crystal maturation time.
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Figure III.37 Estimated % crystallinity and % water content for AS particles precipitated
from EA produced from Ra ratio 1:1000 (w/w) under different stirring speeds at different
crystal maturation times
For Ra ratio 1:1000 (w/w), the % water content decreased in particles produced at all four
stirring speeds. At the end of 1440 minutes of crystallization, the final % water content was
between 2-4%. This decrease in % water content was accompanied by a corresponding increase
in estimated % crystallinity for particles produced at 100 and 200 r.p.m. as shown in Table III.15
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and Figure III.37. For these particles, a significant negative correlation was observed between %
water content and estimated % crystallinity (R = -0.76, p-value < 0.0001) as shown in Figure
III.38. These results were therefore similar to the results obtained for Ra ratios 1:200 and 1:500
(w/w) where particles produced at all four stirring speeds underwent a decrease in % water
content with an accompanying increase in estimated % crystallinity as a function of crystal
maturation time.
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Figure III.38 Correlation analysis between estimated % crystallinity and % water content
for AS particles precipitated from EA produced from Ra ratio 1:1000 under stirring speeds
100 and 200 r.p.m.
However, particles produced from Ra ratio 1:1000 (w/w) at 500 and 800 r.p.m. behaved
differently in terms of crystallization behavior and accompanying water loss. A decrease in %
water content was observed as a function of crystal maturation time reaching ≈ 4.0% at the end
of 1440 minutes which was similar to the final water content for AS particles produced under
other crystallization conditions. However, this decrease was not accompanied by a corresponding
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increase in estimated % crystallinity as shown in Table III.15 and Figure III.37. Therefore, this
difference in crystallization behavior could not be explained by the change in % water content as
a function of crystal maturation time. However, these particles contained significantly lower
levels of water (i.e.; ≈ 10%) at crystal maturation time = 0 compared to particles produced under
other crystallization conditions that contained higher % water contents (i.e.; > 20%). Even
though this initial % water content did not show a relationship with estimated % crystallinity at
crystal maturation time = 0, it nevertheless influenced the subsequent crystallization behavior as
a function of crystal maturation time.
TGA analysis revealed differences in the binding state of water which were related to its
initial level at crystal maturation time = 0. Figure III.39 shows the representative water loss
profiles for the AS particles produced from Ra ratio 1:1000 at 100 and 800 r.p.m. after mixing for
30 minutes (crystal maturation time = 0). The particles produced at 100 r.p.m. containing higher
levels of water started to lose this water at ambient temperatures of 25°C. In contrast, water loss
from the AS particles produced at 800 r.p.m. did not begin until a much higher temperature of
60°C had been attained. These results indicated that the water was bound much more tightly in
the case of these latter particles produced from Ra ratio 1:1000 at higher stirring speeds.

Figure III.39 Representative TGA profiles for AS particles precipitated from EA produced
from Ra ratio 1:1000 at stirring speeds 100 and 800 r.p.m. after crystal maturation time = 0
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These results therefore brought into focus the significant role of water in solution
crystallization of AS. Water can not only induce an amorphous to crystalline transition by its
ability to act as a plasticizer. When incorporated into the amorphous regions of particles, water
brings about an increase in molecular mobility and hence leads to molecular rearrangement
required for crystallization. This is referred to as its plasticizing effect. The plasticizing effect of
water has been described in literature for solid-state crystallization. Hancock and Shamblin
(2001) have investigated the role of water in bringing about molecular mobility of amorphous
pharmaceuticals resulting in solid-state crystallization. Zografi and co-workers (1988) stated that
this plasticizing effect of water is related to both its quantity and existence state in the particles.
Water can exist in either a “solvent-like” or “bound” state in the solids. At higher moisture
contents, water molecules are believed to be able to cluster and to begin the process of forming
“solvent-like” water. In the “solvent-like” state, water molecules have greater mobility. This
existence state of water exerts a much more efficient plasticizing effect compared to the “bound”
water. Therefore, the crystallization behavior in the experimental system described in this thesis
is likely explained by considering the quantity and existence state of water in the albuterol
sulfate particles that are first formed by precipitation. AS particles produced from Ra ratios 1:200
and 1:500 (w/w) under all stirring speeds and those produced from Ra ratio 1:1000 (w/w) at 100
and 200 r.p.m. were shown to contain high water levels approximately 30% by weight.
Moreover, water loss from these molecular associations was observed to start at low
temperatures ~ 25°C. This high level of water appeared to exist in the “solvent-like” state and
behave as efficient plasticizer leading to complete crystallization. In contrast, AS particles
produced from Ra ratio 1:1000 (w/w) at 500 and 800 r.p.m. contained low levels of water which
appeared to be present in a “highly bound” state that could not be as easily removed using TGA.
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It remains possible that these ‘precrystalline forms’ or molecular associations of AS+H2O have
completely different structures where only one converted readily to AS as a function of crystal
maturation time.
In summary, it was demonstrated that at crystal maturation time = 0, the crystallization
conditions did not have a significant influence on final collected particle crystallinity. Regardless
of the crystallization conditions used, incompletely crystalline particles were produced. Longer
crystal maturation times influenced particle crystallinity. This influence was related to the
crystallization conditions wherein particles produced from Ra ratios 1:200 and 1:500 (w/w) under
all four stirring speeds and particles produced from Ra ratio 1:1000 (w/w) under 100 and 200
r.p.m. underwent complete solution crystallization as a function of crystal maturation time.
However, particles produced from Ra ratio 1:1000 (w/w) under 500 and 800 r.p.m. failed to
convert to crystals completely when held for 24 hours in the mother liquor. The role of
supersaturation and water was investigated to explain these differences. It was observed that the
% water content in the particles was influenced by the crystallization conditions and that loosely
bound water was able to promote crystallization while tightly bound water blocked the
phenomenon. These differences in the plasticizing effect of water may have been responsible for
the differences in the solution crystallization behavior of the AS particles. This was an important
finding as it demonstrates the significant role that water plays in the crystallization process.
Harvesting and drying all the products however, resulted in complete crystallization and
formation of a single polymorphic form of AS.

III.D.2.2.3

Particle size distribution of AS particles after crystal maturation time = 24
hours
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The particle size was the second response variable of interest since it was an objective to
produce completely crystalline particles directly in a size range suitable for inhalation (1-5 µm)
without the need for further size reduction by micronization. Investigation of the crystallization
process yielded completely crystalline particles from all crystallization conditions except Ra ratio
1:1000 (w/w) at 500 and 800 r.p.m. Therefore, it was of interest to measure the particle size of
these particles.
Figure III.40 shows the cumulative % undersize volume distribution of AS particles
produced from Ra ratio 1:200 (w/w) at the four different stirring speeds after a crystal maturation
time = 24 hours. The volume frequency distribution of these particles is shown in Figure III.41.
The VMDs and span indices of these particles are shown in Table III.16. As was the case with
the particles harvested at crystal maturation time = 0, particles harvested after crystal maturation
time = 24 hours from Ra ratio 1:200 (w/w) did not reveal any influence of stirring speed on
particle size. This can be seen from Figures IV.40 and IV.41 which show overlying PSDs for the
particles produced under the different stirring speeds. A statistical analysis of the VMDs revealed
no significant difference between the particles produced at 100, 200, 500, and 800 r.p.m. (pvalue > 0.05, Tukey’s HSD). However, compared to the particles harvested at crystal maturation
time = 0, particles produced after crystal maturation time = 24 hours were significantly smaller
in size. Figure IV.42 shows the cumulative % undersize volume distributions of AS particles
produced from Ra ratio 1:200 (w/w) under a stirring speed of 100 r.p.m. at crystal maturation
time = 0 and crystal maturation time = 24 hours. Table III.16 shows the VMDs and span indices
of the particles produced from Ra ratio 1:200 (w/w) under different stirring speeds at a crystal
maturation time = 0 and 24 hours. A statistical analysis of the VMDs revealed that significantly
smaller particles (VMD = 10-12 µm) were produced at crystal maturation time = 24 hours
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compared to crystal maturation time = 0 (VMD = 19-20 µm ) (p-value < 0.05, one-way

Cumulative % volume less than stated size

ANOVA).
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Figure III.40 Cumulative % undersize volume distribution of AS particles precipitated
from EA harvested after a crystal maturation time of 1440 minutes from Ra ratio 1:200
(w/w) under different stirring speeds
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Figure III.41 Volume frequency distribution of AS particles precipitated from EA
harvested after a crystal maturation time of 1440 minutes from Ra ratio 1:200 (w/w) under
different stirring speeds
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Figure IV.42 Cumulative % undersize volume distribution of AS particles precipitated
from EA produced from Ra ratio 1:200 (w/w) at 100 r.p.m. after crystal maturation time =
0 and crystal maturation time = 24 hours

Table III.16 Mean ± SD volume median diameters and span indices of AS particles
precipitated from EA produced from Ra ratio 1:200 (w/w) under different stirring speeds
Crystal maturation time =0
Stirring speed
(r.p.m.)
100
200
500
800

Span
index
7.7
8.9
7.8
8.5

VMD ± SD (µm)
18.9 ± 7.9
17.9 ± 7.4
19.9 ± 8.0
18.7 ± 6.7

Crystal maturation time
=24 hours
Span
VMD ± SD (µm)
index
10.5 ± 1.4
10.2
9.7 ± 0.7
7.7
11.5 ± 1.0
10.3
11.5 ± 1.7
8.9

This influence of crystal maturation time on particle size may appear paradoxical to
crystallization theory that implies only crystal growth occurs with increasing time. However, in
this case the nature of the particles comes into picture. The AS particles at crystal maturation
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time = 0 and crystal maturation time = 24 hours differ in their % crystallinity. At crystal
maturation time = 0, partially crystalline particles were produced which underwent complete
crystallization upon filtration and drying in the solid-state prior to sizing. On the other hand,
particles produced at crystal maturation time = 24 hours were completely crystalline and no
changes in crystallinity were observed in the solid-state prior to sizing. Therefore, it is
hypothesized that the larger size of the particles produced at crystal maturation time = 0
compared to crystal maturation time = 24 hours may be an outcome of solid-state crystallization
which is known for the formation of crystal bridges between adjacent particles, particle fusion
and an increase in particle size. This is particularly detrimental for aerosol formulations where
size is a primary concern. Therefore, these results demonstrate the importance of harvesting
completely crystalline particles that are not prone towards further crystallization in the solid
state. However, even though the particles produced after crystal maturation time = 24 hours were
smaller in size compared to particles produced at crystal maturation time = 0, they were in a size
range of 10-11 µm and hence were not small enough for inhalation (i.e.; between 1-10 µm,
preferably between 1-5 µm).
The cumulative % undersize volume distributions and volume frequency distributions of
particles produced from Ra ratio 1:500 (w/w) under different stirring speeds after crystal
maturation time = 24 hours are shown in Figures III.43 and III.44 respectively. Bimodal
distributions were observed. The VMDs and span indices of these particles are shown in Table
III.17 along with the VMDs and span indices of particles produced from Ra ratio 1:500 (w/w)
under different stirring speeds after crystal maturation time = 0. As was the case with Ra ratio
1:200 (w/w), particles produced from Ra ratio 1:500 (w/w) under all stirring speeds after crystal
maturation time = 24 hours were significantly smaller (p-value < 0.05, one-way ANOVA) than

105

particles produced from Ra ratio 1:500 (w/w) under corresponding stirring speeds at crystal
maturation time = 0. Therefore, these results once again illustrated the importance of harvesting
completely crystalline particles. Another important point was that the particles produced from Ra
ratio 1:500 (w/w) under stirring speeds 100, 200, and 500 r.p.m. after crystal maturation time =
24 hours were significantly smaller in size (VMD = 20-22 µm) than the particles produced at 800

Cumulative % Volume less than stated size

r.p.m. after crystal maturation time = 0 (VMD = 90.3 ± 13.6 µm).
100rpm
200rpm
500rpm
800 rpm

120
100
80
60
40
20
0
0.1

1

10

100

1000

Geometric Diameter (microns)

Figure III.43 Cumulative % undersize volume distribution of AS particles precipitated
from EA harvested after a crystal maturation time of 1440 minutes from Ra ratio 1:500
(w/w) under different stirring speeds
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Figure III.44 Volume frequency distribution of AS particles precipitated from EA
harvested after a crystal maturation time of 1440 minutes from Ra ratio 1:500 (w/w) under
different stirring speeds
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Table III.17 Mean ± SD volume median diameters and span indices of AS particles
precipitated from EA produced from Ra ratio 1:500 (w/w) under different stirring speeds
Crystal maturation time =0
Stirring speed
(r.p.m.)
100
200
500
800

VMD ± SD (µm)
25.6 ± 5.4
28.6 ± 3.3
26.6 ± 10.9
95.6 ± 28.9

Span
index
5.9
6.2
6.1
2.2

Crystal maturation time =24
hours
VMD ± SD (µm)

Span index

19.9 ± 5.7
22.0 ± 3.2
22.4 ± 2.4
90.3 ± 13.6

9.1
6.8
7.8
3.1

However, all of the particles produced from Ra ratio 1:500 (w/w) were significantly
larger in size than the particles produced from Ra ratio 1:200 (w/w) under corresponding stirring
speeds after crystal maturation time = 24 hours and were hence too large for inhalation. For Ra
ratio 1:1000 (w/w), bimodal PSDs were obtained as shown in Figures III.45 and III.46. The
VMDs of the particles (shown in Table III.18) produced at 100 and 200 r.p.m. were comparable
to each other and to those produced from Ra ratio 1:500 (w/w) under corresponding stirring
speeds (p-value > 0.05, one-way ANOVA). However, significantly larger particles were
produced at 500 and 800 r.p.m. for Ra ratio 1:1000 (w/w) compared to 100 and 200 r.p.m. for the
same Ra ratio (p-value < 0.05, Tukey’s HSD). Particles produced from Ra ratio 1:1000 (w/w) at
100 and 200 r.p.m. after crystal maturation time = 0 were also significantly smaller than the
particles produced at crystal maturation time = 0 from the same Ra ratio at corresponding stirring
speeds as shown in Table III.18. However, there was no difference in the VMDs of particles
produced at 500 and 800 r.p.m. after crystal maturation time = 0 and crystal maturation time = 24
hours (p-value > 0.05, one-way ANOVA). It must be remembered that these particles remained
partially crystalline even after crystal maturation time = 24 hours and underwent complete
crystallization in the solid-state in a manner similar to the particles harvested at crystal
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maturation time = 0. These results therefore, supported the hypothesis that the larger size of the
particles that were harvested following a crystal maturation time = 0 was due to solid-state

C umulative % volume less than stated size

crystallization that occurred during the particle isolation process.
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Figure III.45 Cumulative % undersize volume distribution of AS particles precipitated
from EA harvested after a crystal maturation time of 1440 minutes from Ra ratio 1:1000
(w/w) under different stirring speeds
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Figure III.46 Volume frequency distribution of AS particles precipitated from EA
harvested after a crystal maturation time of 1440 minutes from Ra ratio 1:1000 (w/w)
under different stirring speeds
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Table III.18 Mean ± SD volume median diameters and span indices of AS particles
precipitated from EA produced from Ra ratio 1:1000 (w/w) under different stirring speeds
Crystal maturation time =0
Stirring speed
(r.p.m.)
100
200
500
800

VMD ± SD (µm)

Span index

26.7 ± 6.0
32.9 ± 12.6
90.7 ± 8.2
93.4 ± 4.2

6.3
5.9
2.5
2.2

Crystal maturation time
=24 hours
VMD ± SD
Span index
(µm)
20.5 ± 3.8
7.7
21.3 ± 1.3
6.7
99.5 ± 11.6
2.1
95.7 ± 3.0
2.2

Therefore, in a manner similar to the particle size of particles at crystal maturation time =
0, particle size after a crystal maturation time = 24 hours was also found to be a function of the
crystallization conditions wherein variables such as Ra ratio, and stirring speed significantly
influenced the particle size of the AS particles. The smallest particle size was produced from Ra
ratio 1:200 (w/w) under all stirring speeds employed. The stirring speed of 200 r.p.m. yielding
particles with a VMD of 9.7 ± 0.7 µm after crystal maturation time = 24 hours was therefore
found to be the optimized condition among all the crystallization conditions studied.
The possible explanation for the effect of the crystallization variables on particle size was
discussed in section III.D.2.1.2 dealing with particle size distribution at crystal maturation time =
0. However, in a crystallization process, the effect of a single crystallization condition cannot be
treated in isolation since there are interactions between the different variables. Therefore, a
statistical analysis of the particle size distribution data was carried out in the JMP 7.0 software
without any transformation. The model fitting platform was used to analyze the data for each
response variable wherein the variables were split into:
4) Main Factors: Ra ratio, stirring speed, crystal maturation time
5) Interactions: Ra ratio × stirring speed × crystal maturation time
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6) Response variable: Volume Median Diameter
The results for statistical analysis of the volume median diameter are shown in Table III.19.

Table III.19 Statistical analysis of the effect of crystallization variables on Volume Median
Diameter of AS particles
Source
Model
Ra Ratio
Stirring Speed
Crystal maturation time
Ra Ratio × Stirring Speed × Crystal
maturation time
R2

Degrees of
freedom
20
2
8
1
11

F-value

p-value

16.5
50.4
28.7
0.009

<0.0001
<0.0001
<0.0001
< 0.0001

1.3

< 0.0001

0.95

Adj R2

0.92

The model was found to be significant and accounted for 95% of the variability in the
volume median diameter. The three factors showed a significant interaction as is shown by a pvalue < 0.0001. The volume median diameter of the particles was significantly influenced by Ra
ratio, stirring speed, and crystal maturation time interacting with each other and it was not
possible to comment on the influence of any one variable by treating it separately from the
others.
In summary, it was demonstrated that harvesting the completely crystalline particles after
a crystal maturation time = 24 hours resulted in the formation of significantly smaller particles
compared to the partially crystalline particles harvested at crystal maturation time = 0. This
effect was attributed to solid-state crystallization in the partially crystalline particles.
Furthermore, different crystallization variables showed a significant impact on the particle size
wherein the smallest VMD (≈ 10 µm) was obtained from Ra ratio 1:200 (w/w) at 200 r.p.m. after
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a crystal maturation time = 24 hours. However, the PSD of these particles was very broad (span
index = 7.7) and they were not in a size small enough for inhalation. Therefore, further
optimization of the solvent / anti-solvent crystallization process was needed to produce AS
particles small enough for inhalation.
In an attempt to reduce the size of the AS particles the influence of the temperature
difference between the solvent and anti-solvent was investigated. The temperature differences
studied were 20°C and 65°C produced by cooling the anti-solvent in ice and dry ice respectively
for the 30 minute duration of stirring. The temperature of the drug solution was 25°C. The
crystallization conditions chosen for these experiments were a Ra ratio of 1:200 (w/w), a stirring
speed of 200 r.p.m. and a crystal maturation time = 24 hours since it was shown that these
crystallization conditions resulted in the smallest AS particles among all the conditions
investigated. Table III.20 shows the results for particle sizes obtained under a temperature
difference of 20 and 65°C. The particle size results for the temperature difference = 0°C are also
shown for comparison. The cumulative % undersize volume distributions of the particles
produced at the three temperature differences investigated are shown in Figure III.47 with the
volume frequency distributions shown in Figure III.48.

Table III.20 Effect of temperature difference between the drug solution and anti-solvent on
the particle size of AS particles precipitated from EA

Average VMD ± SD (μm)
Volume < 5 μm
Volume < 10 μm
Span index

ΔT = 0°C
9.7 ± 0.7
24.9
46.0
7.7
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ΔT = 20°C
10.4 ± 0.6
29.2
52.5
7.5

ΔT = 65°C
8.8 ± 0.6
34.4
58.3
7.8
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Figure III.47 Cumulative % undersize volume distribution of AS particles precipitated
from EA harvested under different conditions of temperature difference between the drug
solution and anti-solvent
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Figure III.48 Volume frequency distribution of AS particles precipitated from EA
harvested under different conditions of temperature difference between the drug solution
and anti-solvent
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The PSDs obtained were bimodal for all temperature differences studied. A temperature
difference of 20°C did not result in a significant reduction in the particle size compared to a
temperature difference = 0°C (VMD of 10.4 ± 0.6 µm vs. 9.7 ± 0.7 µm). However, a larger
temperature difference of 65°C between the solvent and anti-solvent resulted in a small but
significant reduction (p-value < 0.05, Tukey’s HSD) in particle size (Table III.20). Moreover,
there was also a significant increase in the volume of particles below 5µm (34.4 vs. 24.9%)
which is commonly believed to represent the fraction that is respirable. This effect of
temperature difference may be attributed to the low anti-solvent temperature used to produce it.
A reduced temperature of the anti-solvent would result in reduced AS solubility, higher
supersaturation and hence a greater dominance of nucleation leading to the production of a large
number of smaller particles. The particles produced at a temperature difference of 65°C were
also analyzed for their estimated % crystallinity by DSC. Their heat of fusion was 199.1 ± 1.3 J/g
resulting in an estimated % crystallinity of 99.0 ± 0.5%. Particle morphology was observed to be
tabular as shown in Figure III.49.

Figure III.49 Representative SEM image of AS particles produced from ethyl acetate at Ra
ratio 1:200 (w/w), 200 r.p.m. and a drug solution-anti-solvent temperature difference of
65°C
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Therefore, based on these results, the optimized crystallization conditions in a solvent /
anti-solvent system of water / ethyl acetate that produced completely crystalline and smallest AS
particles were a Ra ratio of 1:200 (w/w), an infusion rate of 1mL/min, a stirring speed of 200
r.p.m. for 30 minutes, a temperature difference of 65°C between the solvent / and anti-solvent
and a total crystal maturation time of 24 hours. However, even though it was possible to reduce
the size of AS particles by optimization of the crystallization conditions, the particles produced
were still not in a size optimum for inhalation (1-5 µm).
In order to produce smaller AS particles, isopropyl alcohol was tested as the anti-solvent
since studies in literature have specifically reported its efficiency as an anti-solvent for albuterol
sulfate (Dhumal et al., 2009). The crystallization conditions used were a Ra ratio 1:200 (w/w), an
infusion rate of 1mL/min, a stirring speed of 200 r.p.m. for 30 minutes and a total crystal
maturation time of 24 hours with no temperature difference between the solvent and anti-solvent.
Figure III.50 and III.51 show the cumulative % undersize volume distributions and volume
frequency distributions for the particles produced from isopropyl alcohol. The PSDs for the
particles produced from ethyl acetate under the optimized conditions discussed above are also

Cumulative % volume less than stated size

shown for comparison.
Isopropyl Alcohol

120

Ethyl Acetate

100
80
60
40
20
0
0.1

1

10

100

1000

Geometric Diameter (microns)

Figure III.50 Cumulative % undersize volume distribution of AS particles produced from
isopropyl alcohol and ethyl acetate
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Figure III.51 Volume frequency distribution of AS particles produced from isopropyl
alcohol and ethyl acetate
The particle size distribution of particles produced from IPA was observed to be
apparently unimodal when compared to the particles produced from ethyl acetate. Furthermore,
the VMD of IPA particles was 4.9 ± 0.3 µm which was significantly smaller relative to the VMD
of 8.8 ± 0.6 µm produced by ethyl acetate (p-value < 0.05, one-way ANOVA). The span values
shown in Table III.21 revealed that isopropyl alcohol resulted in a significantly narrower PSD
compared to ethyl acetate.

Table III.21 Particle size of AS particles produced from isopropyl alcohol and ethyl acetate
under the optimized crystallization conditions

Average VMD ± SD (μm)
Volume < 5 μm (%)
Volume < 10 μm (%)
Span index

Isopropyl alcohol
4.9 ± 0.3
55.6 ± 0.8
82.6 ± 0.6
2.4

Ethyl acetate
8.8 ± 0.6
34.4 ± 1.2
57.1 ± 0.8
7.6

Dhumal et al. have previously carried out the formation of AS particles using a similar
solvent / anti-solvent system of water and isopropyl alcohol (Dhumal et al., 2009). They reported
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that using mechanical stirring alone, particles with a volume median (SD) diameter (VMD) of
22.3 (2.55) µm were produced. In that study, AS particles were produced using water as the
solvent, a saturated drug solution concentration of 250mg/mL, IPA as the anti-solvent and a Ra
ratio of 1:16 w/w, however, no information about the stirring speed was provided. Possible
reasons for the smaller particle size distribution of the AS particles produced in our study include
the optimized stirring conditions taken together with different crystallization vessel geometry.
It was possible that the formation of smaller particles by using IPA as the anti-solvent
may be explained by the relative kinematic viscosities of IPA and ethyl acetate. Kinematic
viscosity is sometimes referred to in terms of diffusivity of momentum. Indeed, dimensionally, it
is given by the ratio of fluid viscosity to fluid density resulting in dimensions indentical to
diffusivity or diffusion coefficient (M2T-1). It describes the ratio of viscous force to inertial force.
Therefore, a fluid having a higher kinematic viscosity will offer more resistance to movement
compared to a fluid with a lower kinematic viscosity. Since drug molecules need to diffuse
through the fluid to deposit on pre-formed nuclei and the solvents also need to mix, an increased
resistance to solute movement should result in reduced diffusion of drug molecules and hence a
lowered growth rate. The kinematic viscositites were calculated for IPA and ethyl acetate as
2.49×10-2 Stokes and 4.75×10-3 Stokes respectively. This 10 fold difference in kinematic
viscosities may be a possible explanation for the formation of smaller particles in IPA compared
to ethyl acetate.
Thermal analysis of the particles produced from isopropyl alcohol revealed a heat of
fusion of 200.2 ± 1.8 J/g which resulted in an estimated % crystallinity of 100.0 ± 1.2% after 24
hours of crystallization indicating complete crystallization. The powder X-ray diffraction pattern
for these particles is shown in Figure III.52 with characteristics peaks comparable to reference
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AS indicating the formation of the same polymorphic form as the reference and the AS particles
produced from EA. Therefore, the issues of solid-state crystallization and crystal bridging
associated with harvesting partially crystalline particles did not arise.
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Figure III.52 Powder X-ray diffractogram for AS particles precipitated from IPA
produced from Ra ratio 1:200 (w/w) at 200 r.p.m. after crystal maturation time 1440
minutes, filtration, sonication, and drying
Isopropyl alcohol also produced particles with a different morphology compared to ethyl
acetate. Figure III.53 shows the representative scanning electron micrograph of AS particles
produced from IPA. Compared to ethyl acetate that generated tabular particles, use of IPA as the
anti-solvent resulted in the formation of elongated, rod-like particles. This effect may be
explained by the relative polarity of IPA vs. ethyl acetate where IPA is a more polar solvent
relative to ethyl acetate. Solvent polarity influences crystal habit and growth of different faces by
the interaction between the solvent molecules and the different crystal faces, which is believed to
change crystal morphology (Mullin, 2001). Albuterol sulfate is a polar molecule with higher
solubility in relatively polar solvents. Therefore, in a non-polar solvent, such as ethyl acetate, the
small particles that are immediately formed tend to agglomerate to reduce the particle surface
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area in contact with the non-polar liquid, and thus to diminish the surface tension established
between the albuterol sulfate polar molecule and the non-polar liquid. In fact, generally, with a
higher amount of polar solvent, crystals are acicular, while the increase of non-polar liquid
favors isodimensional growth and a slight tendency to crystal agglomeration. According to Leger
et al, AS has a monoclinic structure (Leger et al., 1978). The monoclinic unit cell contains 4 AS
molecules. Along the “b” axis, phenol rings are coplanar, in facing positions, interacting with
each other hydrophobically. In presence of hydrophilic solvents, the polar groups can establish
hydrogen bonds with water molecules, so AS molecules tend preferentially to grow along the “b”
axis, which is the more hydrophobic, by the overlap of several phenol rings. By diminishing the
hydrophilic nature of the solvent, the possibility that the polar groups can establish hydrogen
bonds with the solvent diminishes, and thus crystal tends to grow in all directions
isodimensionally.

Figure III.53 Scanning electron micrograph of AS particles produced from isopropyl
alcohol
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Utilizing isopropyl alcohol as the anti-solvent while using the crystallization conditions
previously optimized for ethyl acetate resulted in AS particles that were completely crystalline,
in a size suitable for inhalation (1-5 µm) with a narrower PSD compared to particles formed with
ethyl acetate as the anti-solvent. These results therefore demonstrated the importance of
optimizing the crystallization conditions in particle engineering and revealed that by
investigation and optimization of these conditions, it was possible to utilize a simple solvent /
anti-solvent system to produce particles with the desired characteristics.

III.D.2.3

Comparison of AS particles engineered from solvent / anti-solvent
crystallization with micronized AS

At this point, it is interesting to compare the properties of the engineered particles from
the optimized solvent / anti-solvent processes using water / ethyl acetate and water / isopropyl
alcohol as the solvent / anti-solvent systems with the conventionally used micronized AS
particles for aerosol formulations. Micronized AS particles revealed a heat of fusion of 190.3 ±
1.8 J/g resulting in an estimated % crystallinity value of 95.2 ± 1.3%. Figure III.54 shows the
cumulative % undersize volume distribution of the micronized AS particles. The volume
frequency distribution is shown in Figure III.55. Figure III.56 shows a comparative cumulative
% undersize volume distribution of micronized AS particles with AS particles produced from
IPA and EA under the optimized crystallization conditions discussed in the previous sections.
The PSD parameters for these three types of AS particles are shown in Table III.22. Micronized
AS had a smaller VMD relative to the smallest AS particles produced from IPA (4.9 ± 0.3 µm)
and ethyl acetate (8.8 ± 0.6 µm). The span indices were comparable for micronized AS and AS
particles produced from IPA (i.e.; 2.2). However, ethyl acetate produced a broader PSD evident
from its large span index of 7.7.
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Figure III.54 Cumulative % undersize volume distribution of micronized albuterol sulfate
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Figure III.55 Volume frequency distribution of micronized albuterol sulfate
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Figure III.56 Cumulative % undersize volume distributions of micronized AS particles and
AS particles produced from isopropyl alcohol and ethyl acetate
Table III.22 Particle size distribution parameters for micronized albuterol sulfate
Particles
Micronized AS
Ethyl Acetate AS
Isopropyl Alcohol AS

Average VMD
± SD (µm)
3.9 ± 0.3
8.8 ± 0.6
4.9 ± 0.3

Span index
2.2
7.7
2.2

% Volume <
5 µm
71.8 ± 3.4
34.4 ± 1.2
55.6 ± 0.8

% Volume <
10 µm
92.7 ± 1.2
57.1 ± 0.8
82.6 ± 0.6

Figure III.57 shows a representative SEM image of micronized AS particles. Compared
to the AS particles that exhibited elongated, rod-like morphology (Figure III.52), micronized AS
had a tabular platelet-like morphology which resembled that of AS particles produced from ethyl
acetate (Figure III.49).
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Figure III.57 Representative SEM image of micronized albuterol sulfate
Therefore, AS particles produced from the solvent / anti-solvent crystallization process
possessed different particle characteristics compared to the conventionally used micronized
particles. However, these particle size distributions were obtained from the Malvern which is
calibrated for spherical particles. The AS particles produced from ethyl acetate and
micronization were tabular and plate-like as shown in Figures III.49 and III.56 respectively. The
particles produced from IPA were elongated and rod-like as shown in Figure III.52. Therefore,
PSD obtained from the Malvern may not be an accurate measure. Further, Malvern measures the
geometric diameter of the particles. The aerosol performance of particles is a strong function of
their aerodynamic diameter which cannot be determined using the Malvern. In vitro aerosol
performance studies using impactors are necessary to determine the inhalation efficiency of these
particles. Hence, although ethyl acetate produced large particles (VMD = 8.8 ± 0.6 µm)
compared to micronized particles (VMD = 3.9 ± 0.3 µm) and AS particles produced from IPA

122

(VMD = 4.9 ± 0.3 µm), the in vitro aerosol performance of these three types of AS particles was
tested. These results will be discussed in Chapter V.

III.E

CONCLUSIONS
One of the hypotheses of this project was that an understanding of the degree of influence

of critical crystallization variables upon particle characteristics will allow optimization and
control of the final product. In this chapter, the investigation of the solvent/anti-crystallization
process for albuterol sulfate using water as the solvent and ethyl acetate as the anti-solvent was
carried out using a DoE experimental approach to study the impact of crystallization variables on
particle characteristics; predominantly particle crystallinity and particle size. These studies
yielded insight into the fundamentals influencing the particle characteristics. Hydrodynamic
conditions alone without any external energy source or crystal growth modifiers were shown to
control the particle size distribution of albuterol sulfate with supersaturation levels exercising
significant influence. Significant interactions between the different crystallization variables were
discovered and particle size distribution was found to be influenced by them. This is an
important finding since interpretation of the influence of a single crystallization variable without
taking other interacting variables into consideration is likely to lead to erroneous analysis.
Particle crystallinity was also found to be influenced by the complex interplay between the
crystallization variables and % water content was shown to be a simple surrogate marker for
monitoring solution crystallization. The importance of harvesting completely crystalline particles
was also demonstrated and this required maturation times spent in the mother liquor that
depended upon the way in which crystallization was induced. Temperature difference between
the drug solution and anti-solvent was found to have a small but significant impact on the
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particle size of AS particles produced from ethyl acetate. Optimization of the solvent / antisolvent system of water / ethyl acetate led to the formation of completely crystalline AS particles
with a particle size between 1-10 µm and a VMD of 8.8 µm while those particles were not in the
optimum size range for aerosol formulations (i.e.; 1-5 µm). Further optimization of the solvent /
anti-solvent crystallization process using isopropyl alcohol as the anti-solvent led to the
formation of significantly smaller AS particles with a VMD of 4.9 µm and a narrower PSD
compared to those isolated from ethyl acetate. Complete crystallinity for these particles was also
observed. These particles were therefore deemed to be suitable for inhalation. The aerosol
performance of those particles is discussed in Chapter V. These studies showed that it was
possible to use simple hydrodynamic control and known supersaturation conditions to produce
microcrystals of AS with desirable characteristics for inhalation.
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CHAPTER IV
COMBINATION PARTICLES OF ALBUTEROL SULFATE AND IPRATROPIUM
BROMIDE MONOHYDRATE

IV.A

INTRODUCTION
In this chapter a solvent / anti-solvent crystallization process to produce combination

particles of albuterol sulfate (AS) and ipratropium bromide monohydrate (IB) in varying
proportions is investigated. The commercial combination product containing these two active
pharmaceutical ingredients (APIs) is Combivent® pMDI which is formulated as a physical
mixture of individually micronized AS and IB in a nominal ratio of 6:1 (w/w) suspended in a
CFC propellant with soy lecithin as the surfactant. Since such physical mixtures suffer from
powder segregation and hence, loss of fixed drug ratio during aerosolization, it may be desirable
to produce combination particles with fixed proportions of AS and IB and with suitable
characteristics for inhalation. If these particles can be directly produced in a size suitable for
inhalation, the disadvantages associated with micronization can be overcome. It is hypothesized
that these combination particles can be produced in predictable ratios with suitable
characteristics for inhalation by a single-step crystallization process.

IV.B

CHEMICALS

Albuterol Sulfate ((RS)-1- (4-hydroxy-3-hydroxymethylphenyl)-2-(tert-butylamino) ethanol
sulfate): Spectrum Chemical Mfg. Corp., New Brunswick, NJ
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Ipratropium Bromide monohydrate ([8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3yl] 3-hydroxy-2-phenyl-propanoate): Spectrum Chemical Mfg. Corp., New Brunswick, NJ
HPLC grade ethyl acetate: Fischer Scientific, Pittsburgh, PA
HPLC grade isopropyl alcohol: Fischer Scientific, Pittsburgh, PA
HPLC grade methanol: Fischer Scientific, Pittsburgh, PA
Ammonium Formate: Fischer Scientific, Pittsburgh, PA

IV.C

METHODS

IV.C.1

Solvent / Anti-solvent system used for combination particles
Combination particles of AS and IB were produced in different ratios of 1:1, 2:1, 6:1 and

10:1 (w/w) using a solvent / anti-solvent crystallization setup essentially similar to that employed
for AS described in section III.C.1. The details of the crystallization variables further
investigated and optimized for producing combination particles in a size suitable for inhalation
will be discussed in the following sections.

IV.C.2

Processing variables investigated for combination particles
The processing variables investigated for the combination particles included the anti-

solvent used, the temperature difference between the solvent and anti-solvent, initial
concentration of AS and IB in the aqueous drug solution, and total crystal maturation time.
Investigation of the effect of anti-solvent on particle characteristics was the first step. Ethyl
acetate and mixtures of ethyl acetate and isopropyl alcohol were investigated at fixed conditions
of Ra ratio, initial drug concentrations, and crystal maturation time. The effect of temperature
difference between solvent and anti-solvent was also studied for an optimized mixture of ethyl
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acetate and isopropyl alcohol. Further, isopropyl alcohol was investigated as the anti-solvent at
variable Ra ratios, initial drug concentrations, and crystal maturation time.

IV.C.2.1

Solvent / Anti-solvent crystallization of combination particles using ethyl
acetate as the anti-solvent

In all experiments, water was used as the solvent. The crystallization conditions when
using ethyl acetate as the anti-solvent were same as the optimized crystallization conditions for
AS alone as discussed in chapter III. These conditions are outlined below:
Ra ratio = 1:200 (w/w)
Infusion rate = 1mL/min
Stirring speed = 200 r.p.m.
Stirring time = 30 minutes
Crystal maturation time = 24 hours
Solvent temperature = 25°C
Anti-solvent temperature = 25°C
An aqueous solution of AS and IB was prepared by weighing the appropriate amounts of AS and
IB into a glass beaker and adding water to achieve the required concentration (% w/w). The
beaker was covered with parafilm and heated to 40°C. Following dissolution of AS and IB, the
saturated solution was allowed to cool to room temperature (25-27°C). Table IV.1 describes the
concentration of the two APIs in the starting aqueous solution, the weight of the drug solution,
and the weight of the anti-solvent to achieve a solvent / anti-solvent ratio of 1:200 (w/w) for the
1:1, 2:1, 6:1, and 10:1 (w/w) combination particles.
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Table IV.1 Initial drug solution concentrations of AS and IB and weights of ethyl acetate
used as the anti-solvent for the solvent / anti-solvent crystallization process
Nominal AS:IB
Ratio (w/w)
1:1
2:1
6:1
10:1

AS conc.
(g/g)
0.22
0.22
0.22
0.22

IB conc.
(g/g)
0.22
0.11
0.04
0.02

Wt. of AS+IB
(g)
0.24
0.19
0.16
0.15

Wt. of drug
solution (g)
0.66
0.65
0.65
0.65

Wt. of antisolvent (g)
131.0
130.6
130.0
130.8

The concentration of AS was kept constant and despite of small change in the mass of IB,
the total weight of the drug solution and the weight of the anti-solvent was kept constant. This
was required in order to avoid hydrodynamic changes due to differences in energy transfer and
dissipation during mechanical agitation of the crystallization medium. The aqueous drug solution
of AS and IB was added to ethyl acetate over a 30 second period at a fixed infusion rate of 1
mL/min by means of a syringe pump (Harvard Apparatus, Holliston, MA) using a 500μL
Hamilton gastight syringe. The solution was transferred to the crystallization vessel via a 12 cm
PEEK tubing (ID = 0.007 inches, Upchurch Scientific, Oak Harbor, WA) which was held in a
fixed position 5 cm above the anti-solvent. Mixing between the drug solution and anti-solvent
was achieved by a stirrer (Caframo stirrer type RZR 50, Wiarton, ON, Canada) with paddle
dimensions of 2 × 1 × 0.6 inches. Stirring was initiated with the addition of the drug solution and
was carried out for a fixed 30 minute period. Experiments were carried out at room temperature
(25-27°C) with no temperature difference between the drug solution and anti-solvent unless
otherwise stated. Following the 30 minute stirring, the particles were allowed to remain in the
solvent/anti-solvent mixture for 24 hours. Particles were recovered from the anti-solvent by
vacuum filtration using a 0.45μm membrane filter (45mm diameter; Fischer Scientific,
Pittsburgh, PA) housed in a glass filter unit. The filter paper containing the wet cake was washed
with and the particles were re-suspended in 4mL of the saturated filtrate soluttion. This
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concentrated suspension was sonicated at 40KHz for 45minutes to allow complete evaporation of
the filtrate solution. The particles were then dried overnight at room temperature. Samples were
then stored in sealed containers in a dessicator at room temperature.

IV.C.2.2

Solvent / anti-solvent crystallization of combination particles using isopropyl
alcohol as the anti-solvent

Isopropyl alcohol (IPA) was investigated as the anti-solvent. These studies were carried
out to produce combination AS/IB particles in a nominal 6:1 (w/w) ratio in size suitable for
inhalation. The different crystallization conditions studied are listed in Table IV.2. The infusion
rate of the drug solution was 1mL/min. The stirring speed was 200 r.p.m. for Ra ratio 1:200
(w/w). However, magnetic stirring was used with Ra ratio 1:20 (w/w) due to the small volume of
anti-solvent. Both solvent and anti-solvent temperature was 25°C with no temperature difference
between the two. Particles were harvested using the procedure described in section IV.C.2.1.

Table IV.2 Crystallization conditions investigated with isopropyl alcohol as the anti-solvent

IV.C.2.3

Ra ratio (w/w)

AS conc. (g/g)

IB conc. (g/g)

1:200
1:20
1:20
1:20

0.22
0.38
0.38
0.38

0.04
0.22
0.22
0.06

Crystal maturation
time
24 hours
24 hours
5 minutes
30 seconds

Solvent / anti-solvent crystallization of combination particles using mixtures
of isopropyl alcohol and ethyl acetate as anti-solvents

Combination particles with AS:IB ratios of 1:1, 2:1, 6:1, and 10:1 (w/w) were produced
from anti-solvents containing IPA and EA mixed in different proportions of 1:1, 1:2, 1:5, and
1:10 (w/w). The initial AS and IB concentrations used for the combination particles were same
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as listed in Table IV.1. The crystallization conditions used were also same as those used with
ethyl acetate. The anti-solvent composed of IPA:EA = 1:10 (w/w) was also used for investigating
the effect of temperature difference between the solvent and anti-solvent on particle size. This
anti-solvent was cooled in dry ice for the 30 minute duration of stirring resulting in a temperature
difference of 65°C between the solvent and anti-solvent.

IV.C.2.4

Physical mixtures of AS and IB

In order to confirm the formation of combination particles of AS and IB and differentiate
them from physically mixed AS and IB, physical mixtures of the two APIs were prepared for
comparison. These physical mixtures were prepared by blending of AS and IB in proportions of
1:1, 2:1, 6:1, and 10:1 (w/w) by geometric mixing using a mortar and pestle. The blend
homogeneity of these physical mixtures was determined by weighing and analyzing 10 samples
by the HPLC analysis method described in section IV.C.3.6. A % RSD of less than 5.0% for AS
and IB was taken as evidence of acceptable blend homogeneity.

IV.C.3

Solid-state characterization of combination particles
The combination particles subjected to filtration, sonication and subsequent drying at

room temperature for 24 hours were characterized by different solid-state analytical techniques.

IV.C.3.1

Differential Scanning Calorimetry

DSC analysis was carried out using a DSC 7 (Perkin Elmer, Covina, CA) equipped with a
data station Thermal Analysis Controller 7/DX, Pyris Software for Windows, version 3.81. The
combination particles were transferred into aluminum pans. The pans were immediately sealed
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non-hermetically and the weight of the sample was recorded. The samples were then heated
under a flowing stream of nitrogen as the purge gas at a flow rate of 30-35mL/min. The
temperature program used was: a 10 minute hold at 25°C followed by heating to 150°C at
10°C/min, followed by heating to 250°C at 3°C/min. Figure IV.1 shows a representative
temperature program.

Figure IV.1 DSC temperature program

IV.C.3.2

Hot stage microscopy

Combination particles were observed under a hot stage microscope in order to visually
observe the thermal events taking place. The temperature program employed was similar to that
used for DSC i.e.; holding at 25°C for 10 minutes, heating from 25-150°C at 10°C/min followed
by heating from 150-250°C at 3°C/min.

IV.C.3.3

Optical Microscopy
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The particles were observed and photographed under a polarizing optical microscope
(Optiphot, Nikon, Tokyo, Japan) using different magnifications (50X, 100X, 400X, 600X).
Presence of birefringence was noted as an indicator of crystallinity. Uniform particle
morphology with absence of two distinct particle shapes was also taken as evidence supporting
the formation of combination particles.

IV.C.3.4

Powder X-Ray Diffraction

The particles were subjected to analysis by powder X-Ray diffraction (Panalytical XRPD,
Panalytical Inc, Westborough, MA) by scanning from 5°2θ - 35°2θ over a period of 2 hours at 45
KV and 40mA. The presence of sharp, characteristic diffraction peaks and no halo was taken as
an indicator of crystallinity. Moreover, shifts in peak positions, appearance of new peaks
unrelated to those of pure AS or pure IB, or disappearance of peaks was taken as an indication of
interactions between AS and IB as opposed to physical mixtures.

IV.C.3.5

Scanning Electron Microscopy

Particle morphology was observed using a scanning electron microscope (EVO 50 XVP
scanning electron microscope (SEM) equipped with digital image acquisition). The samples were
prepared for analysis by putting them on double-sided sticky tapes mounted onto aluminum stubs
and sputter coating them for 2 minutes using a EMS 550x sputter coater. Imaging was performed
at 15kV.

IV.C.3.6

Particle Size Determination by Laser Diffraction
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The particle size distribution of the combination particles was measured by laser
diffraction using the Mastersizer 2000 equipped with the Scirocco dry dispersion accessory
(Malvern, Westborough, MA). The air flow and feed rate were adjusted to control the powder
dispersion. The optimized particle size measurement conditions sufficient to achieve
deagglomeration of primary particles without attrition were an air pressure of 2 bar and a feed
rate of 50%. Obscuration limits between 2-6% and a measurement cycle time of 10 seconds were
employed. Triplicate measurements were made for each sample. Crystallization batch to batch
reproducibility was assessed using three replicate crystallization experiments in each case.

IV.C.3.7

High Performance Liquid Chromatography (HPLC)

Samples were assayed for %AS and % IB content by a validated HPLC method. The
method employed a Waters 2690 separations module, a 2996 PDA detector, a Restek Allure PFP
column (15×3.2mm), a mobile phase of 75% methanol and 25% ammonium formate buffer
(20mM, pH 3.4) at a flow rate of 0.75mL/min and an injection volume of 100 µL. Standard
solutions containing both AS and IB were prepared in water. Precision of the method was
estimated by assaying the standard with 0.1 µg/mL of AS and 0.1 µg/mL of IB 9 times and
calculating the % RSD for both AS and IB. The accuracy was determined by using the HPLC
method to analyze the standard containing 0.1 µg/mL of AS and 0.1 µg/mL of IB and then
calculated as a percentage of AS and IB recovered by the assay. LOD and LOQ were estimated
using the method described in section III.C.1.9. Table IV.3 shows the system suitability
parameters for this method. To measure the % AS and % IB content, accurately weighed
particles were dissolved in water to prepare a solution of adequate concentration. UV detection
was performed at 276nm for AS and at 210 nm for IB.
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Table IV.3 System suitability parameters for the HPLC method
System suitability
parameter
Linearity range
Precision
Accuracy
Limit of detection
Limit of quantitation

Value for AS

Value for IB

0.1-100 µg/mL
1.02%
99.6%
0.03 µg/mL
0.1 µg/mL

0.5-100 µg/mL
0.99%
99.8%
0.2 µg/mL
0.5 µg/mL

% AS content was measured as described in equation III.7. % IB content was calculated
according to equation IV.1.

IB mass determined by HPLC

×

% IB content =

100

Equation IV.1

Sample weight

IV.C.4

Molecular Modeling
Molecular modeling tools were used to study the interactions between AS and IB within a

combination particle matrix. The molecular modeling software Sybyl (version 8.0, Tripos, Inc.,
St. Louis, MO) that employs molecular mechanics or the force field method to calculate the
molecular geometry, energies and various other properties of the compound of interest was used
(Tripos force field manual, 2006; Kellogg et al., 2000). AS and ipratropium (IP) crystal
structures were downloaded from the Cambridge crystallographic database using the Conquest
interface. The two crystal structures were manually oriented relative to each other in a random
manner in the Sybyl 8.0 platform. Explicit solvation with water was carried out. Energy
minimization was carried out with 100000 iterations. The constraints employed were Gasteiger-
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Huckel charges, a dielectric constant of 1, and a gradient of 0.05. Post energy minimization
molecules were partitioned to calculate their Log P values which perform the basis of all further
calculations. Hydropathic Interaction (HINT) scores were then calculated between the two
molecules. In order to remove the possibility of bias associated with manual orientation of the
two molecules, another program called GOLD was used. GOLD is a program used to dock
ligands into proteins and works by identifying a cavity in the protein. In order to use this
program, a unit cell for AS was constructed in Sybyl 8.0. Using this unit cell a 2×2×2 cube was
made where 8 unit cells were stacked together. At a time, one albuterol molecule from each
corner of the cube was removed and one IB molecule was docked into this cavity using GOLD.
The GOLD program was set up to perform 10 GA runs. Each of these runs was then scored using
HINT and the positive and negative interactions were identified.

IV.D

RESULTS AND DISCUSSION

IV.D.1

Characterization of albuterol sulfate and ipratropium bromide monohydrate
reference standards
Figure IV.2 shows a reference thermogram for albuterol sulfate reference standard which

was the starting material for all crystallization experiments.

Figure IV.2 Representative DSC thermogram for reference standard albuterol sulfate
heated at 3°C/min
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A single thermal event was observed which was due to the melting of AS. This was
confirmed by hot stage microscopy. Melting is an endothermic process and is shown as the sharp
peak in the thermogram. The mean enthalpy of fusion for AS was 188.6 ± 2.6 J/g with a mean
melting point of 189.5 ± 0.5°C calculated from three replicate measurements employing the DSC
measurement process described in section IV.C.3.1. Figure III.5 showed the X-ray powder
diffraction pattern for reference albuterol sulfate. The characteristic peak positions were
tabulated in Table III.3. However, to compare the peak intensities with those of IB, the
characteristic AS peaks and their intensities are listed again in Table IV.4. The particle size
distribution of reference albuterol sulfate was shown in Figure III.6. The average VMD
measured from three replicate measurements was 9.8 ± 0.2 µm. Figure III.7 showed a
representative microscopic image of reference AS. The particles appeared to be plate-like in
shape.
Figure IV.3 shows a representative thermogram for ipratropium bromide reference
standard.

Figure IV.3 Representative DSC thermogram for reference standard ipratropium bromide

136

Two thermal events were observed. The first endothermic thermal event was due to the
loss of the single molecule of water of crystallization. This endothermic thermal event revealed
two peaks, one at 108°C and the second at 117°C. The loss of water is shown in the
thermogravimetric analysis profile (Figure IV.4). The mean heat of dehydration calculated as
integrating the two endothermic peaks together was 110.2 ± 3.5 J/g as calculated from three
replicate measurements. The second thermal event was also endothermic and was due to the
melting of IB. The mean melting point was 232.6 ± 0.7°C with a mean heat of fusion of 196.5 ±
2.9 J/g as calculated from three replicate measurements. These thermal events were confirmed by
hot stage microscopy and agreed with the reported melting point of 237°C for IB by Corrigan et
al. (2006).

Figure IV.4 Representative TGA thermogram for reference standard ipratropium bromide
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The representative X-ray diffraction pattern for IB reference standard is shown in Figure
IV.5 with the characteristic peak positions shown in Table IV.4. The diffraction pattern agreed
with that reported in literature by Corrigan et al, 2006 as shown in Figure IV.6. The peak
intensities for IB were smaller by orders of magnitude compared to those for AS indicating an
absence of long range order in the IB crystal lattice.

Figure IV.5 Representative powder X-ray diffractogram for reference standard
ipratropium bromide

Figure IV.6 Powder X-ray diffraction of ipratropium bromide monohydrate reported by
Corrigan et al. (2006) (Reproduced with permission from Elsevier)
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Table IV.4 Characteristic X-ray peaks for reference standard ipratropium bromide
Albuterol Sulfate
2θ
Peak intensity
10.45
2097
11.47
494
12.93
248
15.27
508
17.75
885
18.43
1177
19.35
228
20.39
576
21.21
1325
23.03
4058
24.43
694
25.67
280
26.39
642
28.63
652
29.51
434
30.85
448
32.69
388

Ipratropium Bromide
2θ
Peak intensity
13.93
65
15.15
62
17.33
101
20.29
113
22.35
60
22.75
71
24.67
61
27.93
70
31.59
71
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Size
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Figure IV.7 Particle size distribution for reference standard ipratropium bromide
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The particle size distribution of reference ipratropium bromide is shown in Figure IV.7.
The average VMD measured from three replicate measurements was 6.5 ± 0.4 µm. Figure IV.8
shows a representative microscopic image of reference IB. The particles appeared to be
elongated and rod-like in shape.

Figure IV.8 Representative SEM image for reference standard ipratropium bromide
IV.D.2

Effect of different
characteristics

processing

variables

on

combination

particle

Particles produced under different crystallization conditions were characterized using a
number of analytical tools. It was desirable for these particles to possess certain characteristics in
order for them to be suitable for inhalation. Of primary importance was the formation of
individual particles that contained both AS and IB in a fixed ratio and not as separately
precipitated physical mixtures. This was necessary in order to overcome the problem of
segregation of physical mixtures into their individual components during inhalation leading to a
loss of the fixed drug ratio. Another desirable characteristic was particle crystallinity since
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crystalline particles are considered to be more stable compared to their amorphous counterparts.
The final characteristic of interest was particle size since one of the aims of this project was to
produce particles directly in a size suitable for inhalation in order to overcome the detrimental
effects of micronization.

IV.D.2.1

Crystallization of combination particles produced using ethyl acetate as the
anti-solvent

IV.D.2.1.1

HPLC content uniformity analysis

The results for the HPLC analysis of the combination particles are presented in Table
IV.5. The measured proportion of AS and IB in the precipitated particles was similar to the
starting proportions in the aqueous drug solution i.e.; particles with AS:IB ratios of 1:1, 2.1:1,
6.2:1, and 10.7:1 (w/w) were produced from starting drug solutions with AS:IB ratios of 1:1, 2:1,
6:1, and 10:1 (w/w) respectively.

Table IV.5 Mean ± SD measured % AS and IB and their ratios in the combination particles
produced using ethyl acetate as the anti-solvent
Starting AS:IB ratio
(w/w)

Measured AS:IB ratio
(w/w)

% AS

% IB

1:1
2:1
6:1
10:1

1:1
2.1:1
6.2:1
10.7:1

48.7 ± 0.2
67.4 ± 0.8
86.2 ± 0.3
91.4 ± 0.7

51.3 ± 0.3
32.6 ± 0.2
13.8 ± 0.5
8.6 ± 0.9

These results indicated that both drugs precipitated out completely in this solvent / antisolvent system. This was expected since AS and IB have similar solubilities of 5.0 ± 0.2 and 2.6
± 0.2 µg/mL in ethyl acetate. These results are supported by the literature which states that the
composition of the co-precipitated particles is dictated by the relative solubilities of the two
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components with success more likely in a solvent in which the solubilities of the two
components are similar (Chiarella et al., 2007). The % AS and % IB in the combination particles
were reproducible as shown by the associated small standard deviation values thereby suggesting
the formation of combination particles with reproducible proportions of AS and IB.
HPLC revealed the bulk characteristics of the particles produced from ethyl acetate.
However, it is equally important to consider the particle properties at the molecular level. In this
study, DSC and powder X-ray diffraction have been used to investigate these properties. At this
point it is useful to define a number of terms that will be discussed. “Co-crystal” is a term used to
describe the binding of two or more components within one periodic line lattice without making
or breaking covalent bonds (Aakeroy and Salmon, 2005). A new crystal lattice is generated
which is different from either of the individual components. “Combination particle” is a term
used to describe the existence of two or more components in single particles. These components
may exist as a single phase with one of the components included in the crystal lattice of the other
or as separate phases. In combination particles a new crystal lattice is not generated as is the case
with co-crystals. “Physical mixture” is a term used to describe the existence of two or more
components in the form of a blend with each component present as a separate phase. Thermal
analysis and PXRD of the particles produced from ethyl acetate was carried out in order to
elucidate the nature of these particles.

IV.D.2.1.2

Thermal analysis

Table IV.6 shows the results from the thermal characterization of the particles prepared
using ethyl acetate as the anti-solvent. Representative thermograms for the different combination
particles are shown in Figures IV.9, IV.10, IV.11 and IV.12. For the 1:1, 2.1:1, and 6.2:1 (w/w)
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combination particles, two thermal events were observed. The first thermal event was
endothermic and was attributed to the loss of one mole of water of crystallization from IB. The
heats of dehydration are shown in Table IV.6. The numbers in parentheses indicated the
calculated heat of dehydration associated with the loss of one mole of water of crystallization
from IB when present in that particular proportion. No dehydration peak was observed for the
10.7:1 (w/w) particles due to the sensitivity limit of the DSC which was unable to detect the
water loss from the small proportion of IB as shown in Figure IV.12.

Table IV.6 Thermal characteristics of AS / IB combination particles prepared using ethyl
acetate as the anti-solvent
AS:IB
(w/w)
1:1
2.1:1
6.2:1
10.7:1

Measured heat of dehydration
(J/g) (Calculated)
51.3 ± 4.8 (54.9)
31.6 ± 3.3 (34.8)
14.5 ± 3.6 (14.8)
…..

Dehydration
temperature (°C)
114.4 ± 0.6
110.4 ± 0.3
107.5 ± 0.1
…..

Heat of
fusion (J/g)
60.3 ± 2.7
94.2 ± 3.3
153.4 ± 1.3
163.5 ± 2.4

Melting
point (°C)
177.9 ± 0.1
184.3 ± 0.1
183.1 ± 0.1
182.3 ± 0.1

Figure IV.9 Representative differential scanning thermogram for 1:1 (w/w) combination
particles produced using ethyl acetate as anti-solvent
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Figure IV.10 Representative differential scanning thermogram for 2:1 (w/w) combination
particles produced using ethyl acetate as anti-solvent

Figure IV.11 Representative differential scanning thermogram for 6:1 (w/w) combination
particles produced using ethyl acetate as anti-solvent
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Figure IV.12 Representative differential scanning thermogram for 10:1 (w/w) combination
particles produced using ethyl acetate as anti-solvent
The measured heats of dehydration for the different combination particles did not reveal
any statistical difference compared to the calculated heat of dehydration from the loss of one
mole of water of crystallization from IB in the particular ratios (p-values > 0.05, one-way
ANOVA). This suggested that the formed combination particles contained IB in a completely
hydrated form. Moreover, the presence of a dehydration endotherm attributable to the loss of
water of crystallization also pointed strongly towards IB being present in a crystalline form since
this water is incorporated into the crystal lattice. However, the dehydration endotherm had a
single peak as opposed to the double peak present in IB (Figure IV.3).
The second thermal event was attributed to the melting of the combination particles. This
was also confirmed by observing the particles under the hot stage microscope. A single melt was
observed for the combination particles. The 1:1, 2:1, 6:1 and 10:1 combination particles melted
at significantly lower temperatures of 177.9 ± 0.1°C, 184.3 ± 0.1°C, 183.1 ± 0.1°C, and 182.3 ±
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0.1°C respectively compared to AS (189.5 ± 0.5°C) and IB (232.6 ± 0.7°C) (p-values < 0.05,
one-way ANOVA) as shown in Table IV.6 and Figures IV.9, 10, 11, and 12. The melting points
for the 1:1 (w/w) combination particles were significantly lower (p-value < 0.05, Tukey’s HSD)
compared to the melting points for the 2:1, 6:1 and 10:1 (w/w) combination particles which were
statistically comparable (p-value > 0.05, Tukey’s HSD). These 1:1 (w/w) combination particles
also had the lowest heat of fusion at a mean value of 60.3 ± 2.7 /g. The heat of fusion increased
with the proportion of AS in the combination particles. A correlation analysis between the heat
of fusion and the AS:IB ratio revealed a significant positive correlation (R = 0.9045, p-value <
0.0001). However, these heats of fusion remained significantly lower than for pure AS (188.6 ±
2.6 J/g) and pure IB (196.5 ± 2.9 J/g).
Corrigan et al. (2006) had prepared combination particles of AS and IB by co-spray
drying. The thermal analysis of their particles is shown in Figure IV.13. The absence of a sharp
melting peak was indicative of the amorphous nature of these particles. In contrast, the
combination particles prepared using the experimental procedure described for ethyl acetate
resulted in thermograms showing sharp melting peaks as shown in Figures IV.9, IV.10, IV.11,
and IV.12 indicating that they were not amorphous.

Figure IV.13 DSC thermograms for a) AS:IB 10:1 co-spray dried, b) AS:IB 5:1 co-spray
dried, c) AS:IB 2:1 co-spray dried, and d) AS:IB 2:1 physical mixture (Corrigan et al.,
2006) (Reproduced with permission from Elsevier)
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In order to understand whether AS and IB were interacting in these particles or were
present as a physical mixture, the thermal characteristics of the precipitated particles were
compared to those of corresponding physical mixtures of AS and IB. The thermal analysis of the
physical mixtures was performed using the same temperature program employed for the
combination particles. The results for heat of fusion of the combination particles vs. physical
mixtures are shown in Table IV.7 which also shows the calculated heat of fusion for AS in the
absence of any interaction based upon the nominal AS ratio.

Table IV.7 Comparison of heats of fusion of combination particles with the corresponding
physical mixtures
AS:IB
(w/w)
1:1
2.1:1
6.2:1
10.7:1

Measured heat of fusion
for combination
particles
60.3 ± 2.7
94.2 ± 3.3
153.4 ± 1.3
163.5 ± 2.4

Measured heat of
fusion for physical
mixtures
108.4 ± 3.4
134.2 ± 2.2
166.0 ± 2.8
179.7 ± 3.6

Calculated heat of
fusion for AS (J/g)
95.0
126.7
162.9
172.7

A statistical comparison did not reveal any significant difference (p-value > 0.05, oneway ANOVA) between the measured heat of fusion for the physical mixtures and the calculated
heat of fusion for AS in the same proportion provided there is no interaction between AS and IB.
The 1:1, 2:1, 6:1, and 10:1 (w/w) physical mixtures showed heats of fusion of 108.4 ± 3.4 J/g,
134.2 ± 2.2 J/g, 166.0 ± 2.8 J/g, and 179.7 ± 3.6 J/g which were comparable to the calculated
heats of fusion of 95.0 J/g, 126.7 J/g, 162.9 J/g, and 172.7 J/g for AS when present in the
respective stoichiometric proportions. These results indicated that in the physical mixtures
prepared by blending of AS and IB, there was no interaction between the two drugs.
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However, the heat of fusion for the 1:1, 2:1, 6:1, and 10:1 (w/w) combination particles
were significantly lower (p-value < 0.05, one-way ANOVA) compared to the calculated heat of
fusion for AS in these proportions in the absence of any interactions. These results may indicate
interactions between AS and IB in the combination particles resulting in an alteration of their
heats of fusion. Table IV.8 shows the comparison of the melting points for the combination
particles with the corresponding physical mixtures. The melting point for reference standard AS
was 189.5 ± 0.5°C. The melting point for the 1:1 (w/w) physical mixture was 183.5 ± 0.2 °C
which was significantly lower than the melting point for pure AS (p-value < 0.05, one-way
ANOVA). For the 2:1, 6:1, and 10:1 (w/w) physical mixtures, there was no significant difference
in melting points compared to AS (p-value > 0.05, one-way ANOVA). However, the
combination particles in all stoichiometric ratios exhibited significantly lower melting points
compared to AS (p-value < 0.05, one-way ANOVA). These differences once again indicated
interactions between AS and IB when present in the combination particles which led to the
alteration of the melting point. Furthermore, these results were in contrast to the melting points
for the physical mixtures which were comparable to the AS melting point (except for the 1:1
(w/w) physical mixture) and indicated that there was no interaction between the two drugs when
blended together.
Table IV.8 Comparison of melting points of combination particles with the corresponding
physical mixtures
AS:IB
(w/w)
1:1
2.1:1
6.2:1
10.7:1

Combination
particles (°C)
177.9 ± 0.1
184.3 ± 0.1
183.1 ± 0.1
182.3 ± 0.1
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Physical
mixture (°C)
183.5 ± 0.2
185.9 ± 0.2
188.8 ± 0.1
188.8 ± 0.1

The dehydration temperatures of the combination particles and the corresponding
physical mixtures are shown in Table IV.9. All four physical mixtures revealed no significant
difference in the dehydration temperature relative to dehydration at 116.5 ± 2.8°C exhibited by
pure IB (p-value > 0.05, one-way ANOVA).

Table IV.9 Comparison of dehydration temperatures of combination particles with the
corresponding physical mixtures
AS:IB (w/w)
1:1
2.1:1
6.2:1
10.7:1

Combination
particles (°C)
114.4 ± 0.6
110.4 ± 0.3
107.5 ± 0.1
…..

Physical
mixtures (°C)
108.2 ± 0.3
115.2 ± 0.4
107.8 ± 0.2
113.7 ± 0.6
106.9 ± 0.4
111.7 ± 0.2
…..
…..

Furthermore, as shown in Figure IV.3, the loss of one mole of water of crystallization
from IB was in two phases with a small shoulder being observed at ≈ 108°C and a bigger peak at
116.5°C. This water loss was similar to that observed from the dehydration endotherms for the
physical mixtures as shown in Figures IV.14, IV.15, IV.16, and IV.17. In contrast, the
combination particles showed a dehydration endotherm that appeared as a single peak without
any shoulder as shown in Figures IV.14, 15, 16, and 17. Since this mole of water is incorporated
in the IB crystal lattice, any interaction of IB with AS would influence the nature of its release.
Therefore, these results showing differences in the behavior of water of crystallization between
co-precipitated particles and physical mixtures indicated a difference in the interaction between
AS and IB when present in a combination particle matrix relative to a simple physical mixture.
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Figure IV.14 DSC thermograms of 1:1 (w/w) combination particles and the corresponding
physical mixture

Figure IV.15 DSC thermograms of 2:1 (w/w) combination particles and the corresponding
physical mixture
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Figure IV.16 DSC thermograms of 6:1 (w/w) combination particles and the corresponding
physical mixture

Figure IV.17 DSC thermograms of 10:1 (w/w) combination particles and the corresponding
physical mixture
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These studies therefore revealed a difference in the thermal characteristics of the
combination particles relative to simple physical mixtures of AS and IB. It was of interest to see
whether these combination particles resulted in the formation of co-crystals at these AS:IB ratios.
Thermal characterization is a useful tool for this purpose. Stanton et al. (2008) have compared
the melting points of 10 co-crystals to the API and their respective co-crystal formers (coformer).
Each of the cocrystals displayed a melting point that fell between the melting point of the API
and the respective coformer. Schultheiss et al. (2009) compiled a large survey based on reported
cocrystal melting points, and these were compared with the melting points of the coformer and
API. Within the survey, 50 cocrystalline samples were analyzed; 26/50 (51%) cocrystals had
melting points between those of the API and coformer, while 19/50 (39%) were lower than either
the API or coformer, only 3/50 (6%) were higher, and 2/50 (4%) had the same melting point as
either the API or coformer. These statistics clearly show that the melting point of an API can be
altered through forming cocrystals, and the outcome will usually be a product having a melting
point that is in between that of the API and coformer or lower than the API or coformer. The
melting points of the different combination particles produced from ethyl acetate were
significantly lower than AS and IB which can be treated analogous to the API and coformer
respectively. These results therefore agree with the reported melting point behavior for 39% of
co-crystals reviewed by Schultheiss et al. (2009). However, in the absence of supporting crystal
structure data, it is difficult to conclude unambiguously whether co-crystals are being formed or
not. Within a homologous set of cocrystals (either the API or coformer is kept constant), where
single crystal X-ray structures have been determined, comparisons could potentially be drawn
between the intermolecular interactions and/or crystal packing existing within the lattice and the
thermal behavior of the sample.
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Therefore, analysis of the particles produced from ethyl acetate revealed some important
findings. First and foremost, it was possible to precipitate out both AS and IB completely owing
to their similar solubilities in ethyl acetate. This similarity made ethyl acetate an attractive antisolvent for both drugs. The combination AS/IB particles showed different thermal characteristics
from either AS, IB, or physical mixtures of the two. These results indicated that AS and IB did
not precipitate separately as a physical mixture and were present together in combination
particles which can be referred to as combination particles. This was a desirable phenomenon
since one of the aims of this project was to produce such combination particles of AS and IB that
would not segregate into individual components upon inhalation. Although, these results
revealed possible interactions between AS and IB in these combination particles, it was not
possible to conclude from the thermal analysis data whether co-crystals were being produced.
Therefore, these particles were characterized by powder X-ray diffraction to further elucidate the
nature of interaction between AS and IB.

IV.D.2.1.3

Powder X-ray diffraction

Powder X-ray diffraction is used to obtain information about crystal lattice changes
owing to it being a relatively simple technique which can be used with pharmaceutical powders.
The combination particles and the physical mixtures were analyzed by powder X-ray diffraction.
Figures IV.18, and IV.19, show the diffractograms for the 1:1 (w/w) combination particles and
the 1:1 (w/w) physical mixture. The diffractograms for the 2:1 and 6:1 (w/w) combination
particles are shown in Figures IV.20 and IV.21 respectively. The 10:1 (w/w) combination
particles were not characterized by powder X-ray diffraction since thermal analysis did not show
a significant difference between the 6:1 and the 10:1 (w/w) combination particles in terms of
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melting point and heat of fusion (p-value > 0.05, one-way ANOVA). The characteristic
diffraction peaks for the 6:1 (w/w) combination particles are shown in Table IV.10.
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Figure IV.18 Powder X-ray diffractogram for 1:1 (w/w) AS/IB combination particles
produced from ethyl acetate
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Figure IV.19 Powder X-ray diffractogram for 1:1 (w/w) AS/IB physical mixture
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Figure IV.20 Powder X-ray diffractogram for 2:1 (w/w) AS/IB combination particles
produced from ethyl acetate
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Figure IV.21 Powder X-ray diffractogram for 6:1 (w/w) AS/IB combination particles
produced from ethyl acetate
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Table IV.10 Characteristic diffraction peaks for the 6:1 (w/w) combination particles
prepared using ethyl acetate as anti-solvent
Characteristic reference peaks for AS and
AS:IB 6:1 (w/w)
IB
2 theta
Intensity
2 theta Intensity
10.45
2097
10.53
508
11.47
494
12.75a
147a
12.93
248
13.93
65
15.15
62
15.27
508
15.19
207
17.33
101
17.75
885
17.71
338
18.43
1177
18.43
602
19.35
228
19.17
152
20.29
113
20.39
576
20.37
261
21.21
1325
21.29
523
22.35
60
22.75
71
23.03
4058
23.03
954
24.43
694
24.45
353
24.67
61
25.67
280
26.39
642
26.33
260
27.93
70
28.63
652
28.63
260
29.51
434
29.55
253
30.85
448
30.83
221
31.59
71
32.69
388
32.59
145
a Significantly shifted compared to the AS peak based on a % deviation of ± ≥ 1%
calculated with reference to the AS peak
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The % deviation of the 2θ value from the AS peaks was calculated. A % deviation value
of ≥ 1.0% was taken as a criterion for a significant peak shift. As shown in Table IV.10, the 6:1
(w/w) combination particles revealed only a single peak which satisfied this criterion. The
diffractogram for the 1:1 (w/w) and 2:1 (w/w) combination particles revealed peaks that were
significantly lower in intensity compared to AS. These XRPD results therefore corroborated the
DSC results where these 1:1 and 2:1 (w/w) combination particles revealed significantly lower
heats of fusion compared to reference standard AS (Table IV.7). These results were therefore
indicative of lower crystallinity of these particles. This might attributed to the presence of a high
proportion of IB which does not have long range crystalline order. Further, a number of
characteristic AS peaks were absent. However, the particles were not completely amorphous
since the characteristic halo associated with amorphous particles was absent. Such a
characteristic halo has been reported by Corrigan et al. for the combination particles of AS and
IB prepared by co-spray drying an aqueous solution of the two drugs as shown in Figure IV.22
(Corrigan et al., 2006).

Figure IV.22 XRPD of AS:IB 10:1 co-spray dried (continuous line) and crystalline AS
(dashed line) (Corrigan et al., 2006) (Reproduced with permission from Elsevier)
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The diffractogram for the 6:1 (w/w) combination particles on the other hand, showed
significantly higher peak intensities for the characteristic AS peaks compared to the 1:1 and 2:1
(w/w) combination particles. These results supported the DSC results where the heat of fusion
increased as the proportion of AS in the combination particles increased indicating that the
crystal lattice started to resemble AS as the IB percentage decreased.
A plausible scenario explaining the nature of formation of these co-precipitated particles
may be the incorporation of IB in the interstitial spaces within the AS crystal lattice somewhat
akin to the formation of an interstitial crystalline solid solution as shown in Figure IV.23.

(AS)
(IB)

Figure IV.23 Representation of an interstitial crystalline solid solution (Adpated from
Ghaste et al., 2009)
For the 1:1 and 2:1 (w/w) combination particles, the inclusion of a high proportion of IB
may even have resulted in a breaking of the AS crystal lattice which would account for the
reduced crystallinity of these particles. For the 6:1 (w/w) combination particles, this inclusion
may stretch the unit cell of AS resulting in a decrease in crystal robustness which is then
reflected in a decreased melting point and a lower heat of fusion implying that a lower heat /
energy is required to melt the crystal compared to the more robust crystal of AS. This hypothesis
was also supported by the fact that as the % IB in the particles decreased, there was an increase
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in the heat of fusion. A lowered percentage of IB would lead to an increase in the purity of the
crystal lattice which may start to resemble the lattice of AS as the IB percentage goes down. The
increase in heat of fusion with an increase in the proportion of AS in the combination particles
may be indicative of an increasing crystallinity brought about by an increasing purity of the
crystal lattice which was also observed as an increase in the intensity of the X-ray peaks for the
6:1 (w/w) combination particles.

IV.D.2.1.4

Particle size distribution of combination particles produced from ethyl
acetate

One of the primary aims of this project was to produce combination particles with
suitable size characteristics for inhalation. Figure IV.24 shows the cumulative % undersize
distributions of the four combination particles produced using ethyl acetate with their volume

Cumulative % Volume less than stated size

median diameters (VMDs) shown in Table IV.11.
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Figure IV.24 Cumulative % undersize volume distribution of different combination
particles produced using ethyl acetate as the anti-solvent
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Table IV.11 Mean ± SD volume median diameters and cumulative % volumes < 5.0 µm of
combination particles produced using ethyl acetate as the anti-solvent
AS:IB (w/w)
1:1
2.1:1
6.2:1
10.7:1

VMD ± SD (µm)
19.5 ± 4.0
15.6 ± 5.0
15.3 ± 0.9
11.1 ± 1.1

Volume % < 5.0 µm
19.4 ± 2.4
20.7 ± 3.2
26.9 ± 1.8
27.5 ± 1.2

Statistical analysis of the VMD data revealed that the 10:1 combination particles were
significantly (p-value < 0.05, Tukey’s HSD) smaller with a VMD of 11.1 ± 1.1 µm compared to
the 1:1, 2:1, and 6:1 (w/w) combination particles. These particles had significantly higher and
comparable VMDs (p-value > 0.05, Tukey’s HSD) of 19.5 ± 4.0 µm, 15.6 ± 5.0 µm, and 15.3 ±
0.9 µm respectively. These results showed that the combination particles produced from ethyl
acetate were too large for inhalation with VMDs above 10 µm for all particles. Further, The
mean (SD) volumes % < 5.0 µm for 1:1, 2:1, 6:1, and 10:1 (w/w) combination particles were
19.4 (2.4), 20.7 (3.2), 26.9 (1.8), and 27.5 (1.2) % respectively which is not suitable for
inhalation. Therefore, ethyl acetate did not appear suitable for producing combination particles of
AS and IB suitable for inhalation.
Particle morphology showed these particles to be predominantly tabular and plate-like in
shape. Some elongated, rod-like particles were also observed. Figure IV.25 shows the
representative optical microscopic images for a) 1:1 (w/w) combination particles, b) 2:1 (w/w)
combination particles, c) 6:1 (w/w) combination particles, and d) 10:1 (w/w) combination
particles produced from ethyl acetate as the anti-solvent.
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Figure IV.25 Optical microscopic images for a) 1:1 (w/w) combination particles, b) 2:1
(w/w) combination particles, c) 6:1 (w/w) combination particles, d) 10:1 (w/w) combination
particles produced from ethyl acetate
In summary, ethyl acetate was a good anti-solvent for AS and IB leading to the coprecipitation of the two drugs and formation of combination particles. However, use of ethyl
acetate as the anti-solvent did not lead to the formation of particles in a size suitable for
inhalation and hence, further investigation and optimization of the crystallization process was
necessary.
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IV.D.2.2

Crystallization of combination particles produced using isopropyl alcohol as
the anti-solvent

IV.D.2.2.1

HPLC content uniformity analysis

The primary aim of the studies carried out using isopropyl alcohol (IPA) as the antisolvent was to produce 6:1 (w/w) combination particles of AS/IB in a size suitable for inhalation.
Table IV.2 showed the different crystallization conditions used to produce these combination
particles. The HPLC analysis results of the combination particles produced from isopropyl
alcohol under the different conditions are shown in Table IV.12. In the first crystallization
condition, the Ra ratio was 1:200 (w/w). The initial concentrations of AS and IB in the aqueous
drug solution were 0.28 and 0.05 g/g resulting in an initial AS:IB ratio of 6:1 (w/w). However,
the AS:IB ratio in the precipitated particles was measured as 97.1 :1 (w/w) suggesting negligible
precipitation for IB.
Table IV.12 AS IB ratios in the combination particles produced using isopropyl alcohol as
the anti-solvent
Ra ratio
(w/w)

AS conc.
(g/g)

IB conc.
(g/g)

1:200
1:20
1:20
1:20

0.28
0.48
0.48
0.48

0.05
0.28
0.28
0.08

Crystal
maturation
time
24 hours
24 hours
5 minutes
30 seconds

Starting
AS:IB ratio
(w/w)
6:1
1.7:1
1.7:1
6:1

Measured
AS:IB ratio
(w/w)
97.1:1
6.6:1
2.8:1
5.7:1

Therefore, IPA did not act as a good anti-solvent for IB and it was not possible to obtain
complete precipitation of IB under these crystallization conditions. These results may be
explained by the high solubility of IB in IPA (i.e.; 4.9 mg/mL). At a Ra ratio of 1:200 (w/w), the
final concentration of IB in IPA was 0.2 mg/mL which was below the solubility of IB in IPA.
Therefore, no crystallization of IB was achieved under these conditions.
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In order to get 6:1 (w/w) combination particles of AS and IB, the crystallization
conditions were altered. The Ra ratio was decreased to 1:20 (w/w) in order to reduce IB
dissolution. Further, the starting concentrations of both AS and IB were optimized in order to
arrive at a final combination particle ratio of 6:1 (w/w). The starting drug concentrations were
decided based on the solubility values of AS and IB in IPA which would yield a final AS:IB ratio
of 6:1 (w/w) after a crystal maturation time of 24 hours. Using these crystallization conditions,
combination particles with a nominal ratio of 6.6:1 (w/w) were obtained. Chemical analysis by
HPLC revealed that these particles contained a reproducible percentage of AS (86.9%) and IB
(13.1%) with corresponding % RSDs of 0.2 and 1.5 % respectively. However, in vitro aerosol
performance testing of these combination particles carried out by the methods described in
Chapter V revealed a variation in the AS:IB ratio as a function of particle size. Table IV.13
shows the AS:IB ratios (w/w) obtained from these particles on different stages of the next
generation impactor (NGI) during in vitro aerosol performance testing.
Table IV.13 AS:IB ratio (w/w) in the impactor for the combination particles produced from
IPA after 24 hours of crystallization
Stage
Device
MA
Throat
PS
S1
S2
S3
S4
S5
S6

AS:IB (w/w)
6.1:1
5.9:1
6.0:1
6.3:1
5.9:1
7.1:1
8.0:1
9.2:1
10.8:1
11.4:1

These results revealed the presence of distinct particle populations as a function of
particle size with larger (>5µm) particles depositing on the top stages of the next generation
impactor showing a nominal ratio of ≈ 6:1 (w/w) and the smaller (<5 µm) particles depositing on
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the lower stages of the impactor showing varying ratios from 8:1 – 11:1 (w/w). These results
were therefore contrary to the HPLC analysis and showed the formation of different particle
populations as a function of particle size. HPLC, being a bulk analysis technique did not reveal
this. Moreover, the issue of sampling also arises during HPLC analysis. Larger particles will
have a greater tendency to be sampled. As mentioned, in vitro aerosol performance analysis
showed these larger particles had a nominal 6:1 (w/w) AS:IB ratio which might account for the
discrepant HPLC results.
In an attempt to explain the discrepancy between the chemical analysis results obtained
by HPLC (showing the formation of combination particles with a nominal ratio of 6.6:1 (w/w)
and the aerosol results (showing variability in the AS:IB ratio as a function of particle size),
monitoring of the supernatant was carried out as a function of crystal maturation time. These
results are shown in Figure IV.26.
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Figure IV.26 Concentrations of AS and IB in the supernatant over a crystallization period
of 24 hours
It was observed that as soon as the aqueous drug solution was added to the anti-solvent,
precipitation occurred with the drug concentrations in the supernatant remaining relatively stable
for 15 minutes. However, between 15 – 30 minutes, a change occurred, wherein there was a
massive crash out of AS with its concentration in the supernatant reaching approximately its
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solubility limit in isopropyl alcohol. At the same time, there was re-dissolution of IB. This
additional AS precipitation and corresponding IB re-dissolution led to the final concentrations in
the supernatant reaching the solubility limits for the two components at the end of 24 hours
which resulted in a final ratio of 6.6:1 (w/w) in the combination particles.
It is known that dissolution is higher from smaller particles due to larger surface areas.
Therefore, it is expected that re-dissolution of IB from the precipitated particles would preferably
take place from the smaller particles which might account for the lower proportion of IB in these
particles as observed during in vitro analysis. These events occurring after the initial coprecipitation of the two drugs may have resulted in distinct particle populations being formed as
a function of particle size. When the crystallization process was terminated after 5 minutes, the
harvested particles were observed to contain AS and IB in a nominal 2.8:1 (w/w) ratio as shown
in Table IV.12. Moreover, in vitro aerosol performance analysis did not reveal any significant
variability in this ratio as a function of particle size (results presented in Chapter V).
These studies therefore demonstrated that the earlier non-homogeneity observed when the
crystallization process was allowed to continue for 24 hours was due to the ongoing AS
precipitation and IB dissolution processes occurring post the initial co-precipitation. Therefore,
in order to produce combination particles containing AS and IB in a fixed nominal ratio of 6:1
(w/w), the initial concentration of the two drugs in the aqueous drug solution was changed to
0.48:0.08 g/g as shown in Table IV.12. Monitoring of the supernatant revealed that coprecipitation of AS and IB in a 6:1 (w/w) ratio occurred during the initial 30 second duration.
Hence, crystallization was terminated 30 seconds after the infusion of drug solution into the antisolvent. The harvested particles revealed a nominal AS:IB ratio of 5.7:1 (w/w). Chemical
analysis by HPLC revealed that these particles contained a reproducible percentage of AS
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(85.0%) and IB (15.0%) with corresponding % RSDs of 0.2 and 1.1 % respectively. In vitro
analysis revealed uniform deposition in the impactor (results discussed in chapter V).
Therefore, in summary, solvent / anti-solvent crystallization using IPA as the anti-solvent
yielded combination particles with two stoichiometric ratios; 2.8:1 (w/w), and 5.7:1 (w/w). These
particles were further analyzed for their thermal and X-ray diffraction characteristics to
investigate their crystallinity. Particle size distribution studies were also carried out.

IV.D.2.2.2

Thermal analysis of combination particles produced from isopropyl alcohol

Table IV.14 shows the results for thermal characterization of the combination particles
produced from IPA. The numbers in parentheses indicate the calculated heat of dehydration for
IB based on the nominal amount of IB in the particular stoichiometric proportion and the
calculated heat of fusion for AS based on the nominal amount of AS in the particular proportion.

Table IV.14 Mean ± SD thermal characteristics of AS / IB combination particles prepared
using isopropyl alcohol as the anti-solvent
AS:IB
(w/w)

Measured heat
of dehydration
(J/g)
(Calculated)

Dehydration temperature
(°C)

2.8:1

25.2 ± 2.5 (26.1)

107.5 ± 0.5

113.6 ± 0.6

5.7:1

14.6 ± 1.5 (14.8)

102.3 ± 0.2

107.5 ± 0.6

Heat of fusion
(J/g)
(Calculated)
130.2 ± 2.8
(140.6)
188.4 ± 3.4
(162.9)

Melting
point (°C)
182.5 ± 0.6
176.2 ± 0.8

Figures IV.27 and IV.28 show the representative thermograms for the 2.8:1 and 5.7:1
(w/w) combination particles produced from isopropyl alcohol. The dehydration endotherm for
the 2.8:1 (w/w) particles revealed a shoulder at 108.0°C similar to IB. This was different to the
combination particles produced from ethyl acetate where the loss of water from IB was observed
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to occur in a single phase. The heat of dehydration agreed with the calculated heat of dehydration
for IB suggesting the presence of IB in a crystalline form in a manner similar to particles
produced from ethyl acetate.

Normalized Heat Flow (J/g)

6

5.5

5

4.5
25

75

125

175

225

Temperature (°C)

Figure IV.27 Representative DSC thermogram for 2.8:1 (w/w) combination particles
produced from isopropyl alcohol
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Figure IV.28 Representative DSC thermogram for 5.7:1 (w/w) combination particles
produced from isopropyl alcohol
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Further, the melting point, and heat of fusion of the 2.8:1 (w/w) combination particles
were significantly lower compared to AS, and IB and the calculated heat of fusion for AS (pvalue < 0.05, one-way ANOVA) suggesting interactions between the two APIs. The 5.7:1 (w/w)
combination particles produced from IPA also revealed thermal characteristics different from
AS, IB, and a 6:1 (w/w) physical mixture of AS and IB. The mean melting point for the 5.7:1
(w/w) combination particles produced from isopropyl alcohol was 176.2 ± 0.8°C which was
significantly lower than the melting point for AS (189.5 ± 0.5°C) and IB (232.6 ± 0.7°C). The
melting point was also significantly lower compared to a 6:1 (w/w) physical mixture of AS and
IB (188.8 ± 0.1°C). The mean heat of fusion was 188.4 ± 3.4 J/g which was significantly higher
than the calculated heat of fusion for AS in this proportion (162.9 J/g) and also significantly
higher than the heat of fusion for the 6:1 (w/w) physical mixture (166.0 ± 2.8 J/g). These results
were in contrast to the results for the 6:1 (w/w) combination particles produced from ethyl
acetate that showed significantly lower heats of fusion compared to the expected heat of fusion
for AS and physical mixtures. Therefore, the 5.7:1 (w/w) combination particles may have a
different orientation of IB in the AS crystal lattice leading to a more robust crystal structure.
However, it is difficult to come to a conclusion based on these results.

IV.D.2.2.3

Powder X-ray diffraction

To further understand the nature of interactions between AS and IB in the combination
particles produced from IPA, powder X-ray diffraction studies were carried out. Figure IV.29
and IV.30 show the representative powder X-ray diffractograms for the 2.8:1 and 5.7:1 (w/w)
combination particles respectively. The characteristic peak positions are shown in Table IV.15.
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Figure IV.29 Powder X-ray diffractogram for 2.8:1 (w/w) combination particles
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Figure IV.30 Powder X-ray diffractogram for 5.7:1 (w/w) combination particles
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Table IV.15 Characteristic diffraction peaks for 2.8:1 (w/w) and 5.7:1 (w/w) combination
particles produced from isopropyl alcohol
Characteristic reference peaks
AS:IB 2.8:1
AS:IB 5.7:1
for AS and IB
2 theta
Intensity
2 theta
Intensity
2 theta
Intensity
10.45
2097
10.65a
604a
10.71a
1283a
11.47
494
11.47
310
11.69
391
12.93
248
12.87
252
12.95
339
13.93
65
14.09b
206b
a
a
a
15.07
577
15.47
559a
15.15
62
15.27
508
17.33
101
17.15b
1040b
17.75
885
435a
17.95a
813a
17.91a
18.43
1177
18.55
1301
18.61
2105
19.35
228
842a
20.59a
793a
20.17a
20.29
113
20.39
576
21.21
1325
21.43a
876a
21.47a
1791a
b
b
22.17
657
22.35
60
22.75
71
23.03
4058
23.17
1216
2746a
23.25a
24.43
694
24.51
1172
24.65
1096
24.67
61
25.67
280
26.39
642
26.47
652
26.55
750
b
b
27.69
864
27.93
70
28.63
652
28.73
726
28.79
896
29.51
434
29.75
689
29.75
856
30.85
448
30.79
613
31.01
668
31.57b
653b
31.59
71
32.69
388
32.67
356
32.89
436
a Significantly shifted compared to the AS peak based on a % deviation of ± ≥ 1% calculated
with reference to the AS peak
b New peak not attributed to either AS or IB based on peak shift and peak intensity
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The diffractogram for the 2.8:1 (w/w) combination particles showed sharp diffraction
peaks indicating the crystalline nature of these particles. These peaks were also significantly
higher in intensity than the peaks for the 2:1 (w/w) combination particles produced from ethyl
acetate. The diffractogram also revealed changes in peak positions compared to AS and IB. As
shown in Table IV.15, the characteristic AS peak at 2θ 10.45° was absent and a new peak at
10.65° was observed. The characteristic AS peak at 15.27° was absent and a new peak at 15.07°
was observed, the characteristic AS peak at 17.75° was absent and a new peak at 17.91° was
observed, and the characteristic AS peak at 21.21° was absent with a new peak appearing at
21.43° Further, new peaks that could not be attributed to AS or IB were seen at 17.15°, 22.17°,
27.69° and 31.57°. Moreover, some of the characteristic AS peaks such as 18.55°, 24.51°,
28.73°, 29.75°, and 30.79° that did not shift significantly based on the ≥ 1.0% standard deviation
criterion showed higher peak intensities compared to reference AS peaks.
Peak changes were also observed in the diffractogram for the 5.7:1 (w/w) particles. As
shown in Table IV.15, the characteristic AS peaks at 10.45°, 18.43°, 21.21°, and 23.03° were
absent and new peaks were observed at 10.71°, 18.61°, 21.47°, 23.25°, and 24.65°. These
characteristic AS peaks were different in position compared to the 6:1 (w/w) particles produced
from ethyl acetate that revealed characteristic AS peaks close to reference AS (10.53°, 18.43°,
21.29°, and 23.03°). The peak intensities for the 5.7:1 (w/w) particles produced from IPA were
also significantly higher compared to the peak intensities for the 6:1 (w/w) particles produced
from EA. These results therefore supported the DSC results where the 5.7:1 (w/w) particles
produced from IPA had significantly higher heat of fusion of 188.4 ± 3.4 J/g compared to 153.4
± 1.3 J/g heat of fusion for the 6:1 (w/w) combination particles produced from EA. Therefore, it
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appeared from these results that the combination particles produced from IPA were more
crystalline compared to the corresponding particles produced from EA.
If these changes in peak positions for the 2.8:1 and 5.7:1 (w/w) combination particles
produced from IPA are viewed as peak shifts then they may indicate a change in the crystal
lattice of AS by the possible incorporation of IB. These changes can arise due to a variety of
reasons. One of the main reasons is differences in sample preparation. However, given that the
powdered sample is properly prepared i.e.; gently ground to avoid preferred orientation, remove
any hard agglomerates, and be able to make a "monolayer" on the sample holder, any shifts
should be considered as a result of a potentially new crystalline phase.
There are cases, however, where the changes could appear even though the same material
exists. E.g. it could be due to systematic shifting (where all peaks are moved to the same
direction), in result of a different sample prep or the instrument settings. In these studies, the
changes in peak positions due to sample preparation or different instrument settings can be ruled
out since all characterizations were performed on identically prepared samples under similar
instrument settings. Moreover, replicate analysis did not change the peak positions indicating
that the peaks were not a result of slight variations in sample preparation. Also isotropic shifting
i.e.; shifting of all peaks in one direction was not observed. These anisotropic shifts can also
originate from the unit cell expansion or shrinking due to different temperature during the
measurement. However, shrinking or expansion of the unit cell due to a different temperature can
also be ruled out since all runs were performed under controlled temperature conditions.
Shrinking and expansion of a unit cell could be also due to the size of included guest molecule.
Therefore, analysis of the combination particles by powder X-ray diffraction revealed
differences from AS and IB indicating interactions between the two APIs. These results also
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supported the results from the thermal analysis. Moreover, the powder X-ray diffraction results
with sharp peaks and the absence of a halo were indicative of the crystalline nature of these
particles. Particle crystallinity was a desirable property for inhalation particles since crystalline
particles are considered to be more stable compared to their amorphous counterparts. However,
even with a combination of thermal and powder X-ray diffraction data, it was still not possible to
come to an unequivocal conclusion about the formation of co-crystals. As, mentioned before, the
thermal data revealed melting points lower than the two components which has been the case
with 39% of the reported co-crystals in literature. However, although the PXRDs revealed peak
changes, the diffractograms were not significantly different from those of AS and IB. The cocrystals reported in literature and analyzed by a number of analytical techniques such as DSC,
PXRD, raman spectroscopy, near infrared and transmission spectroscopy have powder X-ray
diffractograms with not only peak shifts but characteristic new peaks that are not present in
either of the pure components. Elbagerma et al. (2010) have produced and characterized a
number of different co-crystals by a variety of analytical techniques. Figure IV.31 shows a
PXRD for salicylic acid, nicotinic acid and a 1:1 co-crystal of the two.

Figure IV.31 Powder X-ray diffraction spectra for a) Salicylic acid, b) Nicotinic acid, and c)
1:1 co-crystal of salicylic acid and nicotinic acid (Elbagerma et al., 2010) (Reproduced with
permission from ACS)
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Therefore, with the diffraction spectra for the particles with different proportions of AS
and IB exhibiting only minor peak shifts relative to AS and IB, it was not possible to conclude
the formation of a co-crystal. Co-crystallization is a thermodynamically unfavorable process and
is strongly dictated by the functional groups present on the two components. Co-crystals are
defined as structurally homogeneous crystalline materials that contain two or more neutral
building blocks that are present in definite stoichiometric amounts (Aakeroy and Salmon, 2005).
The two components interact by the formation of non-covalent bonds. Hydrogen bonding is the
most common type of non-covalent bonding reported in literature for the formation of co-crystals
(Vishweshwar et al., 2005; Almarsson et al., 2004; Shan et al., 2008; Rodriguez-Spong et al.,
2004). Co-crystallization is viewed as a thermodynamically unfavorable process. The energy
laws dictate the formation of separate crystals of two components because this process leads to a
reduction of the total energy of the system and is hence favorable. On the other hand, two
different molecules coming together is an energy unfavorable process and hence is difficult to
conceive. Therefore, for co-crystallization to occur, the components should possess favorable
functional groups capable of undergoing non-covalent interactions with each other. Etter and coworkers have proposed the following generalizations that support the formation of co-crystals
between two or more components (Blagden et al., 2008):
1.

All good proton donors and acceptors are used in hydrogen bonding.

2. Six-membered ring intramolecular hydrogen bonds form in preference to intermolecular
hydrogen bonds.
3. The best proton donor and acceptor remaining after intramolecular hydrogen-bond formation
will form intermolecular hydrogen bonds to one another (but not all acceptors will necessarily
interact with donors).
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In order to facilitate the formation of co-crystals between two components, a third
component known as “co-crystal former” is generally added to the system. Co-crystal formers
are small molecules that link the two co-crystal components by favorable non-covalent bonding
between both co-crystal components and help in bringing the two disparate molecules together.
In the absence of such co-crystal formers, spontaneous co-crystallization of two different
compounds is difficult.
The chemical structure of AS and IB is shown in Figure IV.32. The two drugs have
functional groups that might support the formation of a co-crystal. For example, the oxygen atom
on the sulfate group of AS has a tendency to form a hydrogen bond with the hydrogen attached
to the nitrogen atom of IB. Also, the carboxylic oxygen atom of IB has a tendency to form a
hydrogen bond with the hydrogen attached to the tertiary nitrogen of AS. However, in the
absence of any co-crystal formers, the spontaneous formation of a co-crystal between AS and IB
is difficult.

Ipratropium Bromide

Br -

Hydrogen Bond
SO4--

Albuterol Sulfate

Figure IV.32 Chemical structures of albuterol sulfate and ipratropium bromide showing a
possible site for H-bonding
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IV.D.2.2.4

Particle size distribution of the combination particles produced from
isopropyl alcohol

Table IV.16 shows the VMDs and volume % < 5.0 µm for the 2.8:1 and 5.7:1 (w/w)
combination particles produced from isopropyl alcohol. The cumulative % undersize volume
distributions and the volume frequency distributions for the 2.8:1 and 5.7:1 (w/w) particles are
shown in Figures IV.33, IV.34, IV.35, and IV.36.
Table IV.16 Mean ± SD volume median diameters and cumulative % volume < 5.0 µm for
the combination particles produced from isopropyl alcohol
AS:IB ratio (w/w)
2.8:1
5.7:1

VMD ± SD (µm)
5.3 ± 1.0
6.5 ± 0.3

Volume % < 5.0 µm
48.4 ± 1.2
46.7 ± 0.8

Cumulative % Volume less than stated size

120
100
80
60
40
20
0
0

1

10

100

1000

Geometric Diameter (microns)

Figure IV.33 Cumulative % volume undersize distribution of 2.8:1 (w/w) combination
particles produced from the anti-solvent isopropyl alcohol
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Figure IV.34 Volume frequency distribution of 2.8:1 (w/w) combination particles produced
from the anti-solvent isopropyl alcohol

Figure IV.35 Cumulative % volume undersize distribution of 5.7:1 (w/w) combination
particles produced from the anti-solvent isopropyl alcohol

177

Figure IV.36 Volume frequency distribution of 5.7:1 (w/w) combination particles produced
from the anti-solvent isopropyl alcohol
The 2.8:1 and 5.7:1 (w/w) combination particles produced from IPA were similar in their
particle size distributions. Analysis of the VMD data did not reveal any significant differences
(p-value > 0.05, one-way ANOVA). The particle size distributions appeared to be relatively
unimodal. Particle morphology revealed these particles to be small in size and agglomerated
together with a uniform morphology without two distinct particle populations as shown in Figure
IV.37 and IV.38 for the 2.8:1 and 5.7:1 (w/w) combination particles respectively.

Figure IV.37 SEM image of combination particles containing AS and IB in a nominal ratio
of 2.8:1 (w/w) produced using isopropyl alcohol as the anti-solvent
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Figure IV.38 SEM image of combination particles containing AS and IB in a nominal ratio
of 5.7:1 (w/w) produced using isopropyl alcohol as the anti-solvent
Compared to the combination particles produced from ethyl acetate, the particles
produced from IPA therefore appeared to be more uniform. The VMDs and the cumulative %
volume < 5.0 µm for 2.8:1 and 5.7:1 (w/w) combination particles suggested the suitability of
these particles for inhalation. However, these particle size distributions were obtained with the
Malvern Mastersizer which is calibrated for spherical particles. Therefore, the particle size data
obtained from the Malvern should not be used as a criterion for judging the suitability of these
irregular shaped particles for inhalation. The aerosol performance of the particles is determined
by their aerodynamic diameter which can only be assessed by in vitro studies using impactors.
Therefore, conclusions about the aerosol performance of the particles cannot be drawn from the
particle size distribution data obtained from the Malvern. However, despite its limitations, the
Malvern can still be used as an initial screen to make some judgments about the relative size of
the particles produced under different crystallization conditions.
Therefore, in summary, use of isopropyl alcohol as the anti-solvent led to a significant
reduction in particle size compared to combination particles produced from ethyl acetate.
Further, by optimizing the crystallization conditions, it was possible to use IPA to produce
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combination particles in two different stoichiometric ratios of 2.8:1 and 5.7:1 (w/w). The thermal
and X-ray diffraction properties of these particles revealed differences from AS and IB.
However, it was not possible to make conclusions about the formation of co-crystals. The PSD
of these combination particles revealed them to be small in size. However, conclusions about
their aerosol performance could not be drawn. These particles were therefore tested for their in
vitro aerosol performance and the results will be discussed in Chapter V.

IV.D.2.3

Crystallization of combination particles produced using mixtures of
isopropyl alcohol and ethyl acetate as the anti-solvent

It has been discussed that using ethyl acetate as the anti-solvent did not yield particles in
a size small enough for inhalation. In an attempt to reduce the particle size IPA was tried as the
anti-solvent. However, due to the solubility differences between AS and IB in IPA, the
crystallization conditions such as the Ra ratio, crystal maturation time and the initial AS and IB
concentration had to be varied and optimized in order to produce combination particles in a size
small enough for inhalation. Therefore, using IPA as the anti-solvent, it was not possible to
predict the final AS:IB ratio in the combination particles from the initial ratio.
The size reduction properties of IPA can also be utilized by combining it with ethyl
acetate and using the mixture as the anti-solvent. Addition of ethyl acetate will lead to a
reduction in the IB solubility and therefore, complete precipitation of both drugs can be
achieved. This will make it possible to predict the final AS:IB ratio from the initial ratio. Further,
it is easier to produce combination particles from an anti-solvent in which both drugs have
similar solubilities (Chiarella et al., 2007). Therefore, IPA in combination with ethyl acetate was
investigated as the anti-solvent.
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IV.D.2.3.1

Content uniformity analysis by HPLC

Table IV.17 shows the results for the HPLC analysis of the combination particles
produced from mixtures of IPA and ethyl acetate in different proportions of 1:1, 1:2, 1:5, and
1:10 (w/w). The expected percentages of AS and IB in the combination particles were calculated
based on the starting ratio of AS and IB assuming complete precipitation of both drugs which
would result in the final AS:IB ratio being same as the starting AS:IB ratio. The values in
parentheses indicate the % deviation from the expected percentage of AS and IB respectively. A
% deviation of < 5% was taken as an acceptable criterion for the formation of combination
particles of AS and IB in the expected ratio.
Table IV.17 HPLC analysis results for combination particles produced from mixtures of
isopropyl alcohol and ethyl acetate in different proportions
Starting AS:IB
(w/w)
1:1
2:1
6:1
10:1
Starting AS:IB
(w/w)
1:1
2:1
6:1
10:1
Starting AS:IB
(w/w)
1:1
2:1
6:1
10:1
Starting AS:IB
(w/w)
1:1
2:1
6:1
10:1

IPA:EA 1:1 (w/w)
Measured
% AS (% deviation
AS:IB (w/w)
from expected)
No precipitation
…..
28.9:1
96.7 (48.3)
69.5:1
98.6 (32.4)
89.1:1
98.8 (13.3)
IPA:EA 1:2 (w/w)
Measured
% AS (% deviation
AS:IB (w/w)
from expected)
6.8:1
87.2 (42.7)
13.1:1
92.9 (28.2)
36.8:1
97.1 (12.0)
57.4:1
98.3 (7.5)
IPA:EA 1:5 (w/w)
Measured
% AS (% deviation
AS:IB (w/w)
from expected)
1.2:1
54.5 (8.3)
3.3:1
76.7 (13.0)
7.8:1
88.6 (3.3)
15.4:1
93.9 (3.2)
IPA:EA 1:10 (w/w)
Measured
% AS (% deviation
AS:IB (w/w)
from expected)
1.1:1
52.4 (4.6)
2.1:1
67.7 (1.5)
5.6:1
84.8 (-1.1)
11.8:1
92.2 (1.4)
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%IB (% deviation
from expected)
…..
3.3 (-909.1)
1.4 (-921.4)
1.1 (-727.3)
%IB (% deviation
from expected)
12.8 (-290.6)
7.1 (-369.0)
2.6 (-450.0)
1.7 (-435.3)
%IB (% deviation
from expected)
45.5 (-9.8)
23.3 (-42.9)
11.4 (-25.4)
6.1 (-49.2)
%IB (% deviation
from expected)
47.6 (-5.0)
32.3 (-3.1)
15.2 (5.9)
7.8 (-16.7)

These results showed that in anti-solvents containing a high proportion of IPA (IPA:EA
1:1, 1:2 (w/w)), IB did not precipitate out to a significant extent resulting in large % deviations
from the expected percentage. For example, for the 1:1 (w/w) combination particles, the AS:IB
ratio in the particles precipitated from isopropyl alcohol:ethyl acetate = 1:2 (w/w) was 6.8:1
(w/w) even though the starting drug solution contained the two APIs in a 1:1 (w/w) ratio.
Increasing the proportion of ethyl acetate resulted in an increase in IB precipitation for the
combination particles. The solvent / anti-solvent composed of isopropyl alcohol:ethyl acetate =
1:10 (w/w) was found to be suitable for the production of AS/IB combination particles with
acceptable ratios. In these particles, the AS and IB percentages were not found to show large
deviations from the expected and hence the final AS:IB ratio in the combination particles could
be predicted reasonably well from the initial AS:IB ratio in the drug solution.
The influence of temperature difference between the solvent and anti-solvent on particle
characteristics was also investigated for the anti-solvent composed of isopropyl alcohol:ethyl
acetate = 1:10 (w/w). The HPLC analysis results are shown in Table IV.18.

Table IV.18 HPLC analysis results for combination particles produced from isopropyl
alcohol:ethyl acetate = 1:10 (w/w) at a temperature difference of 65°C between the solvent
and anti-solvent
Starting AS:IB
ratio (w/w)
1:1
2:1
6:1
10:1

Measured AS:IB
ratio (w/w)
1:1
1.9:1
6.6:1
8.6:1

% AS (% deviation
from expected)
50.0 (0.0)
65.5 (-1.8)
86.8 (1.3)
89.6 (-1.5)
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% IB (% deviation
from expected)
50.0 (0.0)
34.5 (3.5)
13.2 (8.3)
10.4 (12.5)

These results demonstrated that a temperature difference of 65°C between the solvent and
anti-solvent did not lead to any significant differences in AS and IB precipitation compared to
the studies performed at a temperature difference of 0°C. The percentages of AS and IB in the
combination particles were within the ± 5% acceptable deviation from expected (except for IB in
10:1 (w/w) combination particles) and therefore the final ratio in the combination particles could
be predicted reasonably well from the initial ratio in the drug solution.

IV.D.2.3.2

Thermal analysis of combination particles produced from isopropyl
alcohol:ethyl acetate = 1:10 (w/w)

Table IV.19 shows the thermal characteristics for the combination particles produced
from isopropyl alcohol:ethyl acetate = 1:10 (w/w). The representative thermograms are shown in
Figures IV.39, IV.40, IV.41, and IV.42 for the 1:1, 2:1, 6:1, and 10:1 (w/w) combination
particles.

Table IV.19 Mean ± SD thermal characteristics for the combination particles produced
from isopropyl alcohol : ethyl acetate = 1:10 (w/w)
Measured
AS:IB Ratio
(w/w)
1.1:1
2.1:1
5.6:1
11.8:1

Measured heat
of dehydration
(calculated)
52.8 ± 3.2 (54.9)
31.1 ± 2.8 (34.8)
15.8 ± 1.9 (14.8)
…..

Dehydration
temperature
(°C)
113.8 ± 0.2
111.2 ± 0.1
108.9 ± 0.1

Melting point
(°C)

Heat of fusion
(J/g)

172.5 ± 2.1
185.2 ± 2.3
182.9 ± 0.5
184.2 ± 0.4

37.7 ± 6.9
44.0 ± 10.5
145.2 ± 10.4
161.9 ± 8.3

There was no difference in the dehydration endotherms compared with the results for the
combination particles produced from ethyl acetate described in section IV.D.2.1.2 for similar
drug ratios. The heats of fusion for the 1:1 and 2:1 (w/w) combination particles produced from
isopropyl alcohol:ethyl acetate = 1:10 (w/w) were significantly lower compared to the
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corresponding values for the particles produced from ethyl acetate (p-value < 0.05, one-way
ANOVA) described in section IV.D.2.1.2 indicating lower crystallinity for these particles.
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Figure IV.39 Representative differential scanning thermogram for 1:1 (w/w) combination
particles produced from isopropyl alcohol : ethyl acetate = 1:10 (w/w)
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Figure IV.40 Representative differential scanning thermogram for 2:1 (w/w) combination
particles produced from isopropyl alcohol : ethyl acetate = 1:10 (w/w)
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Figure IV.41 Representative differential scanning thermogram for 6:1 (w/w) combination
particles produced from isopropyl alcohol : ethyl acetate = 1:10 (w/w)
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Figure IV.42 Representative differential scanning thermogram for 10:1 (w/w) combination
particles produced from isopropyl alcohol : ethyl acetate = 1:10 (w/w)

However, for the 6:1 and 10:1 (w/w) combination particles, there was no difference in the
heats of fusion compared to the combination particles with similar drug ratios produced from
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ethyl acetate. In a manner similar to the particles produced from ethyl acetate, the thermal
properties of the combination particles produced from isopropyl alcohol:ethyl acetate = 1:10
(w/w) were significantly different from AS, IB, and their physical mixtures indicating
interactions between AS and IB. However, it was not possible to conclude the formation of cocrystals. The PXRD of the 6.6:1 (w/w) combination particles is shown in Figure IV.43. The peak
intensities were comparable to the 6:1 (w/w) combination particles produced from EA thereby
supporting the DSC results showing similar heats of fusion.
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Figure IV.43 Powder X-ray diffractogram for 6.6:1 (w/w) combination particles produced
from IPA:EA 1:10 (w/w)
Table IV.20 shows the results for the thermal analysis of the combination particles
produced at a temperature difference of 65°C between the solvent and anti-solvent. These results
were similar to the results for the combination particles produced at a temperature difference of
0°C.
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Table IV.20 Mean ± SD thermal characteristics of AS / IB combination particles prepared
using isopropyl alcohol:ethyl acetate = 1:10 (w/w) as the anti-solvent at a temperature
difference of 65°C between the solvent and anti-solvent
Measured
AS:IB
ratio
(w/w)
1.1:1
1.9:1
6.6:1
8.6:1

IV.D.2.3.3

Heat of dehydration
(J/g)

Dehydration
temperature
(°C)

Melting point
(°C)

Heat of
fusion (J/g)

50.2 ± 3.7
33.6 ± 1.5
13.8 ± 2.6
…..

113.7 ± 0.5
110.2 ± 0.2
108.3 ± 0.1
…..

173.8 ± 1.8
184.2 ± 0.9
183.6 ± 0.2
184.2 ± 0.3

39.8 ± 4.5
46.8 ± 6.8
145.6 ± 8.3
164.3 ± 4.2

Particle size distribution of combination particles produced from isopropyl
alcohol:ethyl acetate = 1:10 (w/w)

Figures IV.44, IV.45, IV.46, and IV.47 show the cumulative % undersize volume
distributions of 1:1, 2:1, 6:1, and 10:1 (w/w) combination particles produced from isopropyl
alcohol:ethyl acetate = 1:10 (w/w), isopropyl alcohol:ethyl acetate = 1:10 at a temperature
difference of 65°C, and ethyl acetate. The volume median diameters are shown in Table IV.21
and the cumulative % volumes < 5.0 µm in Table IV.22.
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Figure IV.44 Cumulative % volume undersize distribution for 1:1 (w/w) combination
particles produced from different anti-solvents
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Figure IV.45 Cumulative % volume undersize distribution for 2:1 (w/w) combination
particles produced from different anti-solvents
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Figure IV.46 Cumulative % volume undersize distribution for 6:1 (w/w) combination
particles produced from different anti-solvents
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Figure IV.47 Cumulative % volume undersize distribution for 10:1 (w/w) combination
particles produced from different anti-solvents
Table IV.21 Mean ± SD volume median diameters (µm) of combination particles produced
from different anti-solvents
Nominal AS:IB ratio
(w/w)
1:1
2:1
6:1
10:1

IPA:EA 1:10
(w/w)
16.7 ± 3.0
14.0 ± 1.4
9.5 ± 1.1
11.3 ± 0.7

Ethyl acetate
19.5 ± 4.0
15.6 ± 4.0
15.3 ± 0.9
11.1 ± 1.1

IPA:EA 1:10 ∆ T 65°C
11.2 ± 0.7
11.7 ± 1.0
6.9 ± 1.1
7.1 ± 0.8

Table IV.22 Mean ± SD cumulative % volumes < 5.0 µm for combination particles
produced from different anti-solvents
Nominal AS:IB ratio
(w/w)
1:1
2:1
6:1
10:1

IPA:EA 1:10
(w/w)
23.3 ± 2.5
25.9 ± 1.7
30.1 ± 1.2
28.2 ± 1.9

Ethyl acetate
19.4 ± 1.7
20.7 ± 2.6
21.2 ± 2.3
27.5 ± 1.6
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IPA:EA 1:10 ∆ T 65°C
28.5 ± 1.5
28.7 ± 2.2
42.8 ± 2.3
39.8 ± 2.7

Compared to ethyl acetate, no significant reduction in particle size was observed for the
1:1, 2:1, and 10:1 (w/w) combination particles produced from isopropyl alcohol:ethyl acetate
1:10 (w/w) (p-value > 0.05, one-way ANOVA). However, However, significantly smaller 6:1
(w/w) combination particles with mean ± SD VMD of 9.5 ± 1.1 µm were produced from
isopropyl alcohol : ethyl acetate 1:10 (w/w) compared to the larger 6:1 (w/w) combination
particles with a mean ± SD VMD of 15.3 ± 0.9 µm produced from ethyl acetate (p-value >
0.05, Tukey’s HSD). These differences were also observed in the cumulative % volumes < 5.0
µm. It was also seen that a temperature difference between the drug solution and anti-solvent did
lead to a significant reduction in particle size for all combination particles (p-value < 0.05, oneway ANOVA) compared to the particles produced at a temperature difference = 0°C and the
particles produced from ethyl acetate. For example, the mean VMD ± SD for the 6:1 (w/w)
combination particles decreased significantly to 6.9 ± 1.1 µm when produced from isopropyl
alcohol:ethyl acetate 1:10 (w/w) at a temperature difference of 65°C compared to the particles
produced from ethyl acetate and isopropyl alcohol:ethyl acetate 1:10 (w/w) at a temperature
difference of 0°C. These 6:1 (w/w) particles were of particular interest since this is the ratio in
the commercial formulation of AS and IB (i.e.; Combivent® pMDI). The PSD results indicated
that these particles were in a size suitable for inhalation. However, since aerodynamic
characteristics are a correct measure of inhalation performance, therefore, the 6.6:1 (w/w)
particles produced from isopropyl alcohol:ethyl acetate 1:10 (w/w) were tested for their in vitro
aerosol performance efficiency as discussed in Chapter V.

IV.D.3

A summary of the combination particles produced from different solvent /
anti-solvent systems
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One of the primary aims of this project was to use solvent / anti-solvent crystallization as
a particle engineering technique to produce combination particles of AS and IB in defined
stoichiometric ratios in a size suitable for inhalation. The stoichiometric ratio of primary interest
was AS:IB :: 6:1 (w/w) since this was the ratio employed in the commercial combination
formulation i.e.; the Combivent® pMDI which is a physical mixture of individually micronized
AS and IB. However, since the two drugs are present as a physical mixture, they tend to behave
individually during inhalation and hence show differences in their aerosol performance. This
leads to the loss of the fixed drug ratio of 6:1 (w/w) which is desired from these combination
products. Hence, formulating the two APIs in single combination particles wherein each particle
contains a fixed 6:1 (w/w) ratio of AS:IB is expected to overcome these problems. Furthermore,
if these combination particles can be produced directly in a size suitable for inhalation, the
disadvantages of micronization can also be overcome.
This chapter therefore looked at investigation and optimization of solvent / anti-solvent
crystallization to produce combination particles for inhalation. Furthermore, by preparing these
particles in different stoichiometric ratios, the interactions between AS and IB and the possibility
of formation of co-crystals was also investigated. The first solvent / anti-solvent system of water
/ ethyl acetate revealed the co-precipitation of AS and IB which resulted in the formation of
combination particles in stoichiometric ratios of 1:1, 2:1, 6:1, and 10:1 (w/w). However, these
combination particles were too large for inhalation as revealed by the PSD results which were
used as an initial screen to estimate the suitability of the particles for inhalation based on their
physical size.
Therefore, in an attempt to reduce the size of these particles, isopropyl alcohol was
investigated as the anti-solvent. Due to the solubility differences between AS and IB in isopropyl
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alcohol, the crystallization process required further optimization. Using the optimized conditions,
it was possible to produce combination particles with AS:IB ratios of 2.8:1 (w/w) and 5.7:1
(w/w) in a size suitable for inhalation as demonstrated by the PSD results. However, due to the
inappropriateness of the Malvern to provide a true measure of the aerosol performance of these
particles, in vitro aerosol performance was tested using cascade impactor studies. These results
will be discussed in Chapter V. Thermal and PXRD analysis revealed that the combination
particles produced from IPA were more crystalline compared to the particles produced from EA.
Although isopropyl alcohol resulted in 6:1 AS:IB particles, it was desirable to use an
anti-solvent with similar solubilities of AS and IB in order to simplify the process and aid the
prediction of the final AS:IB ratio from the initial ratio in the drug solution. Therefore, mixtures
of isopropyl alcohol and ethyl acetate were investigated as alternate anti-solvents. Due to
solubility differences between AS and IB in isopropyl alcohol, only isopropyl alcohol:ethyl
acetate 1:10 (w/w) could be used as an effective anti-solvent for complete precipitation of IB.
The 6:1 (w/w) combination particles produced from these anti-solvents revealed a significantly
smaller size compared to ethyl acetate produced particles, however, they were still not small
enough for inhalation. Further optimization of the process looked at reduction in the anti-solvent
temperature wherein isopropyl alcohol : ethyl acetate :: 1:10 (w/w) was used as the anti-solvent.
These experiments resulted in the formation of 6.6:1 (w/w) combination particles in a size range
small enough for inhalation as revealed by the PSD. Therefore, it was of interest to test the
aerosol performance of these combination particles and compare it with the aerosol performance
of the 2.8:1 and 5.7: 1 (w/w) combination particles produced from isopropyl alcohol. The in vitro
aerosol performance studies and the results obtained will be discussed in Chapter V.
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IV.D.4

Molecular modeling of the combination particles
Molecular modeling tools were used in order to study the possible interactions between

AS and IB within a combination particle matrix. These molecular modeling methods function on
the principle of molecular mechanics, often referred to as the Force Field method. Molecular
mechanics is the application of classical mechanics to molecules. Classical mechanics is used to
describe the motion of macroscopic objects. In molecular mechanics, atoms are treated as
spheres whose mass depends on the element. Chemical bonds are treated as springs whose
stiffness depends on which elements are bound together and whether the bond is single, double
or triple. Other types of springs are used to model changes in bond angles, dihedral angles, etc.
Each of these springs will have spring constants associated with them. Experimental and
theoretical methods are used to determine these parameters. Additional equations from classical
physics, such as Coulomb’s law are used to handle any electrostatic interactions present within a
molecule. The sum of all energy terms that apply to a particular molecule are added together to
give the potential energy of the molecule. All the equations and associated parameters used to
calculate each energy term are collectively called the force field.
In real molecules, there are other forces present than those between bonded atoms. There
may be charges present that can repel or attract. Repulsions between non-bonded atoms that are
close together in space might also occur. These forces may act to change bond angles or cause
twisting around single bonds. To describe the energy of the system, all of the different types of
applicable interactions need to be accounted for. The sum of the energy of all of these various
components is the basis of a force field. A force field allows for calculation of all the forces on
the system which in turn gives the energy of the system. There is an intimate connection between
structure and energy and hence, molecular mechanics calculations always involve both. In order
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to find the structure or predict geometry, it is necessary to examine the energy to find where
energy minima and hence the stable geometries exist.
Figures IV.48 and IV.49 show the crystal structures for AS and IB downloaded from the
Cambridge crystallographic database. The interactions between the two molecules could be
studied in vacuum. However, since in practice all interactions occur in the presence of solvent,
solvation using water was carried out. This solvation process where the two manually oriented
molecules were surrounded by water molecules in a water box is shown in Figure IV.50. Post
solvation, energy minimization was carried out. As described before, energy minimization is an
important part of molecular mechanics calculations.

Figure IV.48 AS Crystal

Figure IV.49 IB Crystal
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Figure IV.50 Water box for solvation of AS and IB molecules
Energy is a function of the atomic coordinates and the program attempts to generate the
coordinates which correspond to a minimum energy during the minimization procedure. This is
an iterative process where the atomic coordinates are modified from one iteration to the next in
order to decrease the energy. During the process, force field constraints are used to force
particular atoms or groups into spatial relationships. These constraints are defined and stored
within the molecule. However, it should be understood that these energy minimizations are very
rarely able to find the global energy minimum. Only a local minimum, the one closest to the
starting set of coordinates is reached.
Once the energy minimization process was over, molecular partitioning was carried out
using the eslc platform in HINT. This partitioning performs the basis for all HINT score
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calculations. HINT uses the experimental data from solvent partitioning experiments between
water and 1-octanol (LogPo/w) for interaction classification and quantitative scoring. HINT was
created to specifically include all non-covalent interactions. Hydrophobic and polar interactions,
which are collectively referred to as hydropathy, between molecules in biologically important
systems are empirically quantified. In this scheme, hydropathic attractions between species
include hydrogen-bonding, acid–base interactions, Coulombic attractions as well as hydrophobic
interactions. All of these are related to solvent partitioning phenomena because the dissolution of
a ligand in a mixed solvent system (such as water/1-octanol) involves the same fundamental
processes and atom–atom interactions as biomolecular interactions within or between proteins
and ligands. HINT scores each atom-atom interaction, within or between the molecules with the
following equation (Kellogg et al., 2000):

bij = aiSi ajSj TijRij + rij

Equation IV.2

where bij is the interaction score between atoms i and j, a is the hydrophobic atom constant, S is
the solvent accessible area, Tij is a logic function which returns a value of 1 or -1 depending on
the character of the interacting polar atoms (a<0 for polar atoms), there are three possibilities:
acid-acid, base-base and acid-base of which only the acid-base interactions are scored
positively/favorably. Rij is the exponential e-r (r is the distance between the atoms i and j) and rij
is an implementation of the Lennard-Jones potential function. The total HINT interaction score is
given by the sum of the individual interaction scores (ΣΣbij). The HINT convention is that
favourable interactions are scored with bij > 0 and unfavourable interactions are scored with bij
< 0. The logic function Tij returns a value of 1 or –1 depending on the character of the
interacting polar atoms (i.e. a < 0): there are three possibilities: acid–acid, acid–base, or base–
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base; only acid–base is scored favourably. Tij also flags hydrogen bonds which are in the HINT
model a special case of acid–base interactions.
Out of the 25 manual orientations between AS and IB, 3 orientations gave positive HINT
scores. The favorable orientation of AS and IB with the highest positive HINT score is shown in
Figure IV.51. The positive interactions were mainly between hydrophobic carbon atoms and
hydrogen bond formation while majority of the negative interactions were contributed by those
between hydrophobic carbon atoms and polar atoms such as nitrogen and oxygen. The breakup
of the different interactions that contribute to this highest total positive HINT score is shown in
Table IV.23. These results imply that in a combination particle matrix, AS and IB will preferably
arrange in a way such that the hydrophobic carbon atoms of one molecule are oriented away
from the polar atoms such as the nitrogen and oxygen on the other molecule. For e.g., the tertiary
nitrogen of AS will try and orient away from carbon atoms of IB.
As mentioned before, manual orientation lends itself to the possibility of bias. Moreover,
an interaction study involving a single molecule of AS and IB is not realistic since in the
combination particle matrix, the likelihood is that the IB molecules will orient themselves in the
interstitial spaces in the AS crystal lattice. In this situation, each IB molecule will be surrounded
by a number of AS molecules. In order to simulate this situation, a unit cell of AS was
constructed using the AS crystal structure. 8 of these unit cells were then used to build a 2×2×2
cube. This is shown in Figure IV.52.
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Figure IV.51 Manual orientation between AS and IB with the highest HINT score

Table IV.23 Favorable and unfavorable interactions between AS and IB
Contribution to
HINT score
405.92
219.44
458.13
-6.46
-616.89
-303.44

Interaction type
Hydrogen Bond
Acid/Base
Hydrophobic
Acid/Acid
Hydrophobic/Polar
Base/Base
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Figure IV.52 Albuterol Sulfate cube constructed of unit cells
At a time, one molecule of albuterol was removed from each corner of the cube and IB
was docked into this cavity using GOLD program as shown in Fig. IV.53. This resulted in a total
of 8 dockings. These dockings resulted in one IB molecule being in close proximity to 9
albuterol molecules, a situation simulating a combination particle with a nominal 6:1 (w/w) ratio
of albuterol sulfate to ipratropium bromide. GOLD is a program for calculating the docking
modes of small molecules in protein binding sites. However, in this case, the large cube
consisting of the AS unit cells was used as the protein with IB functioning as the ligand. 10
genetic algorithm (GA) runs were performed for each docking run. Post docking, each of the GA
run was cored with HINT. This scoring process once again involved molecular partitioning and
Log P calculation.
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Figure IV.53 A representative docking of IB in the AS crystal lattice
The total HINT scores obtained for each of the dockings were negative except for one run
which will be discussed shortly. At first glance, these negative total HINT scores implied an
overall unfavorable interaction between AS and IB. However, upon looking into the breakup of
the total HINT scores (Appendix), it was observed that there were positive components as well
that were contributed mainly by hydrogen bonding and hydrophobic interactions. However, since
the IB molecule was surrounded by tightly packed AS molecules, the close proximity led to
unfavorable acid-acid and base-base interactions which resulted in a total negative HINT score.
These studies however showed that there were a number of positive interactive sites present on
both molecules. The one docking that resulted in a positive total HINT score is shown in Figure
IV.54.
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Figure IV.54 IB orientation with the highest HINT score
This HINT score was 248.2 and incorporated favorable hydrophobic interactions and
favorable hydrogen bonding interactions. Figure IV.54 shows IB in a net. The bar designates the
lipophilic potential. Higher the lipophilic potential, more hydrophobic is the particular site. It can
be observed that IB has oriented itself in a way that its hydrophobic bonding sites
(predominantly the benzene ring) are close to the hydrophobic binding sites of albuterol sulfate
while the polar sites are close to the polar AS sites such as the one resulting the formation of a Hbond between the IB hydrogen atom and the oxygen atom of the (SO4)2- group of AS. These
studies therefore show us some of the plausible interactions between AS and IB in a combination
particle matrix.
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IV.E

CONCLUSIONS
Combination particles containing AS and IB in reproducible stoichiometric proportions

were produced by the optimized solvent / anti-solvent crystallization process using ethyl acetate
as the anti-solvent. However, the process required further optimization in order to bring the size
of these combination particles in a range suitable for inhalation. Combination particles
containing AS and IB in a stoichiometric 6:1 (w/w) ratio were produced from two different
solvent / anti-solvent systems of isopropyl alcohol and isopropyl alcohol:ethyl acetate 1:10
(w/w). These particles had VMDs ≈ 6.5 µm and revealed ≈ 45% of the particle mass < 5 µm.
Hence, they were deemed suitable for inhalation. Characterization of the combination particles
indicated a difference in characteristics between these particles and physical mixtures. However,
it was not possible to conclude unequivocally about the formation of co-crystals. The plausible
scenario explaining the different results was the formation of an interstitial crystalline solid
solution with IB molecules incorporated within the interstitial spaces of the AS crystal lattice.
These studies therefore led to the development of a single step particle engineering
technique to produce combination particles of AS and IB. These particles were crystalline and in
a size suitable for inhalation thereby presenting two major advantages. They did not have to be
micronized which therefore offered a solution over the well known disadvantages of particle
charging, cohesiveness and generation of partially amorphous domains associated with
micronization. These particles, by virtue of containing AS and IB in single combination particles,
were also expected to show uniform co-deposition during in vitro testing which will be discussed
in the next chapter.

202

CHAPTER V
IN VITRO AEROSOL PERFORMANCE TESTING OF ALBUTEROL SULFATE
PARTICLES AND COMBINATION PARTICLES OF ALBUTEROL SULFATE AND
IPRATROPIUM BROMIDE MONOHYDRATE

V.A

INTRODUCTION
In this chapter the in vitro aerosol performance testing of the engineered albuterol sulfate

particles and combination particles of albuterol sulfate and ipratropium bromide monohydrate
will be discussed. Since one of the primary specific aims of this project is to develop a particle
engineering technique capable of directly producing albuterol sulfate particles and combination
particles of AS and IB suitable for inhalation, it is hypothesized that the engineered particles will
have equivalent or superior aerosol performance compared to the commercial products which are
comprised of either micronized drug (as in the case of albuterol sulfate commercial formulations)
or a physical mixture of two individually micronized drugs (as in the case of combination
products of albuterol sulfate and ipratropium bromide monohydrate).

V.B

MATERIALS

Albuterol sulfate ((RS)-1- (4-hydroxy-3-hydroxymethylphenyl)-2-(tert-butylamino) ethanol
sulfate): Spectrum Chemical Mfg. Corp., New Brunswick, NJ)
Ipratropium bromide monohydrate ([8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3yl] 3-hydroxy-2-phenyl-propanoate): Spectrum Chemical Mfg. Corp., New Brunswick, NJ)
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Micronized albuterol sulfate: In-house Lot Number 970118
Lactose monohydrate (Pharmatose® 90M): DMV Fonterra Excipients, Princeton, NJ
Novolizer® Dry Powder Inhaler: Meda Pharmaceuticals, Somerset, NJ
Rotahaler® Dry Powder Inhaler: Allen and Hanburys
Nektar PDS® Dry Powder Inhaler: Nektar Pharmaceuticals, San Carlos, CA
Next Generation Impactor: MSP Corporation, Shoreview, MN
Vacuum Pump: Copley Scientific, MSP Corporation, Shoreview, MN
Flow Controller: Copley Scientific, MSP Corporation, Shoreview, MN

V.C

METHODS

V.C.1

Aerosol performance testing of albuterol sulfate particles
AS particle production from the solvent / anti-solvent crystallization process was

discussed in chapter III. Section III.D.2.2.2 described the production of AS particles from two
optimized solvent / anti-solvent systems of water / ethyl acetate and water / isopropyl alcohol.
These optimized processes resulted in AS particles with 100% crystallinity and smallest size
among the crystallization conditions investigated. These particles will henceforth be designated
as EA-AS and IPA-AS respectively. Table V.1 shows the crystallization conditions used to
produce these particles. The average volume median diameters of these particles as measured by
laser diffraction described in section III.C.1.8 are also shown. The EA-AS and IPA-AS particles
were tested for their in vitro aerosol performance as drug only formulations and as drug / lactose
blends. These studies are described in the subsequent sections.
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Table V.1 Description of optimized crystallization conditions used to produce albuterol
sulfate particles

Particles

Initial AS
concentration
(g/g)

EA-AS

0.22

IPA-AS

0.22

Antisolvent
Ethyl
Acetate
Isopropyl
Alcohol

Ra ratio
(w/w)

∆T between
drug solution
and antisolvent (°C)

Crystal
maturation
time (hours)

Average
VMD ±
SD (µm)

1:200

65

24

8.8 ± 0.6

1:200

0

24

4.9 ± 0.3

MIC-AS

V.C.1.1

3.9 ± 0.3

Drug only studies

The prototype dry powder inhalers used for these studies were the Novolizer®,
Rotahaler® and the Nektar PDS®. The nominal dose of albuterol sulfate in each of these studies
was 200 µg which was weighed and filled into either the Novolizer® cartridge, the Rotahaler®
capsule or the Nektar PDS® blister. The aerosol performance was tested by firing a single dose
into the NGI operating at 60L/min for 4 seconds. This flow rate was achieved by means of a
vacuum pump connected to a flow controller. It is recognized that 60L/min is not the optimum
flow rate that achieves a pressure drop of 4KPa for all three devices. For the Novolizer®, Nektar
PDS®, and Rotahaler®, the optimum flow rates are 72L/min, 28.3L/min, and 90L/min.
However, in order to compare the powder performance across devices, a single flow rate of
60L/min was chosen. Impactor stages were coated with silicone to prevent particle bounce and a
glass fiber filter (Type A/E, Gilman, Ann Arbor, MI) was employed in the NGI internal filter
holder. The device, mouth-piece adapter, throat, pre-separator and the NGI stages were washed
with water and the samples were tested by the previously described HPLC method (Section
III.C.1.9). The aerosol performance of the engineered albuterol sulfate particles was compared to
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that of micronized albuterol sulfate (designated henceforth as MIC-AS). The characteristics for
the MIC-AS particles were discussed in section III.D.2.3. The in vitro aerosol performance
testing of MIC-AS particles was carried out in the same way as those for the IPA-AS and EA-AS
particles.
The in vitro aerosol performance was characterized by a number of parameters. These
included the emitted fraction, fine particle fraction, mass median aerodynamic diameter
(MMAD), and geometric standard deviation (GSD). These parameters were calculated using the
following equations:

Emitted Fraction =

Mass of drug emitted from the inhaler

% Fine Particle Fraction =

Nominal drug dose

Mass of drug < 5µm in size
Emitted drug dose

Geometric Standard Deviation = (X/Y)0.5

× 100

× 100

Equation V.1

Equation V.2

Equation V.3

In Equation V.3, X and Y are the sizes associated with a cumulative count of 84% and
16%, respectively based on the mass percentages calculated relative to the impactor dose. The
MMAD was directly calculated as the size associated with a cumulative count of 50% based on
the mass percentages calculated relative to the impactor dose.

V.C.1.2

Drug / lactose blend studies
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Because of the limitations associated with metering a 200 µg dose, a more practical
approach was to blend albuterol sulfate particles with lactose monohydrate as a carrier. These
studies were only performed for IPA-AS particles since these particles showed a significantly
improved aerosol performance compared to the EA-AS particles in the drug only studies as will
be discussed in section V.D.1.1. For these studies, the Novolizer® was used as the test DPI.
Lactose monohydrate (Grade: Pharmatose® 90M) was chosen as the carrier. The VMD of this
lactose was measured as 67.5 ± 0.2 µm and the volume % of particles < 10 µm was 9.7 ± 0.4%.
The drug / lactose blend studies employed a nominal dose of 120 µg and a nominal metered mass
of 11.5 mg. The drug : lactose ratio was 1:95 (w/w) which was the same as that employed in the
commercial Novolizer® dry powder formulation for albuterol sulfate. A homogeneous blend of
the AS particles in lactose monohydrate (Pharmatose® 90M) was produced by geometric
addition and manual mixing using a mortar and pestle. The blend homogeneity was tested by
accurately sampling a mass of powder equivalent to the nominal dose of 11.5 mg. The sample
was dissolved in an appropriate volume of water and the amount of AS was determined using the
previously described HPLC method (Section III.C.1.9). A % RSD of less than 5.0% calculated
from the analysis of 10 samples was taken as an indication of acceptable blend homogeneity. The
in vitro aerosol performance of the drug / lactose blend was measured using the method
described in section V.C.1.1 and compared to the commercial Novolizer® dry powder
formulation for albuterol sulfate. In vitro aerosol performance parameters as mentioned in
section V.C.1.1 were similarly calculated.

V.C.2

Aerosol performance testing of combination particles
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Combination particle formation from the solvent / anti-solvent crystallization process was
discussed in chapter IV. Sections IV.D.2.3 and IV.D.2.2 described the production of combination
particles with a nominal 6:1 (w/w) ratio of AS:IB from two different optimized solvent / antisolvent crystallization processes. These particles will henceforth be referred to as Combination 1
and Combination 2. In addition to the 6:1 (w/w) combination particles, a further set of particles
with a nominal AS:IB ratio of 2.8:1 (w/w) were also produced as described in section IV.D.2.2.
These particles will henceforth be referred to as Combination 3. Table V.2 shows the
crystallization parameters used to produce these particles. In addition, the average VMDs of
these particles measured by laser diffraction as described in section IV.C.3.6 are also shown. The
PSDs of these particles were shown in Section IV.D.2.3 for Combination 1 and IV.D.2.2 for
Combination 2 and 3. The in vitro aerosol performance testing of these particles was carried out
as drug only formulations and drug/lactose blends as described in the subsequent sections.

Table V.2 Description of crystallization conditions used to produce combination particles of
AS/IB

Particles
Combination
1
Combination
2
Combination
3

Anti-solvent

Ra ratio
(w/w)

∆T between
the drug
solution and
anti-solvent

0.28:0.04

1:10 IPA:EA
(w/w)

1:200

65

24 hours

6.6:1

6.9 ± 1.1

0.38:0.06

IPA

1:20

0

30 seconds

5.7:1

6.5 ± 0.3

0.38:0.22

IPA

1:20

0

5 minutes

2.8:1

5.3 ± 1.0

Initial AS:IB
concentration
(g/g)

Average
Crystallization Final AS:IB
VMD ± SD
time
ratio (w/w)
(µm)

V.C.2.1

In vitro aerosol performance testing of combination particles

V.C.2.1.1

Drug only studies
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Combination 1, 2, and 3 were tested for their in vitro aerosol performance as drug only
formulations using the Novolizer® as the test inhaler. The nominal powder mass of 5.0 mg was
weighed and filled into the Novolizer® cartridge. The aerosol performance was tested by firing a
single dose of 5.0 mg into the NGI operating at 60L/min for 4 seconds. This flow rate was
achieved by means of a vacuum pump connected to a flow controller. Impactor stages were
coated with silicone to prevent particle bounce and a glass fiber filter (Type A/E, Gilman, Ann
Arbor, MI) was employed in the NGI internal filter holder. The device, mouth-piece adapter,
throat, pre-separator and the NGI stages were washed with water and the samples were tested by
the previously described HPLC method (Section IV.C.2.2). In vitro aerosol performance
parameters were calculated as mentioned in section V.C.1.1. The aerosol performance of the
engineered combination particles was compared to that of the commercial formulation
(Combivent® pMDI) which is a physical mixture of individually milled AS and IB in a nominal
6:1 (w/w) ratio suspended in CFC propellant.

V.C.2.1.2

Drug / lactose blend studies

Combination particles 1, 2, and 3 were tested as drug / lactose blends. For these studies,
the Novolizer® was used as the test DPI. Lactose monohydrate (Grade: Pharmatose® 90M) was
chosen as the carrier. The drug / lactose blend studies employed a nominal dose of 120 µg for the
combination particles and a nominal blend mass of 11.5 mg. The combination particle:lactose
ratio was 1:95 (w/w). A homogeneous blend of the combination particles in lactose monohydrate
(Pharmatose® 90M) was produced by geometric addition and manual mixing using a mortar and
pestle. The blend homogeneity was tested by accurately sampling a mass of powder equivalent to
the blend mass during aerosolization. The sample was dissolved in an appropriate volume of
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water and the amount of AS and IB were determined using the previously described HPLC
method (Section IV.C.2.2). A % RSD of less than 5.0% for both AS and IB calculated from the
analysis of 10 samples was taken as an indication of acceptable blend homogeneity. The nominal
blend mass of 11.5 mg was loaded into the Novolizer® cartridge. The in vitro aerosol
performance of the drug / lactose blend was measured by firing a single dose of 11.5 mg into the
NGI operating at 60L/min for 4 seconds. This flow rate was achieved by means of a vacuum
pump connected to a flow controller. Impactor stages were coated with silicone to prevent
particle bounce and a glass fiber filter (Type A/E, Gilman, Ann Arbor, MI) was employed in the
NGI internal filter holder. The device, mouth-piece adapter, throat, pre-separator and the NGI
stages were washed with water and the samples were tested by the previously described HPLC
method (Section IV.C.2.2). In vitro aerosol performance parameters were calculated as
mentioned in section V.C.1.1.

V.D

RESULTS AND DISCUSSIONS

V.D.1

Aerosol performance testing of albuterol sulfate particles

V.D.1.1

Drug only studies

The particles shown in Table V.1 were selected for in vitro aerosol performance
characterization. These particles were produced from the optimized solvent / anti-solvent
crystallization process using isopropyl alcohol and ethyl acetate as anti-solvents and had the
smallest size (VMDs shown in Table V.1). Since one of the primary aims of this project was to
produce AS particles with suitable inhalation characteristics from a single-step solvent / antisolvent crystallization process, the in vitro aerosol performance of these particles was compared
with conventionally used micronized albuterol sulfate (MIC-AS). The results for drug only
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studies for the three different types of AS particles are shown in Table V.3. The performance of
the different types of AS particles will be discussed under emitted fraction dealing with device
emptying and powder flow, fine particle fraction dealing with device deagglomeration principles
and powder dispersivity, and fine particle dose indicating the overall performance of the
particles.

Table V.3 Mean ± SD in vitro aerosol performance characteristics of AS particles tested
from different DPIs as drug only formulations (n=3)
Novolizer®

MIC-AS
EA-AS
IPA-AS

% Emitted
Fraction
40.8 ± 0.7
61.0 ± 9.9
68.8 ± 1.8

MIC-AS
EA-AS
IPA-AS

21.9 ± 0.7
66.5 ± 5.6
61.4 ± 1.2

MIC-AS
EA-AS
IPA-AS

36.4 ± 0.2
33.6 ± 4.8
53.2 ± 0.4

AS Particles

Fine Particle Dose (µg)
51.4 ± 0.1
28.3 ± 4.8
70.2 ± 6.4
Rotahaler®
24.6 ± 0.3
9.6 ± 4.7
21.8 ± 0.2
Exubera®
56.6 ± 0.6
29.6 ± 7.8
39.8 ± 4.3

59.4 ± 0.1
23.6 ± 7.1
46.6 ± 1.3

MMAD
(μm)
2.7 ± 0.0
3.2 ± 0.4
2.8 ± 0.1

2.0 ± 0.0
2.2 ± 0.2
2.2 ± 0.0

53.3 ± 0.7
5.6 ± 1.0
16.1 ± 0.1

2.6 ± 0.0
5.7 ± 0.6
3.3 ± 0.0

2.6 ± 0.0
2.1 ± 0.2
2.9 ± 0.0

68.5 ± 0.4
38.7 ± 1.4
34.8 ± 2.1

3.3 ± 0.0
3.7 ± 0.0
3.3 ± 0.1

1.9 ± 0.0
2.5 ± 0.0
2.3 ± 0.0

% FPF

GSD

The emitted fraction of a dry powder formulation is used to estimate the amount of drug
coming out from the device since it is only this amount that is available for deposition. This
emitted fraction is dependent on both powder and device characteristics. The emitted fractions
for the AS particles will therefore be discussed based on these two parameters. Table V.3 shows
that MIC-AS resulted in emitted fractions < 40% when aerosolized from all three devices. MICAS when aerosolized in the Rotahaler® produced a significantly smaller emitted fraction of 21.9
± 0.7% compared to both the Novolizer® and the Nektar PDS® (p-value < 0.05, Tukey’s HSD).
The emitted fraction for MIC-AS was comparable between Novolizer® and Nektar PDS® (p211

value > 0.05, Tukey’s HSD). When tested using the Novolizer® and the Rotahaler®, EA-AS
drug only formulation produced similar (p-value > 0.05, one-way ANOVA) emitted fractions of
61.0 ± 9.9 and 66.5 ± 5.6% respectively. IPA-AS particles also showed similar (p-value > 0.05,
one-way ANOVA) emitted fractions of 68.8 ± 1.8 and 61.4 ± 1.2% when tested from the
Novolizer® and the Rotahaler® respectively. This performance was significantly improved
compared to the % emitted fraction observed for the MIC-AS. However, aerosolization using the
Nektar PDS® resulted in significantly smaller emitted fractions for both EA-AS (33.6 ± 4.8%)
and IPA-AS (53.2 ± 0.4%) particles when compared to the emitted fractions obtained from the
Novolizer® and the Rotahaler® (p-values < 0.05, Tukey’s HSD).
For a dry powder formulation, the dose emission efficiency is determined by a complex
interplay between the particle characteristics and device properties (de Boer et al., 2003; Dunbar
et al., 1998). Inhaler devices contain special design features to empty and deagglomerate the
powder (Crowder et al., 2001). The Novolizer® is a multi-dose, passive, breath-actuated,
moderate airflow resistance inhaler which utilizes the air-classifier technology to achieve particle
deaggregation (de Boer et al., 2006; de Boer et al., 2006; Fenton et al., 2003). Figure V.1 shows
a schematic diagram of the Novolizer®. The powder is contained in a reservoir cartridge from
which it empties into a powder channel and is then inhaled through the mouthpiece. The drug
emptying from this inhaler is improved by a hammer which shakes the powder reservoir during
the device actuation. The hammer also helps to remove the powder on the powder channel walls
and therefore aids emptying (Fenton et al., 2003).
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Figure V.1 Schematic diagram of a Novolizer® (Fenton et al., 2003) (Reproduced with
permission from Wolters Kluwer)
Nektar PDS® is an active inhaler with the drug packaged into a unit-dose blister. The
actuation process requires lifting the handle above the base once and squeezing it until it snaps
shut (Davis et al., 2008). This pulls in compressed air into the air pump shown in Figure V.2.

Figure V.2 Schematic diagram for the Nektar PDS® dry powder inhaler (Davis et al., 2008)
(Reproduced with permission from Elsevier)
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Upon actuation, the blister is pierced and the stored compressed air rushes into the blister
and fluidizes the powder which is then expelled into the release unit and then into the spacer
chamber. The active fluidization process aids both blister emptying and powder deaggregation.
In contrast to the Novolizer® and Nektar PDS® devices which have inbuilt design features to
promote device emptying, Rotahaler® which is a first generation dry powder inhaler does not
incorporate any special features to aid device emptying (Hallworth, 1977). As shown in Figure
V.3, a small capsule containing the drug is loaded into a small hole at the end of the barrel. The
barrel is then twisted to allow the plastic blade inside to separate the capsule body from the cap,
thus exposing the powder for dispersion. Upon patient inhalation, the powder is emptied by the
rattling motion of the capsule body and dispersed through the grid in the mouthpiece by the
entraining air (Chew et al., 2002).

Figure V.3 Schematic diagram of a Rotahaler® (Chew et al., 2002) (Reproduced with
permission from Elsevier)
The absence of any special design features in the Rotahaler® in contrast to the Novolizer® and
Nektar PDS® may have accounted for the lowest emitted fraction for MIC-AS observed from
this device compared to the other two DPIs. However, IPA-AS and EA-AS particles when

214

aerosolized from the Novolizer and Rotahaler resulted in comparable emitted fractions which
were significantly higher compared to MIC-AS particles from both the Novolizer® and the
Rotahaler®. These observations may be explained by an interplay between the device and
formulation. The emitted fraction of a powder is a function of its flow properties with better
flowing powders exhibiting improved device emptying (Terzano and Colombo, 1999; Chow et
al., 2007; Iida et al., 2001). Micronized powders are generally cohesive due to two
characteristics: small size and electrostatically charged surfaces produced during the milling
process, filling and device manipulation (Terzano and Colombo, 1999; Chow et al, 2007, Louey
et al., 2006; Danniher and Zhu, 2008; Iida et al., 2001). The small size brings about particle
cohesion by reducing the interparticulate distances. This results in an increase in Van der Waals
forces of interaction thereby making the powders stick together as clumps and adversely
affecting their flowability (Terzano and Colombo, 1999). Electrostatically charged surfaces are
subject to Coulombic forces of interaction and it has been suggested in literature that such
interactions are comparable in strength to the Van der Waals forces (Chan, 2006; Keil et al.,
2006). The emitted fraction is strongly and negatively influenced by the electrostatic deposition
in the inhalers and on the mouthpieces (Chan, 2006). The lower emitted fraction for the
micronized albuterol sulfate from both the Novolizer® and Rotahaler® compared to EA-AS and
IPA-AS particles may be attributed to the high cohesive properties of these particles which lead
to significant device retention by the particles adhering to the device. The EA-AS and IPA-AS
particles produced from a controlled crystallization process were not subjected to micronization.
This might have led to a reduction in particle cohesion, and hence improved flow properties.
Furthermore, the EA-AS and IPA-AS particles had a higher percentage of larger particles > 10
µm compared to the MIC-AS particles (% Volume < 10 µm = MIC-AS: 92.7 ± 1.2%; IPA-AS:
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82.6 ± 0.6%; EA-AS: 57.1 ± 0.8%). These larger particles may act as an in built binary mixture
akin to the presence of larger carrier particles to improve flow properties and hence help device
emptying. Figures V.4 and V.5 showing the individual site deposition expressed as % mass
relative to the nominal drug dose for the AS particles aerosolized from the Rotahaler® and
Novolizer® also reveal the poor device emptying for the MIC-AS particles relative to the IPAAS and EA-AS particles.
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Figure V.4 Individual site deposition of different types of AS particles aerosolized from the
Rotahaler® as drug only formulations (n=3)
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Figure V.5 Individual site deposition of different types of AS particles aerosolized from the
Novolizer® as drug only formulations (n=3)
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The comparable emitted fractions for EA-AS and IPA-AS particles between the
Novolizer® and the Rotahaler® may be a result of a decreased device dependency for these
particles relative to MIC-AS particles. The emitted fraction of the EA-AS and IPA-AS particles
from the Nektar PDS® was significantly lower (p-value < 0.05, Tukey’s HSD) compared to that
obtained from the Novolizer® and the Rotahaler®. These results may be attributed to the fact
that the Nektar PDS® device was designed to work most efficiently with a formulation
consisting of a flow aid such as mannitol as an excipient. Therefore, the device emptying might
be adversely affected when testing drug only formulations. Further, the large spacer incorporated
in the Nektar PDS® design presents a possible site for particle adherence. It was observed that
IPA-AS particles produced a significantly higher emitted fractions (p-value > 0.05, Tukey’s
HSD) compared to MIC-AS and EA-AS particles when aerosolized from the Nektar PDS® as
shown in Figure V.6.
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Figure V.6 Stage-wise deposition of different types of AS particles aerosolized from the
Nektar PDS® as drug only formulations (n=3)
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These differences might be attributed to the particle characteristics. The IPA-AS
particles shown in Figure III.52 were elongated, rod-like in shape. Therefore, they are likely to
have lower cohesive and adhesive forces compared to the tabular particles of EA-AS shown in
Figure III.49 and the tabular, possibly electrostatically charged MIC-AS particles (Fig. III.56).
The poor device emptying of Nektar PDS® when aerosolizing drug only formulations may be
more significant for the cohesive MIC-AS and EA-AS particles compared to the less cohesive
IPA-AS particles resulting in the differences in emitted fractions. Therefore, in summary, the
emitted fraction was found to be significantly influenced by both powder and device
characteristics. The IPA-AS and EA-AS particles produced a significantly improved emitted
fraction from the Novolizer® compared to MIC-AS particles.
The % FPF results also revealed differences in the aerosol performance of the three types
of AS particles together with the device. The % FPF represents the mass fraction of the aerosol
less than 5.0 µm and is considered to be respirable. The % FPF is calculated as the percentage of
drug mass < 5.0 µm (mass of drug depositing on stage 2 and below in the NGI operating at 60
L/min) relative to the emitted drug dose and is representative of powder dispersivity. This is the
ability of the particle agglomerates to disperse into discrete individual particles during
aerosolization.
Table V.3 shows that MIC-AS particles resulted in similar % FPFs (p-value > 0.05,
Tukey’s HSD) of 59.4 ± 0.1 % and 68.5 ± 0.4 % when aerosolized from the Novolizer® and the
Nektar PDS® respectively. Rotahaler® resulted in the smallest % FPF (p-value < 0.05, Tukey’s
HSD) of 53.3 ± 0.7 % for MIC-AS particles compared to the Novolizer® and the Nektar PDS®.
The EA-AS particles also showed a similar trend with similar % FPFs of 23.6 ± 7.1 % and 38.7 ±
1.4 % (p-value > 0.05, Tukey’s HSD) being produced from the Novolizer® and the Nektar
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PDS® respectively. Rotahaler® once again produced a significantly smaller (p-value < 0.05,
Tukey’s HSD) % FPF of 5.6 ± 0.9 % for the EA-AS particles when compared to the Novolizer®
and the Nektar PDS®. With the IPA-AS particles also, Rotahaler® resulted in the lowest % FPF
of 16.1 ± 0.1 % compared to the Novolizer® and the Nektar PDS® which resulted in
significantly higher % FPFs (p-values> 0.05, Tukey’s HSD) of 46.6 ± 1.3 % and 34.8 ± 2.1 %
respectively. Dry powder inhaler dispersion efficiency is influenced once again by an interplay
between the device and formulation.
MIC-AS particles resulted in the highest % FPFs regardless of the employed device. This
might be attributed to their smallest size which results in higher deposition on stages < 5.0 µm.
However, the % FPFs obtained were significantly lower than the volume % of particles < 5.0 µm
obtained from laser diffraction sizing. These results are shown in Table V.4.
Table V.4 Volume / mass fraction of AS particles < 5.0 µm obtained during laser
diffraction and aerosolization (n=3)

Volume / Mass % < 5.0 µm

Particles
Laser
Diffraction
MIC-AS
IPA-AS
EA-AS

71.8 ± 3.4
55.6 ± 0.8
34.4 ± 1.2

Aerosolization
Novolizer
59.4 ± 0.1
46.6 ± 1.3
23.6 ± 7.1

Rotahaler
24.6 ± 0.3
16.1 ± 0.1
5.6 ± 1.0

Exubera
68.5 ± 0.4
34.8 ± 2.1
38.7 ± 1.4

The volume fractions < 5.0 µm obtained from laser diffraction are indicative of
completely dispersed particles since the laser diffraction method was developed to achieve
complete deagglomeration without particle attrition. The lower volume / mass fractions obtained
during aerosolization are therefore indicative of incomplete dispersion of the AS particles from
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all devices. However, Novolizer® and Nektar PDS® resulted in significantly higher % FPFs
compared to the Rotahaler indicating more efficient dispersivity.
Novolizer® employs the principle of air classifier technology to bring about particle
dispersion. This air classifier technology is depicted in Figure V.7.

Figure V.7 Air classifier technology in a Novolizer® dry powder inhaler (de Boer et al.,
2003) (Reproduced with permission from Elsevier)
The air classifier technology classifies particles based on particle size. The basic design
of such a classifier has a cylindrical chamber with a tangential air supply channel and a discharge
channel starting from the centre of one of its circular ends. The larger particles in such a
classifier can be retained and only detached / deagglomerated drug particles are discharged with
the inspiratory airstream. The classification is the result of the counter acting of two forces; the
drag force (FD) and the centrifugal force (FC). This air classifier technology in the Novolizer®
therefore brings about efficient particle deagglomeration and increased dispersivity (de Boer et
al., 2003).
Nektar PDS® also employs specific design principles to bring about particle
deagglomeration. This is active powder fluidization by compressed air. Discharge of compressed
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air through the powder blister upon actuation releases the powder which is then dispersed into
primary particles by the energy of compressed air discharged through the release unit. The
particles are inhaled as a standing cloud from the holding chamber (Davis et al., 2008). In
contrast to the Novolizer® and the Nektar PDS®, the deagglomeration principles employed in
the Rotahaler® are relatively less efficient (Chew et al., 2002). The powder released from the
capsule upon actuation passes through the grid shown in Figure V.3 which disperses it into
primary particles together with the rattling of the capsule produced during inhalation. These
device differences in terms of the mechanisms for deagglomeration may explain the lowest %
FPF for all types of AS particles when aerosolized from the Rotahaler® compared to Novolizer®
and Nektar PDS®.
The % FPF was also observed to be a function of the AS particles themselves with
differences being seen in the same device. Rotahaler®, with its weakest dispersivity principles
can be used to assess the inherent powder dispersivity. In this device, the MIC-AS particles
resulted in a significantly higher (p-value > 0.05, one-way ANOVA) % FPF of 53.3 ± 0.7%
compared to the IPA-AS particles (% FPF = 16.1 ± 0.1%). Thus once emitted, the small mass of
the MIC-AS particles was more efficiently dispersed compared to IPA-AS particles. This might
be attributed to the smaller size of MIC-AS particles relative to IPA-AS particles. EA-AS
particles, once again produced the smallest % FPF of 5.6 ± 1.0% among the three types of
particles. In this case the maximum loss in % FPF occurred due to deposition of the EA-AS
particles in the pre-separator as shown in Figure V.4. The pre-separator collects the large
particles in the powder and hence, the highest drug loss in the pre-separator for the EA-AS
particles may be due to their largest particle size compared to MIC-AS and IPA-AS particles. In
the Novolizer® also, MIC-AS resulted in a significantly higher % FPF of 59.4 ± 0.1 % compared
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to the % FPFs of 46.6 ± 1.3 % and 23.6 ± 7.1 % produced by IPA-AS and EA –AS respectively.
Therefore, once emitted, MIC-AS showed significantly higher dispersivity compared to the IPAAS and EA-AS particles. This may once again be attributed to the smallest size of the MIC-AS
particles. The Nektar PDS® showed a similar trend to the Rotahaler® and Novolizer® wherein
the MIC-AS particles resulted in a significantly higher % FPF (p-value < 0.05, one-way
ANOVA) of 68.5 ± 0.4% compared to IPA-AS particles (% FPF = 34.8 ± 2.1%) and EA-AS
particles (% FPF = 38.7 ± 1.4 %). This higher dispersivity of MIC-AS particles may once again
be related to their small size compared to IPA-AS and EA-AS particles.
Therefore, the results for % FPF revealed that MIC-AS particles had the highest
dispersivity compared to the particles engineered from the solvent / anti-solvent crystallization
process. This was attributed to their smaller size. However, it was also observed that MIC-AS
particles had significantly lower emitted fractions compared to the engineered particles
particularly in the Novolizer® and Rotahaler®. Both emitted fraction and % FPF are important
aerosol performance features and it is necessary to arrive at an optimum balance between the
two. Therefore, IPA-AS particles with higher emitted fractions compared to MIC-AS and
reasonably high % FPFs for a dry powder formulation may have more benefits.
The overall efficiency of a dry powder formulation can be assessed in terms of its fine
particle dose (FPD) which represents the total mass of drug < 5.0 µm and indicates the respirable
amount. Since it takes into account both powder emission and powder dispersivity, it is a useful
parameter to classify the formulation efficiency. The FPD for the different types of AS particles
were shown in Table V.3. It was observed that in the Novolizer®, IPA-AS particles had a
significantly higher FPD of 70.2 ± 6.2 µg compared to MIC-AS (FPD = 51.4 ± 0.1 µg) and EAAS (FPD = 28.3 ± 4.8 µg) (p-value < 0.05, Tukey’s HSD). Therefore, even though MIC-AS had
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higher dispersivity from the Novolizer®, IPA-AS particles showed improved overall
performance by virtue of their higher emitted fractions. In the Rotahaler®, comparable FPDs of
24.6 ± 0.3 µg and 21.8 ± 0.2 µg were produced by MIC-AS and IPA-AS particles respectively
(p-value > 0.05,Tukey’s HSD) with EA-AS particles producing the smallest FPD of 9.6 ± 4.7 µg.
Therefore, in spite of their significantly higher dispersivity, MIC-AS particles did not show any
significant improvement in the overall performance. When aerosolized from the Nektar PDS®,
MIC-AS particles produced the highest FPD of 56.6 ± 0.6 µg compared to IPA-AS (FPD = 39.8
± 4.3 µg) and EA-AS (FPD = 29.6 ± 7.8 µg). These differences were attributed to the very high
dispersivity of MIC-AS particles compared to the IPA-AS and EA-AS particles.
These results therefore demonstrated that the performance was dependent on both particle
properties as well as device characteristics. The significantly improved aerosol performance of
IPA-AS particles from the Novolizer® was therefore indicative of the highest efficiency for this
particle / device combination.
Figures V.8, V.9, and V.10 show the cumulative % undersize mass distributions based on
the mass percentage as a function of the impactor dose for the Novolizer®, Rotahaler®, and
Nektar PDS® respectively. The differences in the in vitro aerosol performance for the three types
of AS particles and the interdependency of the device and formulation were also reflected in the
MMADs wherein EA-AS particles resulted in the highest MMAD of 5.6 ± 1.0 µm when
aerosolized from the Rotahaler®. The MMADs of the AS particles when aerosolized from the
other devices were comparable. No differences were observed in the GSD values for the
different types of AS particles aerosolized from different devices indicating similarity in the
width of the particle size distribution within the impactor.
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Figure V.8 Cumulative % undersize mass distribution for the three types of AS particles
tested from the Novolizer® as drug only formulations (n=3)
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Figure V.9 Cumulative % undersize mass distribution for the three types of AS particles
tested from the Rotahaler® as drug only formulations (n=3)
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Figure V.10 Cumulative % undersize mass distribution for the three types of AS particles
(n=3)

Therefore, in summary, drug only studies of the AS particles revealed that the
performance of the formulation was an interplay between particle and device characteristics. AS
particles engineered from the solvent / anti-solvent crystallization process using isopropyl
alcohol and ethyl acetate resulted in significantly higher emitted fractions compared to the
conventionally used micronized particles when aerosolized from the Novolizer® and
Rotahaler®. These higher emitted fractions were indicative of better flow properties of these
particles and were attributed to decreased cohesive forces. The reasons for these decreased
cohesion was attributed to the presence of larger particles acting as inbuilt binary mixtures as
well as reduced surface energy for these engineered particles relative to micronized particles.
Powder dispersivity represented as the fine particle fraction was found to be highest for
micronized AS. However, this increased powder dispersivity did not translate into improved
overall performance of these particles represented by the fine particle dose. AS particles
produced from the solvent / anti-solvent crystallization process using isopropyl alcohol as the
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anti-solvent resulted in a superior aerosol performance compared to micronized albuterol sulfate
when aerosolized from the Novolizer®. These results once again reiterated the complex
interaction between the device and formulation affecting the overall dry powder performance.

V.D.1.2

Drug / lactose blend studies

In the previous section, it was found that IPA-AS particles in drug only DPI formulations,
produced the highest emitted fraction and fine particle dose when tested in the Novolizer® DPI.
These particles were selected for further investigation in drug / lactose blend formulations using
the Novolizer®. The drug / lactose blend studies were carried out to overcome the practical
limitations of metering out a small mass of 200 µg of the drug alone. A homogeneous blend of
these particles was prepared with lactose monohydrate as described in section V.C.1.2. The
blend homogeneity was measured as described in section V.C.1.2. The % RSD obtained during
the blend homogeneity studies was 2.9% which was therefore acceptable. In order to test the
aerosol performance of micronized AS when present as a homogeneous binary mixture with
carrier lactose, the commercial Novolizer® dry powder formulation for AS was chosen since it
contained a physical mixture of micronized AS blended with lactose monohydrate. The results
for drug / lactose blend studies are shown in Table V.5.
Table V.5 In vitro aerosol performance of IPA-AS particles tested from the Novolizer® as
drug / lactose formulations (n=3)
Formulation
Novolizer®
Blend
IPA-AS Blend

Emitted
Fraction (%)

Fine Particle
dose (µg)

% FPF

MMAD
(μm)

GSD

88.0 ± 7.9

25.1 ± 2.1

23.7 ± 2.6

3.2 ± 0.1

2.1 ± 0.2

90.3 ± 3.9

33.4 ± 0.8

32.6 ± 0.6

2.5 ± 0.5

2.6 ± 0.6
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These results will once again be discussed in terms of the emitted fraction, fine particle
fraction and fine particle dose. The emitted fractions for the commercial formulation and IPA-AS
blend were comparable (p-value > 0.05, One-way ANOVA) at 88.0 ± 7.9 % and 90.3 ± 3.9 %
respectively. These emitted fractions were also significantly higher (p-value < 0.05, One-way
ANOVA) compared to the values obtained in the drug only studies for MIC-AS (40.8 ± 0.7 %)
and IPA-AS (68.8 ± 1.8 %) particles. Furthermore, the emitted fractions for the commercial
Novolizer® formulation were similar to the emitted fraction of 90.0% reported in literature (de
Boer et al., 2006). These results can be explained by the presence of the larger size lactose
particles. The drug only formulations consist of small drug molecules which exhibit strong
interparticulate forces. These interparticulate forces were discussed in detail in section V.D.1 and
include the Van der Waal’s forces and possibly electrostatic forces in micronized particles
(Visser, 1981). The Van der Waal’s forces become particularly noticeable when the
interparticulate distance is small. These Van der Waal’s forces lead to interparticulate cohesion
which adversely effects powder flow and therefore produces a low emitted dose fraction
(Daniher and Zhu, 2008; Louey et al., 2004). Addition of large (50-100 µm) carrier particles in
the form of lactose results in an increase in the interparticulate distances which therefore reduces
the Van der Waal’s forces making the particles less cohesive (Daniher and Zhu, 2008; Chow et
al., 2007; Iida et al., 2001). The drug particles adhere to the surfaces of the carrier lactose
particles. This adherence further reduces the cohesive forces between the drug-drug particles and
promotes powder flow. The improvement in powder flow for dry powder formulations of
fluticasone propionate in the presence of lactose as a carrier has been studied by Louey et al.
(2004). They employed measures of flowability such as the Carr’s compressibility index
calculated from tapped and bulk powder density and the vibrating spatula method to generate
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powder mass flow vs. time profiles. They showed an increase in powder flow with an increase in
the lactose proportion in the dry powder formulation. Therefore, it is believed that the increase in
emitted fraction in drug / lactose blend formulations is attributed to the role of lactose in
promoting powder flow.
Comparison between the % FPFs of IPA-AS particles tested as a drug / lactose
formulation and commercial Novolizer® formulation revealed that the IPA-AS particles
produced a significantly higher % FPF (p-value < 0.05, one-way ANOVA) of 33.4 ± 0.8 %
compared to a % FPF of 23.7 ± 2.6 % produced by the commercial Novolizer® formulation. The
higher % FPFs for the IPA-AS blend are also evident from Figure V.11 which shows higher AS
deposition on stages 4, 5, 6, and 7 of the NGI from the IPA-AS blend compared to the
commercial Novolizer® formulation.
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Figure V.11 Stage-wise deposition of commercial Novolizer® formulation and IPA-AS
particles tested as drug / lactose formulations (n=3)
Dhumal et al. (2009) have produced AS particles by a sonocrystallization technique and
tested their in vitro aerosol performance from the Rotahaler® as drug / lactose formulations
(drug : lactose = 1:67.5 (w/w)) at 28.3 L/min. They have reported a high % FPF of 44.2 ± 1.3 %
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as a function of nominal dose. However, due to the differences in the device and the drug :
lactose ratio between the IPA-AS blend and the sonocrystallized AS particles, no direct
comparisons are possible.
The significantly higher % FPF of the IPA-AS particles when tested as a drug / lactose
formulation compared to the commercial Novolizer® formulation may be explained by the
relative strength of adherence of the drug particles to the lactose particles. Commercial
Novolizer® formulation contains micronized AS. These micronized particles have surfaces with
higher energy as a function of the micronization process and therefore might adhere more
strongly to the lactose particles compared to the particles engineered from isopropyl alcohol and
not subjected to micronization (Islam et al., 2003; Louey et al., 2004; Zeng et al., 1996; Sriracha
et al., 1998). The stronger adherence will lead to reduced deaggregation and hence account for
the smaller % FPF for the commercial Novolizer® formulation compared to the IPA-AS blend.
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Figure V.12 Cumulative % undersize mass distribution for IPA-AS blend and the
commercial Novolizer® formulation aerosolized from the Novolizer® (n=3)
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The improved aerosol performance of the IPA-AS / lactose blend compared to the
commercial Novolizer formulation was also represented by their MMADs wherein IPA-AS /
lactose blend had an MMAD of 2.5 ± 0.5 µm which was significantly lower (p-value < 0.05,
one-way ANOVA) compared to the MMAD of 3.2 ± 0.1 µm for the commercial Novolizer®
formulation. This difference in MMAD is illustrated in Figure V.12.
The improved aerosol performance of the IPA-AS blend compared to the commercial
Novolizer® formulation can also be seen from the fine particle dose with IPA-AS blend
producing a significantly higher amount of FPD (33.4 ± 0.8 µg) compared to the commercial
Novolizer® formulation (FPD = 25.1 ± 2.1 µg). In order to compare the IPA-AS blend
performance with the IPA-AS drug only formulation, the fine particle dose had to be normalized
with respect to the nominal dose because of the different nominal doses in the two formulations.
The IPA-AS drug only formulations employed a nominal dose of 200 µg whereas the IPA-AS /
lactose blend used a nominal dose of 120 µg. Table V.6 shows the comparison between the fine
particle dose normalized with respect to nominal dose and expressed as a percentage for the two
formulations.

Table V.6 Comparison between aerosol performance of IPA-AS drug only formulation and
IPA-AS / lactose blend (n=3)
Formulation
IPA-AS drug only
IPA-AS / lactose blend

(Fine Particle Dose / Nominal
Dose) × 100 (µg)
32.0 ± 0.6
29.4 ± 0.7

The fine particle dose normalized with respect to the nominal dose was comparable
between IPA-AS drug only formulation and IPA-AS / lactose blend (p-value >0.05, one-way
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ANOVA). These results demonstrated that the performance of IPA-AS particles was not
significantly different when tested either as drug only formulations or as drug / lactose blends.
To summarize the drug / lactose blend studies, significantly higher emitted fractions were
obtained compared to the drug / only studies for both IPA-AS blend and the commercial
Novolizer® formulation due to the effect of lactose on the cohesive interactions between the
drug particles. However, this increase in emitted fraction was accompanied by a decrease in the
% FPF (when calculated with respect to emitted dose) for both these formulations relative to the
drug only formulations. This was attributed to adherence of drug particles to lactose carrier
particles resulting in decreased deaggregation compared to drug only formulations. Furthermore,
IPA-AS blend produced a significantly higher % FPF relative to the commercial Novolizer®
formulation indicating improved aerosol performance characteristics.

V.D.2

Aerosol performance testing of combination particles
Combination particles 1, 2, and 3 produced from the three separately optimized solvent /

anti-solvent crystallization processes were selected for testing their in vitro aerosol performance.
These particles were comparable in terms of their physical diameter as shown in Table V.2.
Combination 1 and 2 were revealed to contain a nominal AS:IB ratio of ≈ 6:1 (w/w) as described
in sections IVD.2.3 and IV.D.2.2. These particles were produced from different solvent / antisolvent systems as shown in Table V.2. It was discussed in section IV.D.2.3.1 that the relative
solubilities of the two drugs in the anti-solvent influence the co-precipitation as combination
particles. Since, it was a primary research aim of this project to produce combination particles
with a nominal AS:IB ratio of 6:1 (w/w) that show uniform co-deposition, it was of interest to
characterize the in vitro aerosol performance of combination 1 and 2 to verify whether the
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produced particles contained AS and IB in a uniform proportion or not. Furthermore,
combination 3 contained AS:IB in a nominal ratio of 2.8:1 (w/w). Therefore, in vitro aerosol
performance of these particles was characterized to see whether the solvent / anti-solvent
crystallization process is capable of producing combination particles in different stoichiometric
ratios and also whether the ratio of AS and IB in the combination particles influences their
aerosol performance or not.

V.D.2.1

Drug only studies

One of the primary aims of this project is to produce homogeneous combination particles
to obtain uniform co-deposition of AS and IB in a fixed nominal ratio if 6:1 (w/w). This is
because the conventional combination product containing AS and IB is Combivent® pMDI
which is a physical mixture of individually micronized AS and IB in a nominal ratio of 6:1 (w/w)
suspended in CFC propellants and soya lecithin (Combivent® package insert). However, such a
physical mixture undergoes segregation into individual components resulting in a loss of the
fixed drug ratio (Jin et al., 2006). The in vitro aerosol performance of the commercial
Combivent® pMDI was carried out by Jin et al. (2006) using a NGI at a flow rate of 28.3 L/min.
The AS:IB ratios (w/w) across the impactor are shown in Table V.7.
Table V.7 Variation in the AS:IB ratio during aerosolization of the Combivent® pMDI
Stage
Throat
S1
S2
S3
S4
S5
S6

AS:IB (w/w)
5.4:1
5.2:1
4.4:1
4.0:1
5.2:1
10.7:1
20.1:1
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Co-deposition of AS and IB in ratios close to the claimed 6:1 (w/w) nominal ratio was
observed in the throat and upper impactor stages, However, on the lower stages of the impactor,
there were wide variations in the AS:IB ratio with higher AS deposition compared to IB
indicating a difference in the aerosolization performance of the two drugs in a physical mixture.
Such segregation is undesirable if a uniform co-deposition of the two drugs is needed. Therefore,
formulation of combination particles with a fixed proportion of AS and IB that show uniform codeposition is advantageous and hence constituted a primary aim of this project. Figures V.13 and
V.14 show the % AS and % IB expressed as a percentage of the nominal AS and IB dose
respectively for combination 1 and 2.
It was seen that the percentage of AS was similar to the percentage of IB on each stage
indicating uniform co-deposition for both combination 1 and 2. The AS:IB ratios on the different
impactor stages are shown in Tables V.8 and V.9 for combination particles 1 and 2 respectively.
The ratios remained consistent at ≈ 6:1 (w/w) thereby proving that AS and IB deposited
uniformly throughout the impactor. These results were therefore superior in terms of codeposition of AS and IB compared to the commercial Combivent® pMDI.
These results demonstrated that using two different solvent / anti-solvent crystallization
systems operating under optimized crystallization conditions, it was possible to produce
combination particles which resulted in a uniform in vitro co-deposition for the two drugs in a
6:1 (w/w) ratio. Apart from particles containing a 6:1 (w/w) AS:IB ratio, combination particles
with a nominal AS:IB ratio of 2.8:1 (w/w) were also produced (combination 3). Figure V.15
shows the % AS and % IB expressed as a percentage of the nominal AS and IB dose respectively
for combination particles 3. It was seen that the percentage of AS was similar to the percentage
of IB on each stage indicating uniform co-deposition. The AS:IB ratios on the different impactor
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stages are shown in Table V.10. The ratios remained consistent at ≈ 2.8:1 (w/w) thereby proving
that AS and IB deposited uniformly throughout the impactor.
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Figure V.13 % mass depositions of AS and IB from combination 1 aerosolized through the
Novolizer® as drug only formulations (n=3)

Table V.8 AS and IB ratio for combination particles 1 aerosolized through the Novolizer®
as drug only formulations
Stage
Device
MA
Throat
PS
S1
S2
S3
S4
S5
S6

AS:IB (w/w)
6.2:1
6.2:1
6.5:1
6.2:1
6.5:1
6.6:1
6.5:1
6.6:1
6.5:1
5.9:1
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Figure V.14 % mass depositions of AS and IB from combination 2 aerosolized through the
Novolizer® as drug only formulations (n=3)

Table V.9 AS and IB ratio for combination particles 2 aerosolized through the Novolizer®
as drug only formulations
Stage
Device
MA
Throat
PS
S1
S2
S3
S4
S5
S6

AS:IB (w/w)
6.0:1
5.9:1
5.7:1
5.8:1
5.6:1
5.5:1
5.5:1
5.7:1
6.1:1
6.7:1
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Figure V.15 % mass depositions of AS and IB from combination particles 3 aerosolized
through the Novolizer® as drug only formulations (n=3)

Table V.10 AS and IB ratio for combination particles 3 aerosolized through the Novolizer®
as drug only formulations
Stage
Device
MA
Throat
PS
S1
S2
S3
S4
S5
S6
S7

AS:IB (w/w)
3.1:1
3.1:1
3.1:1
3.1:1
2.9:1
3.0:1
2.9:1
2.9:1
2.9:1
2.9:1
2.6:1

These results therefore revealed that it was possible to produce combination particles in
different proportions using optimized solvent / anti-solvent crystallization processes. These
combination particles showed uniform co-deposition on different stages of the impactor during in
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vitro aerosol performance characterization thereby indicating that the produced particles
contained AS and IB in fixed proportions in single particles which resulted in similar aerosol
performance for both drugs.
Table V.11 shows the aerosol performance characteristics for combination 1, 2, and 3.

Table V.11 In vitro aerosol performance characteristics of combination 1, 2, and 3 tested as
drug only formulations (n=3)
Formulation
Combination 1
Combination 2
Combination 3
Formulation
Combination 1
Combination 2
Combination 3

Albuterol Sulfate
Fine Particle Dose (µg)
% FPF MMAD (µm)
729.5 ± 24.9
22.3 ± 1.4
3.5 ± 0.1
898.6 ± 92.9
28.6 ± 2.6
3.6 ± 0.5
1118.3 ± 117.3
39.0 ± 4.0
2.5 ± 0.1
Ipratropium Bromide
% Emitted Fraction Fine Particle Dose (µg)
% FPF MMAD (µm)
72.9 ± 2.2
112.2 ± 4.7
21.9 ± 1.7
3.4 ± 0.1
73.5 ± 1.2
165.9 ± 17.0
30.3 ± 2.7
3.7 ± 0.5
76.4 ± 1.4
416.7 ± 48.4
43.8 ± 4.5
2.5 ± 0.1

% Emitted Fraction
75.4 ± 5.5
74.0 ± 1.5
78.4 ± 2.9

GSD
2.3 ± 0.2
2.3 ± 0.0
2.2 ± 0.0
GSD
2.4 ± 0.0
2.3 ± 0.1
2.2 ± 0.0

The total emitted fractions for combination 1, 2, and 3 calculated as a function of the total
nominal dose of AS+IB were 75.3 ± 5.3 %, 73.9 ± 1.6 %, and 77.4 ± 2.2 % respectively. These
emitted fractions were comparable to each other (p-value > 0.05, Tukey’s HSD). However, the %
FPFs for combination 3 were significantly higher compared to combination 1 and 2 (p-value <
0.05, Tukey’s HSD) indicating improved dispersivity. The improved aerosol performance for
combination 3 was also reflected in the higher fine particle dose for these particles compared to
combination 1 and 2 (p-value < 0.05, Tukey’s HSD). This improved aerosol performance for
combination 3 may be attributed to their smaller particle size compared to combination 1 and 2
as shown in Table V.2. Furthermore, combination 3 also had a higher volume fraction < 5.0 µm
of 48.4 ± 2.2 % compared to combination 1 (42.8 ± 1.6 %) and combination 2 (46.7 ± 1.5 %)
which may have contributed to their higher dispersivity and hence a higher fine particle fraction.
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Table V.10 also demonstrates that AS and IB exhibited similar emitted fractions, fine particle
fractions, MMADs and GSDs in combination 1, 2, and 3. These similarities indicated that AS
and IB behaved in a similar manner during aerosolization and there were no particle size
differences for the two drugs which indicated the formation of combination particles.
These studies therefore revealed that it was possible to produce homogeneous
combination particles with a 6:1 (w/w) nominal ratio from two different solvent / anti-solvent
systems different. The nature of these combination particles was confirmed by uniform codeposition and similar aerodynamic characteristics of emitted fraction, % FPF, MMAD and GSD
for AS and IB during in vitro aerosolization. Furthermore, it was also possible to produce
homogeneous AS/IB particles with different stoichiometric ratios that showed uniform codeposition during in vitro characterization from the solvent / anti-solvent crystallization process.

V.D.2.2

Drug / lactose blend studies

Combination 1, 2, and 3 were tested as drug / lactose blends as described in section
V.C.2.1.2. The % RSDs for AS and IB for combination 1, 2, and 3 lactose blends are shown in
Table V.12. % RSDs < 5% for all combination particles were indicative of acceptable blend
homogeneity.

Table V.12 Blend homogeneity for combination 1, 2, and 3
Formulation

% RSD
AS
2.2
2.0
2.1

Combination 1 / lactose blend
Combination 2 / lactose blend
Combination 3/ lactose blend
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IB
4.9
3.8
3.0

The AS:IB (w/w) ratios on the different stages of the impactor for combination 1, 2, and 3 are
shown in Table V.13.

Table V.13 AS:IB (w/w) ratios deposited on different stages of the impactor after
aerosolization of combination 1, 2, and 3 as drug / lactose blends
Stage
Device
MA
Throat
PS
S1
S2
S3
S4
S5
S6

Combination 1
6.2:1
6.2:1
6.5:1
6.2:1
6.5:1
6.6:1
6.5:1
6.6:1
6.5:1
5.9:1

Combination 2
6.1:1
5.7:1
5.7:1
6.1:1
6.0:1
5.8:1
5.7:1
5.9:1
5.8:1
6.5:1

Combination 3
2.9:1
2.8:1
3.0:1
3.1:1
2.9:1
3.0:1
2.8:1
2.9:1
3.0:1
3.0:1

These results demonstrated that AS and IB co-deposited during aerosolization of combination 1,
2, and 3 as drug / lactose blends. Table V.14 shows the in vitro aerosol performance
characterization results for combination 1, 2, and 3.

Table V.14 In vitro aerosol performance characteristics of combination 1, 2, and 3 tested as
drug / lactose blends (n=3)
Albuterol Sulfate
Formulation
Combination 1
Combination 2
Combination 3
Formulation
Combination 1
Combination 2
Combination 3

% Emitted
Fraction
77.3 ± 0.6
81.8 ± 1.9
96.4 ± 0.9
% Emitted
Fraction
77.4 ± 0.6
80.7 ± 2.0
94.7 ± 0.8

Fine Particle Dose

% FPF

MMAD (µm)

GSD

20.3 ± 0.3
21.2 ± 1.1
14.6 ± 1.3

3.3 ± 0.0
3.3 ± 0.1
2.8 ± 0.1

2.7 ± 0.0
2.6 ± 0.0
3.5 ± 0.0

Fine Particle Dose

% FPF

MMAD (µm)

GSD

2.3 ± 0.1
2.9 ± 0.2
4.6 ± 0.4

20.1 ± 0.3
21.3 ± 1.2
15.6 ± 1.4

3.3 ± 0.0
3.4 ± 0.1
2.7 ± 0.1

2.7 ± 0.0
2.6 ± 0.0
3.6 ± 0.0

15.2 ± 0.4
16.8 ± 1.3
13.0 ± 1.2
Ipratropium Bromide
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Comparisons between the aerosol characteristics such as emitted fraction, % FPF, MMAD, and
GSD of AS and IB for all three types of combination particles did not reveal any significant
differences (p-values > 0.05, one-way ANOVA) between the aerodynamic performances of the
two drugs. For example, combination particles 1 produced an emitted fraction of 77.3 ± 0.6 %
for AS and 77.4 ± 0.6 % for IB. The corresponding % FPFs were 20.3 ± 0.3 and 20.1 ± 0.3 %
respectively. Similarly, combination particles 2 produced an emitted fraction of 81.8 ± 1.9 % for
AS and 80.7 ± 2.0 % for IB. The corresponding % FPFs were 21.2 ± 1.1 and 21.3 ± 1.2 %
respectively. Combination particles 3 produced an emitted fraction of 96.4 ± 0.9 % for AS and
94.7 ± 0.8 % for IB. The corresponding % FPFs were 14.06± 1.3 and 15.6 ± 1.4 % respectively.
These results indicated that AS and IB interacted in a similar fashion with lactose carrier
particles by virtue of being present as combination particles.
Combination particles prepared by other particle engineering techniques have been
reported in literature. Using the SAXS technique, Dhillon et al have produced 1:1 (w/w)
combination particles of theophylline and fluticasone propionate with a reported VMD of 1.6
µm. They tested the in vitro aerosol performance of these particles as dry powder formulations
by preparing a 1.6 % w/w blend with lactose monohydrate and testing it via a Cyclohaler and
NGI at 90 L/min. Their results indicated that upon aerosolization more theophylline was
delivered compared to fluticasone propionate (% FPF of 33.4 (7.7) % vs. 15.5 (1.1) %). The
authors have attributed this difference to mechanical disruption of particles upon blending with
lactose. These results were therefore in contrast to the similar fine particle fractions for AS and
IB in our studies and therefore suggested the formation of combination particles.
The drug / lactose blend studies therefore provided further proof for the formation of
combination particles in which both AS and IB interacted in a similar fashion with lactose by
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virtue of being present in fixed proportions in single combination particles. These combination
particles showed uniform co-deposition of AS and IB during in vitro aerosolization and were
therefore superior to the commercial Combivent® pMDI formulation containing a physical
mixture of individually micronized AS and IB.

V.E

CONCLUSIONS
The in vitro aerosol performance testing of the engineered AS particles and combination

particles of AS and IB revealed several important points. For AS particles, the single most
overriding conclusion was that using an optimized solvent / anti-solvent crystallization process
with hydrodynamic control alone led to the formation of particles with suitable characteristics for
inhalation. The aerodynamic characteristics of these engineered AS particles were found to be
superior to the conventionally used micronized AS in terms of higher emitted fractions and %
fine particle fraction. However, the aerosol performance was a strong function of the device used
to aerosolize these formulations with the best performance being achieved from the Novolizer®
DPI. This was attributed to the design features incorporated in the Novolizer® for device
emptying and powder dispersion.
The in vitro aerosol performance characterization of combination particles of AS and IB
revealed similar aerodynamic characteristics of AS and IB due to the incorporation of the two
drugs into single combination particles. These combination particles resulted in uniform codeposition of the two drugs in a fixed nominal ratio throughout the impactor. This was contrary
to the undesirable segregation behavior of a physical mixture of individually micronized AS and
IB employed in the commercial combination formulation, Combivent® pMDI.
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CHAPTER VI
OVERALL DISCUSSION AND SUMMARY
Dry powder inhalers (DPIs) are becoming increasingly popular for pulmonary drug delivery. A
critical component of the DPI system is the drug particle used in the formulation. The drug
particles should possess a number of key properties for successful formulation and lung delivery.
They should be of a suitable aerodynamic diameter for inhalation; the particles should be
crystalline for long term shelf life formulation stability and have a reproducible morphology.
Presently, the most commonly used technique to produce inhalation drug particles is
micronization which is an energy intensive milling process to reduce the size of large particles to
a suitable size for inhalation. However, this technique offers limited opportunities to optimize
and control the physical and chemical particle properties described above. Micronization is also
known to induce crystalline disorder in the particles leading to formulation instability. Therefore,
it would be advantageous to develop single step particle engineering processes capable of
directly yielding particles suitable for inhalation without the need for further size reduction.
Several particle engineering processes have been studied in literature. These include
spray drying, supercritical fluids and controlled precipitation. Among controlled precipitation,
sonocrystallization (Dennehy et al., 2003; Dhumal et al., 2009; Kaerger et al., 2003), in situ
micronization (Rasenack et al., 2002), and high gravity controlled precipitation (Chiou et al.,
2007) have been investigated. These controlled precipitation techniques employ solvent / antisolvent crystallization coupled with an external energy source (sonocrystallization, high gravity
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controlled precipitation) or crystal growth modifiers (in situ micronization) to control the particle
size. However, most of these techniques are either complex with special equipment needs or
difficult to scale up. The solvent / anti-solvent crystallization process has a number of parameters
that lend themselves to optimization and control in order to manipulate the final product
characteristics. It would therefore be desirable to develop a simple solvent / anti-solvent
crystallization process that controls particle size through optimization of the hydrodynamic
factors alone. However, to do so, it is important to understand the mechanism of solvent / antisolvent crystallization and the influence of critical processing variables on particle
characteristics.
In this project, a design of experiment (DoE) approach was used to investigate the
influence of critical crystallization variables associated with solvent / anti-solvent crystallization
of albuterol sulfate on two response variables: particle crystallinity and particle size. The aim
was to produce completely crystalline particles of albuterol sulfate in a single step in a size
suitable for inhalation, using hydrodynamic control alone without any crystal growth modifiers
or an external energy source. Water and ethyl acetate have been used as solvent and anti-solvent
for albuterol sulfate (Nocent et al., 2001). Complete crystallization of albuterol sulfate after a
crystal maturation time of 30 minutes is reported. Using this solvent / anti-solvent system, the
crystallization variables investigated included the solvent / anti-solvent ratio (Ra ratio; w/w) at
three levels of 1:200, 1:500, and 1:1000 (w/w), stirring speed at four levels of 100, 200, 500, and
800 r.p.m., and crystal maturation time varying from 0-24 hours. Particle formation was
observed to be complete after 30 minutes of stirring designated as crystal maturation time = 0. In
contrast to the results reported in literature by Nocent et al., the particles were found to be
partially crystalline under all crystallization conditions at crystal maturation time = 0. However,
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complete crystallization of these particles was observed when they were harvested and dried
under ambient conditions indicating that the particle crystallinity reported in literature is a
function of harvesting and drying the particles. The particle size of these particles was found to
be too large for inhalation (i.e. > 20 µm for all crystallization conditions). It was hypothesized
that the large particle size was contributed in part by solid-state crystallization of these partially
crystalline particles upon harvesting which led to the formation of crystal bridges between
adjacent particles and particle fusion. This was an undesirable phenomenon particularly for
aerosol formulations where size is a primary concern.
Therefore, to bring about complete crystallization prior to harvesting, the effect of longer
crystal maturation times was investigated. As a function of longer crystal maturation time,
differences in crystallization behavior of the particles were observed. Particles produced from Ra
ratio 1:200 and 1:500 (w/w) at all stirring speeds were observed to increase in crystallinity as a
function of increasing crystal maturation time and were observed to be completely crystalline at
the end of 24 hours. A similar increase in crystallinity was demonstrated by the particles
produced from Ra ratio 1:1000 (w/w) produced under low stirring speeds of 100 and 200 r.p.m.
when they were allowed to remain in the solvent / anti-solvent mixture. In contrast, particles
produced at higher stirring speeds of 500 and 800 r.p.m. did not undergo an increase in
crystallinity as a function of longer crystal maturation times and remained incompletely
crystalline at the end of 24 hours. These studies therefore revealed a significant influence of
crystallization conditions on particle crystallinity. A statistical analysis of the effect of different
crystallization variables on particle crystallinity revealed that Ra ratio, stirring speed, and crystal
maturation time demonstrated significant interaction with each other and the effect of any one
crystallization variable could not be discussed in isolation with the rest. This was a potentially
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important finding since there are currently no studies in literature that characterize the effects of
different crystallization variables on solution crystallinity of albuterol sulfate particles.
The differences in crystallization behavior of the particles were explained by the role of
supersaturation and the % water content of the particles. The plasticizing effect of water has been
extensively studied in literature and it has been shown that water uptake into the partially
crystalline regions results in re-crystallization (Crowley and Zografi, 2002; Marsac et al., 2008;
Wu and Yu, 2006; Ward and Schultz, 1995). However, any studies characterizing the role of
water in solution crystallization are currently absent. The studies with albuterol sulfate revealed a
significant role of water in solution crystallization, wherein particles undergoing complete
solution crystallization (Ra ratio 1:200, 1:500 at all stirring speeds and Ra ratio 1:1000 at 100 and
200 r.p.m.) contained water at higher levels (> 20%) at crystal maturation time = 0 compared to
particles that did not show complete solution crystallization within 24 hours (Ra ratio 1:1000 at
500 and 800 r.p.m.). These latter particles contained significantly lower % water contents (910%). Further, TGA analysis revealed that the higher % water content was lost at lower
temperatures (25°C) compared to the lower % water contents which were lost at higher
temperatures (60°C). This indicated that the lower % water was bound more tightly to the
particles compared to the higher % water. Zografi et al. have reported lower plasticizing
efficiency of water when it is present in a tightly bound form (Zografi et al., 1988). This lower
plasticizing efficiency may have contributed towards the incomplete solution crystallization for
the particles produced from Ra ratio 1:1000 (w/w) at higher stirring speeds of 500 and 800 r.p.m.
Measurement of particle size distribution of the particles at crystal maturation time = 24
hours revealed the formation of significantly smaller particles compared to crystal maturation
time = 0 for all particles except those produced from Ra ratio 1:1000 (w/w) under 500 and 800
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r.p.m. This finding lent support to the hypothesis that the large particle sizes observed at crystal
maturation time = 0 were a function of incomplete solution crystallization, subsequent solid-state
crystallization and formation of crystal bridges between particles. Therefore, these results
emphasized the importance of harvesting completely crystalline particles. The particle size was
found to be significantly influenced by an interaction between Ra ratio, stirring speed and crystal
maturation time in a manner similar to that observed for particle crystallinity. The smallest
particles among all crystallization conditions were produced from Ra ratio 1:200 (w/w) at 200
r.p.m. after a crystal maturation time of 24 hours and had a VMD of 9.7 ± 0.7 µm. These results
were explained by the supersaturation levels for the three Ra ratios. Ra ratio 1:200 (w/w) with the
highest supersaturation ratios of 5.2 compared to Ra ratio 1:500 and 1:1000 (w/w) with lower
supersaturation ratios of 4.5 and 3.4 would exhibit a higher driving force for nucleation, cause a
narrower MSZW and result in increased formation of smaller particles as described in section
III.D.2.1.2.
These studies cast insight into the mechanisms of solvent / anti-solvent crystallization and
the influence of crystallization variables on particle crystallinity and particle size. Further, the
effects of the crystallization variables were not treated in isolation from each other which has
been the case with similar studies reported in literature (O’Grady et al., 2001; Abdel-Al et al.,
2004; Genoveva et al., 2007). Crystallization is a dynamic process with a complex interplay
between the different crystallization conditions influencing the particle characteristics.
Therefore, it is necessary to understand these interactions in order to control and optimize the
crystallization variables and produce particles with the desirable characteristics.
The investigational studies with solvent / anti-solvent crystallization yielded a set of
crystallization conditions resulting in the smallest AS particles with a VMD of 9.7 ± 0.7 µm.
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However, these particles were not in a size suitable for inhalation. Therefore, in order to reduce
the particle size, the role of temperature difference between the solvent and anti-solvent was
investigated. These studies were carried out for the optimized set of crystallization conditions
i.e.; a Ra ratio of 1:200, a stirring speed of 200 r.p.m. and a crystal maturation time of 24 hours.
A temperature difference of 65°C between the drug solution and anti-solvent resulted in the
formation of AS particles with a smaller VMD of 8.8 ± 0.6 µm. Though the particles obtained
were small, they were not in the particle size range suitable for inhalation. Further, this diameter
was obtained using Malvern Mastersizer which is calibrated with spherical particles. Therefore,
accuracy in the particle size for non-spherical particles such as the ones in these studies cannot
be ascertained. But, it still serves as a useful estimate to get a preliminary idea about the size of
the produced particles. However, it is the aerodynamic diameter of the particles that is important
for their aerosol performance and not the geometric diameter obtained from the Malvern
Mastersizer. Therefore, it is necessary to carry out in vitro aerosol performance tests using
impaction studies in order to estimate the inhalation efficiency of these particles.
Based on the PSD results, ethyl acetate did not result in particles small enough for
inhalation. Therefore, isopropyl alcohol was investigated as an alternate anti-solvent. Dhumal et
al. have reported the formation of inhalation sized particles with IPA when used in conjunction
with ultrasonication (Dhumal et al., 2009). Using the previously optimized set of crystallization
conditions (Ra ratio 1:200, stirring speed 200 r.p.m., crystal maturation time 24 hours) and
isopropyl alcohol as the new anti-solvent, significantly smaller AS particles with a VMD of 4.9 ±
0.3 µm were produced. These particles were in a size range of 1-5 µm and were therefore
deemed to be suitable for inhalation. These particles were smaller compared to the ≈ 20 µm
particles reported by Dhumal et al. from the solvent / anti-solvent system of water / IPA using
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mechanical stirring alone in the absence of ultrasonication. These results therefore, reiterated the
importance of optimization of crystallization conditions and demonstrated that it was possible to
utilize hydrodynamic control alone without the use of an external energy source or crystal
growth modifiers to produce particles with suitable size characteristics for inhalation. However,
as was the case with the ethyl acetate particles, in vitro aerosol performance testing of these
particles was necessary in order to make judgments about their inhalation efficiency.
Proceeding forward from the development of an optimized single step solvent / antisolvent crystallization process for the production of inhalation particles of albuterol sulfate, this
project also aimed at extending this process to produce combination particles of albuterol sulfate
and ipratropium bromide monohydrate in different ratios in a size suitable for inhalation. It was
hypothesized that these combination particles would result in uniform co-deposition of AS and
IB and hence overcome the disadvantages of segregation and loss of fixed drug ratio associated
with physical mixtures of individually micronized AS and IB. Such segregation has been
reported by Jin et al. (2006) for Combivent® pMDI which is a physical mixture of AS and IB in
a nominal 6:1 (w/w) ratio.
The initial solvent / anti-solvent system chosen for these studies was water / ethyl acetate
with a Ra ratio of 1:200, a stirring speed of 200 r.p.m. and a crystal maturation time of 24 hours.
This process resulted in the formation of combination particles containing AS and IB in a
nominal ratio of 1:1, 2.1:1, 6.2:1, and 10.7:1 (w/w). These ratios were achieved from starting
drug solutions containing similar AS:IB ratios of 1:1, 2:1, 6:1, and 10:1 (w/w). These results
indicated complete precipitation of AS and IB and demonstrated that ethyl acetate acted as a
good anti-solvent for both drugs. Further, it was possible to predict the final AS:IB ratio based on
the known initial ratio of the drug solution which is a useful characteristic.
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Thermal analysis of these particles revealed them to have a single melting peak and the
heat of fusion of this melt was observed to increase with the proportion of AS. Furthermore, IB
was found to be in a completely hydrated form in these particles containing one mole of water of
crystallization. Since this water is incorporated in the IB crystal lattice, this observation indicated
the crystalline nature of IB in these particles. Thermal analysis coupled with powder X-ray
diffraction analysis revealed these particles to have different properties compared to pure AS,
pure IB, or a physical mixture of AS and IB. These results indicated interactions between AS and
IB which were not present when these drugs were blended together. However, the exact nature of
these interactions could not be elucidated and the presence or absence of co-crystals could not be
concluded. Therefore, these particles were designated as combination particles. All of these
particles were revealed to be in a size range too large for inhalation (VMD = 11 - 20 µm) with
the smallest size obtained for the 10:1 (w/w) combination particles.
Further optimization of the process to reduce the particle size investigated IPA as antisolvent since it had earlier resulted in smaller AS particles. Due to the solubility differences
between AS and IB in IPA, the initial drug concentrations, solvent anti-solvent ratio, and crystal
maturation time had to be optimized in order to achieve co-precipitation and form combination
particles from this anti-solvent. The optimized Ra ratio was 1:20 (w/w). Starting with an initial
AS:IB ratio of 0.48:0.28 g/g (AS:IB = 1.7:1 w/w), combination particles with a final AS:IB ratio
of 2.8:1 (w/w) were produced after a crystal maturation time of 5 minutes. Changing the initial
AS:IB ratio to 0.48:0.08 g/g (AS:IB = 6:1 w/w), resulted in combination particles with a final
AS:IB ratio of 5.7:1 (w/w). Therefore, it was not possible to predict the final ratio in the
combination particles from the initial ratio in all cases. The VMDs for the 2.8:1 (w/w), and 5.7:1
(w/w) combination particles were 5.3 ± 1.0 µm and 6.5 ± 0.3 µm respectively. These particles
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were therefore deemed to be in a size range suitable for inhalation. However, as was the case
with AS particles, it was important to test the in vitro aerosol performance of these particles to
make conclusions about their inhalation efficiency. Thermal analysis and PXRD revealed
differences from AS, IB and physical mixtures. However, no conclusions about the formation of
co-crystals could be drawn.
Although IPA yielded combination particles in a stoichiometric ratio in a size suitable for
inhalation, the solubility differences between AS and IB make it a difficult anti-solvent for the
production of combination particles (Chiarella et al., 2007). Further, it is not possible to predict
the final AS:IB ratio from the initial ratio in the drug solution. Therefore, in an attempt to utilize
the size reduction efforts of IPA and achieve co-precipitation of AS and IB, IPA was mixed with
ethyl acetate in different proportions of 1:1, 1:2, 1:5, and 1:10 (w/w) and used as the anti-solvent
at a Ra ratio of 1:200 (w/w), a stirring speed of 200 r.p.m. and a crystal maturation time of 24
hours. Co-precipitation of AS and IB was only achieved from IPA:EA 1:10 (w/w). However, this
anti-solvent did not produce particles in an optimum size for inhalation. Therefore, in an attempt
to reduce the particle size, the anti-solvent comprised of IPA:EA 1:10 (w/w) was cooled in dry
ice to achieve a temperature difference of 65°C between the solvent and anti-solvent. These
studies led to the formation of significantly smaller combination particles with AS:IB ratios of
1.:1, 1.9:1, 6.6:1, and 8.6:1 (w/w) when starting with an initial AS:IB ratio of 1:1, 2:1, 6:1, and
10:1 (w/w) respectively. These results demonstrated that AS and IB precipitated out completely
from this anti-solvent and it was possible to predict the final ratio in the combination particles
based on the starting drug concentrations of AS and IB. The thermal properties of these
combination particles were similar to the combination particles with the corresponding drug
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proportions produced from ethyl acetate. However, the formation of co-crystals could not be
concluded.
The particles of particular interest were the 6.6:1 (w/w) particles since they contained AS
and IB in a similar stoichiometric ratio as the commercial formulation; Combivent® pMDI.
Using IPA:EA 1:10 (w/w) as the anti-solvent at a temperature difference of 65°C resulted in the
formation of combination particles with a nominal AS:IB ratio of 6.6:1 (w/w) and a VMD of 6.9
± 1.1 µm. These particles were therefore in a size suitable for inhalation. However, it is
necessary to test the in vitro aerosol performance of these particles to further assess their
inhalation efficiency.
These studies therefore demonstrated that it was possible to optimize the solvent / antisolvent crystallization process developed for AS to produce combination particles of AS and IB
in a size suitable for inhalation. These combination particles also revealed differences from AS,
IB, and their physical mixtures indicating that AS and IB interacted with each other within a
combination particle matrix. A plausible scenario explaining the thermal and powder X-ray
diffraction results for the combination particles was the formation of interstitial crystalline solid
solution with IB molecules occupying the interstitial spaces within the AS crystal lattice. Pilot
molecular modeling studies were carried out to investigate the nature of interaction between AS
and IB. Using computational methods employing HINT to classify and score the interactions
between AS and IB molecules revealed sites on both molecules with the capability to participate
in non covalent interactions. Manual orientation studies revealed three orientations between AS
and IB that resulted in an overall positive HINT score indicating favorable interactions. The
highest HINT score obtained was 156.71. The positive interactions contributing to this overall
score were H-bonding, acid-base interactions and hydrophobic interactions while the negative
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interactions were acid-acid, hydrophobic-polar and acid-base interactions. These studies
therefore revealed that within a combination particle matrix, AS and IB will orient in a way to
maximize the positive interactions.
Due to the possibility of bias associated with manual orientation studies, docking studies
using GOLD were carried out where a single ipratropium molecule was docked in a 2×2×2 cube
constructed of AS unit cells with a cavity created in it by the removal of a single AS molecule.
The total HINT scores obtained for each of the dockings were negative except for one GA run in
docking position # 5 which resulted in a positive HINT score of 248.2. At first glance, these
negative total HINT scores implied an overall unfavorable interaction between AS and IB.
However, upon looking into the breakup of the total HINT scores, it was observed that there
were positive components as well that were contributed mainly by hydrogen bonding and
hydrophobic interactions. However, since the IB molecule was surrounded by tightly packed AS
molecules, the close proximity led to unfavorable acid-acid and base-base interactions which
resulted in a total negative HINT score. These studies however showed that there were a number
of positive interactive sites present on both molecules. These computational studies therefore
revealed that within a combination particle matrix, IB will orient itself to present its hydrophobic
bonding sites close to the hydrophobic binding sites of albuterol sulfate and its polar binding
sites close to the polar AS sites which will favor the formation of H-bonds and other noncovalent positive interactions.
Since this project hypothesized that the engineered AS particles and combination
particles of AS and IB would have a superior aerosol performance compared to conventionally
used micronized drug and individually micronized physical mixtures respectively, the in vitro
aerosol performance testing of AS particles and combination particles of AS and IB was carried
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out. AS particles produced from the optimized crystallization conditions using ethyl acetate (EAAS) and IPA (IPA-AS) were tested as drug only formulations from three DPIs; Novolizer®,
Rotahaler®, and Nektar PDS®. The aerosol performance was compared with micronized AS
(MIC-AS). A significant powder-device interaction was observed. IPA-AS and EA-AS particles
resulted in significantly higher emitted fractions compared to the conventionally used micronized
particles when aerosolized from the Novolizer® and Rotahaler®. These higher emitted fractions
were indicative of better flow properties of these particles and were attributed to decreased
cohesive forces. The reasons for these decreased cohesion was attributed to the presence of
larger particles acting as inbuilt binary mixtures as well as reduced surface energy for these
engineered particles relative to micronized particles. Powder dispersivity represented as the fine
particle fraction was found to be highest for micronized AS. However, this increased powder
dispersivity did not translate into improved overall performance of these particles represented by
the fine particle dose. AS particles produced from the solvent / anti-solvent crystallization
process using isopropyl alcohol as the anti-solvent resulted in a superior aerosol performance
compared to micronized albuterol sulfate when aerosolized from the Novolizer®. Drug / lactose
blend studies also revealed a significantly improved aerosol performance for IPA-AS blend
compared to the commercial Novolizer® dry powder formulation for AS. These results therefore
demonstrated that the optimized solvent / anti-solvent crystallization process yielded AS
particles with superior aerosol performance characteristics compared to conventionally used
micronized particles. This was an important observation since it signified the applicability of a
well understood and controlled solvent / anti-solvent crystallization process as a simple singlestep particle engineering technique to produce inhalation particles.
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In vitro aerosol performance testing of the combination particles as drug only
formulations from the Novolizer® revealed uniform co-deposition of AS and IB in a fixed
nominal ratio throughout the impactor from 2.8:1 and 5.7:1 (w/w) combination particles
produced from IPA and 6.6:1 (w/w) combination particles produced from IPA:EA 1:10 (w/w).
These studies were in contrast to the results reported by Jin et al. for the commercial
Combivent® pMDI (Jin et al., 2006). This commercial formulation is a physical mixture of
individually micronized AS and IB which shows segregation and loss of the fixed drug ratio
during aerosolization. Testing of these combination particles as lactose blends from the
Novolizer® also revealed uniform co-deposition of AS and IB in a fixed nominal ratio.
Combination particles prepared by other particle engineering techniques have been reported in
literature. Corrigan et al. have used spray drying to prepare combination particles of AS and IB.
These particles were however amorphous in nature (Corrigan et al., 2006). Using
sonocrystallization, Pitchayajittipong et al. have reported combination particles of formoterol and
budesonide. However, in vitro aerosol performance testing of these particles has revealed a loss
of the fixed drug ratio (Pitchayajittipong et al., 2009).
Therefore, in these studies, it was possible to produce combination particles
demonstrating co-deposition of AS and IB from two separate solvent / anti-solvent systems.
These combination particles demonstrated advantages over conventionally used physical
mixtures and signified that it was possible to develop a simple solvent / anti-solvent
crystallization process that could be used as a particle engineering technique to produce
combination particles of AS and IB.
In summary, crystallization conditions were found to significantly influence particle
characteristics of AS. Investigation and optimization of these conditions resulted in the
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development of a solvent / anti-solvent crystallization process capable of producing albuterol
sulfate particles and combination particles of albuterol sulfate and ipratropium bromide with
suitable characteristics for inhalation. These particles engineered from the optimized solvent /
anti-solvent crystallization process showed superior aerosol performance characteristics
compared to the conventionally used micronized powders for inhalation therapy by dry powder
formulations. It was also possible to extend the solvent / anti-solvent crystallization process to
produce combination particles of AS and IB in different ratios in a size suitable for inhalation.
These combination particles resulted in co-deposition of AS and IB in a fixed ratio during in
vitro studies and hence provided a significant advantage over the physical mixtures used for
combination therapy. Further, as it was possible to produce these combination particles from a
simple single-step particle engineering technique, they also offered advantages over the
conventionally used micronized particles. Therefore, these studies revealed that if investigated
and optimized, it was possible to use only hydrodynamic conditions associated with solvent /
anti-solvent crystallization to produce particles for inhalation.
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APPENDIX

Table A.1 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#1
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-659.47
-1135.24
-662.6
-544.11
-734.18
-559.15
-688.96
-523.27
-978.3
-601.37

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
0
914.9
-2447.73
677.5
726.37
-2543.56
0
921.84
-2297.51
419.05
432.82
-1446.75
0
858.33
-2247.49
480.83
876.67
-2198.16
0
894.14
-2243
0
346.59
-1608.19
0
639.8
-2313.64
666.64
784.05
-2474.69

Table A.2 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#2
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-901.83
-1116.85
-1103.05
-262.7
-1503.08
-737.16
-835.09
-1223.42
-934.74
-723.06

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
728.66
520.17
-2030.23
944.18
777.76
-2259.99
760.99
684.36
-2531.83
0
479.01
-1550.62
0
687.17
-2509.35
1746.32
698.05
-1947.96
1649.46
648.15
-2108.98
930.7
666.63
-2497.84
347.49
502.77
-2207.75
0
604.05
-2013.59
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Table A.3 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#3
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-287.94
-453.7
-232.71
-343.69
-506.35
-824.53
-364.35
-595.2
-396.54
-201.96

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
363.9
668.36
-1694.57
0
558.06
-1828.95
420.77
679.35
-1707.69
366.04
689.37
-1716.42
296.37
651.21
-1809.39
0
660.31
-1619.99
468.22
660.89
-1790.87
0
628.3
-1723.89
415.18
676.65
-1753.61
0
701.48
-1637.18

Table A.4 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#4
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-1138.43
-2321.9
-1245.18
-1439.12
-1345.87
-703.29
248.23
-868.76
-687.56
-1440.82

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
0
878.35
-2976.05
399.93
340.09
-2330.86
0
543.31
-2234.72
0
247.25
-2232.02
0
666.46
-2787.31
237.79
263.69
-1779.13
506.49
443.32
-1343.2
272.32
304.28
-1871.62
107.33
101.66
-1431.53
349.07
336.46
-2169.64
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Table A.5 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#5
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-1537.5
-776.43
-1427.99
-1146.87
-1374.51
-1414.49
-850.31
-1065.54
-3015.7
-1342.53

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
0
502.08
-2346.56
0
595.05
-2276.32
0
488.88
-2343.99
211.76
590.43
-2599.49
591.26
492.23
-2283.36
0
461.02
-2302.5
295.81
579.89
-2297.27
317.44
538.13
-2383.92
1255.91
614.72
-2193.77
0
499.8
-2403.15

Table A.6 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#6
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-685.55
-829.1
-1104.3
-2064.46
-886.8
-2445.42
-823.42
-747.98
-2457.78
-600.74

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
521.31
831.9
-2197.52
398.79
671.95
-2280.88
101.7
656.99
-2548.71
0
632.3
-2720.23
500.84
800.93
-2132.84
348.59
660.68
-3015.63
97.88
697.85
-2001.78
514.18
859.68
-2173.38
677.19
821.96
-3317.01
627.59
807.44
-2123.21
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Table A.7 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#7
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-541.88
-3651.08
-834.42
-1555.39
-540.49
-627.71
-730.17
-1358.18
-2902.78
-2701.99

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
96.16
667.5
-1934.32
1023.65
613.41
-2821.45
0
574.44
-2224.53
0
667.38
-2417.18
0
680.93
-1947.66
0
475.91
-1673.77
0
586.52
-1985.24
0
540.49
-2104.87
569.99
620.19
-3509.82
0
663.57
-3579.83

Table A.8 Summary of HINT interaction scores for the 10 GA runs performed in Docking
#8
GA Run #
1
2
3
4
5
6
7
8
9
10

LOGP
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63
-0.63

Total HINT Score
-1058.21
-1097.05
-1231.66
-1492.2
-962.9
-1121.36
-1682.57
-1114.71
-569.41
-1079.49

Hydrogen Bonding Hydrophobic-Hydrophobic Interactions Hydrophobic-Polar Interactions
400.96
577.72
-1952.62
0
658.46
-2075.8
0
726.52
-2146.54
418.87
937.04
-2341.4
348.76
986.5
-2186.2
0
768.76
-2026.21
0
802.6
-2831.23
0
840.63
-2338.83
0
882.47
-1997.01
0
805.33
-2031.73
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